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Abstract 
	 Triple-negative breast cancer (TNBC) represents an aggressive subtype associated 
with progression to metastasis and poor prognosis. The NFkB co-factor B-cell lymphoma 
3 (Bcl-3) is a proto-oncogene commonly dysregulated in a range of cancers and has been 
shown to be up-regulated in metastatic breast cancer lesions. In this study we 
investigated the therapeutic potential of targeting Bcl-3 in TNBCs.

	 Knockdown of Bcl-3 with siRNA in a panel of TNBC cell lines resulted in reduced 
cellular proliferation, collective migration, single-cell motility, NFkB-targeted 
transcriptional activity and increased apoptosis-mediated cell death. Ectopic 
overexpression of wild type (WT) Bcl-3 protein in TNBC cells resulted in increased 
proliferation, single cell motility, and NF-kB activity; however, substantially increased 
apoptosis-mediated cell death was also observed, resulting in an overall reduced cell 
turnover. Affymetrix gene expression profiling of MDA-MB-231-Luc cells treated with 
Bcl-3 siRNA revealed enrichment of up-regulated genes associated with BCL2-mediated 
apoptosis regulators (MCL1, TP53, BAX, BAK1, BCL2); as well as enrichment of down-
regulated genes associated with migration including Rho GTPase signalling (CDC42, 
RHOB, CFL2, ROCK1, PAK1, PFN2).

	 In a murine in vivo xenograft metastasis model, MDA-MB-231 cells treated with 
Bcl-3 siRNA were injected via the tail vein, resulting in significantly fewer pulmonary 
metastatic lesions at experimental endpoint when compared with controls. Tail vein 
injection of MDA-MB-231 cells overexpressing WT Bcl-3 resulted in significantly 
increased pulmonary and hepatic metastatic lesions when compared with controls, as 
well as colonisation at novel distal organs including the heart, mammary gland and bone 
marrow (femur).

	 Pharmacological inhibition of Bcl-3 with novel small molecule inhibitors, JS6 and 
CB1, were able to recapitulate Bcl3 siRNA responses in functional assays. Affymetrix 
gene expression profiling of MDA-MB-231-Luc cells treated with CB1 revealed a 
significant proportion of the genes that responded to siRNA treatment also responded to 
this pharmacological inhibitor (including TFGB1, INPP4B, IL1B, IL24), highlighting 
mechanistic similarities. In a murine in vivo xenograft tail vein metastasis model, daily 
treatment of CB1 significantly inhibited early metastatic seeding events and reduced 
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average metastatic burden, as well increased the proportion of disease free animals at 
experimental endpoint when compared to controls.

	 The findings from this study highlighted Bcl-3 as a promising therapeutic target in 
TNBCs and we were able to demonstrate that the novel Bcl-3 inhibitor, CB1 functioned as 
an effective anti-metastatic agent in murine models of advanced TNBC.
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Chapter 1:
General Introduction
Chapter 1: General Introduction
1 General Introduction 
1.1 Hallmarks of cancer 
	 The hallmarks of cancer first proposed by Hanahan and Weinberg, comprised of a 
number of common biological capabilities acquired during the complex multistep 
processes of human tumourigenesis. Outlining these hallmarks provides us with an 
organised approach for rationalising the complexities of this neoplastic disease. They 
include ‘sustaining proliferative signalling’, ‘evading growth suppressors’, ‘resisting cell 
death’, ‘enabling replicative immortality’, ‘inducing angiogenesis’, ‘activating invasion and 
metastasis’, ‘genome instability’, ‘inflammation’, ‘reprogramming of energy metabolism’ 
and ‘evading immune destruction’. Furthermore, cancer cells exhibit another dimension of 
complexity as they contain a repertoire of recruited, ostensibly normal cells that continue 
to contribute towards the acquisition of hallmark traits and creates what we know as the 
tumour microenvironment. Recognition and understanding these concepts will help us 
develop new means to combat human cancers (Hanahan and Weinberg, 2011).

FIG. 1.1 THE TEN HALLMARKS OF CANCER 
Figure adapted from Hanahan and Weinberg, 2011.
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1.2 Breast cancer 
	 Breast cancer remains one of the leading causes of cancer related deaths in 
women worldwide and is the most common form of cancer in the United Kingdom, with a 
steadily increasing incidence rate in recent years (Torre et al., 2016).

1.2.1 Triple-negative breast cancer 
	 Triple-negative breast cancer (TNBC) accounts for 15-20% of all diagnosed breast 
tumours (Torre et al., 2016). Molecularly, TNBC is defined by the absence of oestrogen 
(ER), progesterone (PR) receptors and the lack of any overexpressed human epidermal 
growth factor receptor 2 (HER2 or ERBB2) proteins. Despite these common identifying 
features, TNBC is in fact a highly heterogeneous disease that can be further classified 
according to clinical, histopathologic, and molecular profiles.

	 Patients with TNBC are often young (<40 years), African American and have worse 
prognoses compared with other breast cancer subtypes; as well as a high prevalence of 
highly proliferating grade 3 tumours at diagnosis (Heitz et al., 2009). They feature earlier 
relapse after standard anthracycline and/or taxane-based chemotherapy treatments, 
typically 1-3 years after diagnosis and TNBC patients often develop visceral metastases. 
TNBCs typically have better pathologic complete response (pCR) rates following 
neoadjuvant chemotherapy compared with non-TNBCs, and patients who experience 
pCR have great long-term clinical outcomes. However, conversely TNBC patients with 
residual disease after neoadjuvant chemotherapy have extremely poor prognoses (Lin et 
al., 2012). Therefore, despite their high sensitivity to chemotherapy, the median survival of 
patients with metastatic disease very rarely exceeds 12 months, exemplifying a ‘triple-
negative paradox’ (Bulut et al., 2008).

	 Patients with TNBC do not benefit from traditional hormonal or trastuzumab-based 
therapies due to loss of receptors. Hence, standard of care for patients with early or 
advanced TNBC remains surgery and chemotherapy, yet few effective novel drugs have 
been introduced in the last few decades. Many studies have been done to determine 
whether TNBC patients were more likely to undergo mastectomy or lumpectomy. Though 
the results show that despite the fact that TNBC tend to be more aggressive, surgical 
decision making tend to rest more on traditional clinicopathological variables and patient 
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preferences (Ajay and Radhakrishnan, 2017). The local recurrence rate following breast 
conservative surgery is not as high in TNBC compared to other subtypes of BC, so this 
remains yet an appropriate candidate for breast conservation (Freedman et al., 2009). 
Traditionally, radiotherapy is given following surgery, however there is still controversy 
surrounding this practice (Dawood, 2010). 

	 Typical current therapeutic TNBC management strategies include targeting DNA 
repair complexes (platinum compounds or taxanes) or cell proliferation (anthracyclines) 
(Berrada et al., 2010). While the most effective specific adjuvant regimes for TNBC 
therapy remains incompletely defined for both early or advanced stages of the disease, 
third-generation chemotherapy regimens using dose dense or metronomic 
polychemotherapies are among the most effective tools available (Cardoso et al., 2010). 
Ultimately due to the a lack of predictors of therapy response in TNBC, there is also an 
ever increasing need for specific targetable markers for personalised therapies. For these 
reasons, identification of molecular targets and development of new therapeutic options 
remains critical for these patients.

1.2.2 Sub-typing within TNBC 
	 Breast cancer in general is comprised of a large group of heterogeneous diseases 
that can be classified by gene expression profiling into luminal A, luminal B, basal-like, 
normal-like and HER2-enriched subgroups (Perou et al., 2000). Although both terms like 
‘basal-like’ and ‘triple-negative’ are often used synonymously, it is important to highlight 
that not all TNBC are identified as basal-like by gene expression profiling, and 
immunohistochemical assays show that not all basal-like tumours are TNBC. There are 
about a 70-80% concordance between the terms (Lehmann and Pietenpol, 2014). A 
recent landmark publication by Lehmann et al. categorised TNBC into six different 
subtypes following gene expression profiling: basal-like 1 and 2 (BL1 & BL2), 
immunomodulatory (IM), mesenchymal-like (M), mesenchymal stem-like (MSL) and 
luminal androgen receptor (LAR) (Lehmann et al., 2011).

	 The BL1 subtype exhibits high rates of cellular proliferation and Ki67 levels, due to 
being heavily enriched in cell cycle-related genes and pathways involving DNA repair. The 
BL2 subtype expresses high levels of glycolysis and gluconeogenesis pathways, as well 
as tyrosine kinase receptor signalling. The IM subtype is enriched for genes involved in 
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immune processes such as B, NK and T cell, cytokine signalling, chemokine receptor/
ligand activity, complement cascades and antigen presentation. This subgroup has also 
been correlated with the highest levels of tumour-infiltrating lymphocytes (TILs) and has 
an expression profile that overlaps with medullary breast cancer (Bertucci et al., 2006). 
The M and MSL subtypes show gene signatures overlapping with chemo-resistant 
metaplastic breast cancer and have up-regulated genes associated with cell motility, 
epithelial-mesenchymal transition (EMT), differentiation and extracellular matrix 
remodelling. More specifically, the M subtype displays overexpression of proliferation 
genes, while the MSL subtype is more enriched in mesenchymal stem-cell associated 
genes, as well as angiogenesis and growth factor pathways. The MSL subtype overlaps 
with the previously defined ‘claudin-low’ subtype (Prat et al., 2010). Finally, the LAR 
subtype expresses androgen receptors (AR) and features hormonally regulated pathways 
leading to increased steroid metabolism and synthesis (Ring et al., 2016). Patients with 
the LAR subtype have the shortest relapse-free survival and this subtype overlaps with 
the previous descried ‘apocrine’ subtype (Farmer et al., 2005).

1.2.3 Genetic markers in TNBC and targeted therapies 
	 The molecular and genetic profiles of TNBC can be complex and diverse and 
studies have focused on identifying markers that influence prognosis and/or predict 
response to therapy. One unfortunate nature of TNBC is the tendency to develop 
multidrug resistance to conventional therapies and often progresses rapidly despite an 
often good initial response. For this reason, many recent targeted therapies have focused 
on the identification of either biologic or immunologic agents. The genomic profile of 
tumours has been shown to frequently change during chemotherapy, and these 
potentially explain mechanisms for acquired resistances (Balko et al., 2014). Therefore 
molecular analysis of post-treatment biopsy samples is crucial for patients who do not 
experience pCR after neoadjuvant chemotherapy to help identify new druggable targets 
and improve TNBC outcomes.

	 It is worth noting, to date, stratifying TNBC into additional subtypes by gene 
expression analysis is not a routinely performed clinical practice. However by doing so, it 
may offer novel therapeutic approaches and many studies have investigated different 
strategies targeting specific TNBC subtypes. For example, BL1 and BL2 subtypes may 
respond preferentially to anti-mitotic and DNA-damaging agents either alone or in 
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combination with platinum or taxane-based chemotherapy or poly-ADP ribose 
polymerase (PARP) inhibitors. On the other hand, the M and MSL subtypes might better 
respond to PI3K, c-MET, VEGFR2 or mammalian target of rapamycin (mTOR) inhibitors. 
The LAR subtype could demonstrate sensitivity to the AR antagonist bicalutamide 
(Gucalp et al., 2013), enzalutamide (Caiazza et al., 2016) and PI3K inhibitors (Lehmann et 
al., 2014).

	 Recent studies on primary TNBC patient samples, analysing genomic DNA copy 
numbers, methylation, exome-sequencing, mRNA arrays, microRNA sequencing and 
reverse-phase protein arrays have consistently observed genes with frequent somatic 
mutations and copy number aberrations (Cancer Genome Atlas Network, 2012). We will 
outline and discuss the significance of some of these important markers below.

1.2.3.1 TP53 
	 TP53 is one of the most important genes involved in the maintenance of genomic 
integrity throughout cell-cycle arrest, DNA repair and apoptosis. Aberrant p53 expression 
has been described in all breast cancer subtypes (Hussain and Harris, 2006). In TNBC, 
TP53 is the most frequently mutated gene and in one recent study, the rate of mutation in 
basal-like tumours was 62% and in non-basal TNBCs it was 43% (Shah et al., 2012). 
These mutations result in increased genetic instability and a range of cytogenetic 
changes. Recent findings have linked decreased p53 functions with worse overall survival 
and increased metastatic risk in TNBC patients (Powell et al., 2016). Other studies found 
TP53 mutations to be a predictor of chemoresistance (Aas et al., 1996). Taken together, 
this gene is mutated in a majority of TNBCs and therefore presents an attractive 
candidate for anti-tumour therapies. Such therapies include inhibition of Chk1 in p53-
deficient TNBC tumours, leading to sensitisation to DNA damaging agents (Bryant et al., 
2014); or the emerging approach of inhibiting a downstream Chk1 target, WEE1 resulting 
in decreased toxicity and enhanced tumour growth suppression when combined with 
cisplatin (Zheng et al., 2017).

1.2.3.2 BRCA1/2 
	 Breast-related cancer antigen 1 (BRCA-1) and BRCA-2 tumour suppressor genes 
plays an essential role in DNA double-strand break repairs through homologous 
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recombination (HR) pathways. About 15-20% of TNBC patients carry germline mutations 
of these two genes (Turner et al., 2004). Over 2000 different mutations have been 
identified with BRCA1 and BRCA2 and the most common are deletions or insertions, as 
well as single-nucleotide substitutions in either coding and/or non-coding sequences, 
resulting in protein dysfunction (Lips et al., 2013). Benefits from neoadjuvant 
chemotherapies such as PARP inhibitors were found to be higher in TNBC patient with 
germline BRCA1/2 mutations (von Minckwitz et al., 2014).

	 Poly ADP ribose polymerase (PARP) is a family of proteins involved in the DNA 
base excision repair pathway and PARP inhibition leads to the persistence of single-
strand DNA breaks that collapse replication forks resulting in double-strand breaks. These 
legions are typically repaired by the high-fidelity HR system that requires functional BRCA 
genes. Subsequently, in BRCA-deficient cells, double-strand breaks are repaired by the 
alternative error-prone non-homologous repair processes, resulting in chromosomal 
instability, cell cycle arrest and apoptosis. This is a model of synthetic lethality where the 
combination of two mutations in two or more genes results in cell death, whereas a 
mutation in only one of these genes has no effect (Robson et al., 2017).

	 Combination of a PARP inhibitor (olaparib/AZD2281) and cisplatin or carboplatin 
prolonged overall survival of mice implanted with BL breast cancer mouse tumours 
(Rottenberg et al., 2008). Olaparib has also been tested in clinical trials and high doses 
showed better objective responses with acceptable toxicity, although resistance has been 
observed in patients (Tutt et al., 2010).

1.2.3.3 PI3K pathway 
	 Increased PI3K/Akt/mTOR signalling is frequently observed in TNBCs and causes 
changes in cells survival, differentiation, proliferation and the stability of double-strand 
DNA breaks through the HR complex (Gonzalez-Angulo et al., 2009). In basal-like 
tumours, PTEN and INPP4B alterations are more common than PIK3CA mutations as this 
is more typically associated with ER positivity. PTEN is an important negative regulator of 
the PI3K pathway and its loss contributes to both rapid tumour proliferation as well as 
poor prognosis in TNBC (Beg et al., 2015). The INPP4B phosphatase is another negative 
regulator of PI3K and is associated with high clinical grade, increase tumour size, loss of 
hormone receptors and aggressive basal-like breast cancers (Fedele et al., 2010). 
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Furthermore, mutations of PIK3CA, which encodes a catalytic subunit of PI3K, occurs in 
about 10% of TNBCs and can further activate PI3K signalling. Among the TNBC 
subtypes, LAR features the highest PIK3CA mutation prevalence, so combined 
therapeutic targeting of AR and PIK3CA could prove beneficial (Lehmann et al., 2014). 
Preclinical data have shown that TNBC tumours are more sensitive to combination 
therapy. PI3K inhibition has been shown to disrupt HR of DNA in TNBCs by down-
regulating BRCA1/2 and sensitising BRCA-proficient tumours to PARP inhibitors (Ibrahim 
et al., 2012).

	 The PI3K/mTOR inhibitor, BEZ235 enhanced the tumour suppressive effects of 
chemotherapy agents carboplatin and docetaxel in an orthotopic MDA-MB-231 murine 
model as a proof of concept experiment (Montero et al., 2014). In addition, many clinical 
trials have evaluated the clinical benefits of combining PI3K or mTOR inhibitors with 
chemotherapy in TNBC. A phase II showed that 36% of metastatic TNBC patients 
benefited from the combination of everolimus and carboplatin. However another phase II 
trial of a PI3K inhibitor, GDC-0941, plus cisplatin in TNBC was terminated (Singh et al., 
2014). All in all, recent studies generally suggest further analysis is required for 
determining the effectiveness of these combinatory chemotherapies and which TNBC 
subpopulation will benefit most from PI3K/mTOR inhibitors.

1.2.3.4 Tyrosine kinase receptors 
	 Tyrosine kinase receptors from the EGFR, FGFR and VEGFR families have all been 
reported to have clinical relevance in TNBCs (Cheng et al., 2015). EGFR (HER1) mediates 
proliferation, angiogenesis, metastasis, inhibition of apoptosis and is overexpressed in 
about 60% of TNBCs. Results from trials testing EGFR tyrosine kinase inhibitors as well 
as anti-EGFR monoclonal antibodies either alone or in combination have thus far been 
disappointing (Nakai et al., 2016) Addition of the anti-EGFR antibody, cetuximab to 
cisplatin significantly increased the response rate in TNBC patients (Baselga et al., 2013). 
However, another phase I trial of erlotinib plus the nitrogen mustard derivative alkylating 
agent, bendamustine, in TNBC patients resulted in severe lymphopenia and only 1 out of 
11 patients had partial responses (Layman et al., 2013). FGFR mediates proliferation, 
survival, migration and differentiation. Alterations in FGFR genes occur in about 10% of 
TNBCs and tumours with constitutively activation of this receptor is sensitive to the FGFR 
ATP-competitive inhibitor brivanib (Shiang et al., 2010). Preliminary studies with the FGFR 
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inhibitor, PD173074, inhibited the growth of BL breast cancer cell line xenografts (Sharpe 
et al., 2011). The VEGFR family plays an important role in angiogenesis, which in turn 
affects cancer development and the addition of bevacizumab to chemotherapy has 
improved pCR rates in a number of TNBC patients (von Minckwitz et al., 2012).

1.2.3.5 Androgen receptors 
	 Along with ER and PR, AR belongs to the nuclear steroid hormone receptor family 
and plays an important role in cell signalling through the Wnt pathway. It is able to 
regulate genes involved in metastasis, PTEN, p53, along with other cell-cycle regulators, 
as well as the PI3K/Akt/mTOR pathways (Peters et al., 2009). In TNBC, AR positivity is 
found in 13-37% of cases and associates with the LAR subtype. It typically has a lower 
Ki67 index when compared with AR-negative TNBCs and is therefore less sensitive to 
chemotherapy (Barton et al., 2015). AR presents an easily detectable marker than can 
identify a subgroup of TNBCs that could benefit from targeted AR antagonist therapy. A 
phase II clinical trial of bicalutamide resulted in 19% of patients showing a therapeutic 
response to this agent for at least 6 months and the treatment toxicity was moderate 
(Gucalp et al., 2013).

1.2.3.6 BCL2 
	 BCL2 is an anti-apoptotic mitochondrial protein with oncogenic effects. The role of 
BCL2 in TNBC is not well established, but its absence in pre-chemotherapy samples 
correlate with high probability of pCR to neoadjuvant doxorubicin-based chemotherapy 
(Pusztai et al., 2004). Similarly in the adjuvant setting, low BCL2 expression was 
associated with better TNBC outcome when treated with anthracycline-based 
chemotherapy (Bouchalova et al., 2015). Adding BCL2 to the clinical screening panel 
would be easy and could provide useful prognostic predictive information pertaining to 
TNBC patients.

1.2.4 Immunotherapy in TNBC 
	 Despite evidence that breast cancer in general is not considered an immunogenic 
cancer, TNBC has been shown to be a lymphocyte-predominant breast cancer, with high 
stromal TIL percentages of 50-60% (Coates et al., 2015). Clinical studies have 
 23
Chapter 1: General Introduction
demonstrated that tumour infiltration of certain immune cell types (CD8+, CD4+ TH1 T 
cells, NK cells and M1 macrophages) correlated with more favourable prognoses. 
Presence of lymphocytes in the tumour proximity have served as a surrogate marker for 
the immune response against tumour antigens and acts as an independent prognostic 
marker. Both high levels of intra-tumoural and stromal TILs have been associated with 
better disease outcome and various trials have demonstrated for every 10% increase in 
stromal TILs, there is a 15-20% reduction in recurrence and mortality (Loi et al., 2013). 
Conversely, higher intra-tumoural presence of tumour-associated macrophages (TAM), 
myeloid-derived suppressor cells (MDSC), CD4+ Treg and TH2 cells, as well as their 
associated cytokines (IL6, TNF, IL10, IL23 and TGF-β) have been associated with a 
worsening prognosis.

	 TNBCs often exhibit genomic instabilities causing greater immunogenicity and 
neoantigen production, complementing higher expressions of PDL1. Clinical trials 
investigating the roles of PD1 and PDL1 inhibition in the adjuvant, neoadjuvant and 
metastatic settings are ongoing (Mittendorf et al., 2014). The high TIL levels within TNBCs 
are possibility due to various mutations resulting in the creation of new epitopes that are 
better able to elicit an immune-mediated anti-tumour response. The presence of a 
lymphocytic infiltrate has also been associated with better responses to neoadjuvant 
chemotherapy and can better predict pCR, especially in TNBCs over other breast cancer 
subtypes (Mao et al., 2014).

1.2.5 TNBC metastatic progression 
	 Metastatic disease remains incurable and the eventual dissemination of breast 
cancer cells to distal organs such as the bone, lungs and brain represents a significant 
clinical challenge. Metastatic progression is a complex process that is poorly understood 
and is the primary cause of death for the vast majority of TNBC patients. There are 
several steps involved, including the acquisition of invasive properties through genetic 
and epigenetic alternations, angiogenesis, tumour-stromal interactions, intravasation 
through the basement membrane, survival in the circulation and extravasation of cancer 
cells to distal tissues (Fig 1.2) (Nguyen and Massagué, 2007). However, disseminated 
cells that complete this process often remain quiescent in the secondary organs 
undergoing long periods of latency known as the dormancy period (Giancotti, 2013). It 
has been well established that the expansion of metastatic cells in a foreign tissue 
 24
Chapter 1: General Introduction
microenvironment is a highly inefficient process and is considered as the rate-limiting step 
for breast cancer metastasis. Though during this stage, the disease is difficult to detect 
and exhibits resistance to chemotherapy due to their low proliferating nature. This 
highlights the current clinical problems pertaining to patients who respond well to initial 
therapy, but can often develop metastatic disease years later.

	 Disseminated tumour cells (DTC) can achieve a state of indefinite dormancy by 
balancing the proliferative cycle with apoptosis. Successful emergence from this state is a 
result of further molecular evolution possibly acquired through interactions with the 
tumour microenvironment. While significant progress has been made to understand 
specific processes required for breast cancer initiation, it is important to shift our efforts 
towards elucidating the underlying mechanisms and signalling pathways involved in the 
fatal late stages of metastatic dissemination. Development of effective treatments against 
the metastasis of TNBC cells therefore remains of the utmost importance (Neophytou et 
al., 2018).



FIG. 1.2 PROCESSES INVOLVED IN METASTATIC PROGRESSION OF THE PRIMARY TUMOUR 
Figure adapted from Neophytou et al., 2018.

1.2.5.1 Local invasion and intravasation 
	 Following tumour initiation, TNBC cells in the primary tumour must acquire 
properties such as self-renewal, migration and the ability to invade surrounding normal 
tissue. During local invasion, cancer cells undergo epithelial-to-mesenchymal transition 
(EMT), a highly orchestrated transcriptional program associated with embryonic 
development in the normal context. This involves the remodelling of cytoskeleton, loss of 
apico-basolateral polarity, dissolution of cell-cell junctions along with down-regulation of 
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epithelial markers and up-regulation of mesenchymal genes (De Craene and Berx, 2013). 
This process is controlled by EMT-master regulatory genes such as Slug, Snail and Twist 
to promote TNBC migration and intravasation into the circulation. The TGFB signalling 
pathways plays a prominent role in regulating this early metastatic event and it is able to 
promote the expression of many of the EMT-regulators listed above as well as silencing 
epithelial genes, like CDH1 (Papageorgis et al., 2010).

1.2.5.2 Survival in circulation 
	 Following entry into the blood vessels, circulating tumour cells express anti-
apoptotic and pro-survival proteins which also allow them to attach and infiltrate specific 
secondary sites. Neurotrophic tyrosine kinase receptor (TRKB) has been shown to inhibit 
anoikis, a form of cell death caused by the lack of adhesion via the PI3K/Akt signalling 
pathway (Douma et al., 2004). The ability to bind platelets has also been shown to be 
essential for the survival of circulating TNBC cells and have been shown to be involved in 
their survival and evasion of pro-apoptotic signals (Wenzel et al., 2010).

1.2.5.3 Extravasation 
	 Many common genetic aberrations associated with intravasation are also 
implicated in extravasation since these two processes are considered ‘mirrored’ to each 
other. The TGFB/Smad pathways are able to assemble a mutant-p53/Smad complex that 
inhibits the function of the metastasis suppressor TP63 (Adorno et al., 2009). TGFB also 
induces angiopoietin-like 4 (ANGPTL4) expression, enhancing the retention of cancer 
cells in the lungs through disruption of vascular endothelial cell-cell junctions (Padua et 
al., 2008).

1.2.5.4 Metastatic colonisation 
	 Once extravasation and infiltration has taken place, EMT plasticity and the reversal 
to a MET phenotype has been shown to be important factors for colonisation 
(Gunasinghe et al., 2012). During this process, the epithelial phenotype is re-established 
through miR-200-mediated down-regulation of genes such as ZEB1 (Gregory et al., 
2008). Various chemokines and inflammatory microenvironment signals have been 
implicated in the promotion of colonisation and escape from dormancy (Dongre et al., 
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2017). It is also important to note that cellular and genetic context is critical in determining 
whether a protein acts as a tumour suppressor or metastatic promoter. One controversial 
example is LOXL4, which has been shown to facilitate colonisation of TNBC in the lungs 
via a HIF1a-dependent mechanism (Wong et al., 2011). However another study showed 
that knockdown of LOXL4 expression in TNBC cells promoted primary tumour growth 
and further lung metastasis due to associations with thickening collagen bundles and 
remodelling of the extracellular matrix within tumours (Choi et al., 2017).

1.3 Apoptosis pathways 
	 Underneath the intricacy of every cancer lies different and mysterious events that 
impel tumour cells into abnormal growth and tissue invasion. Oncogenic mutations such 
as those resulting in elevated Bcl-3 disturb normal regulatory circuits and permit tumour 
cells to endure deregulated proliferation, invade and erode normal tissues and above all 
escape apoptosis.

	 Apoptosis or otherwise known as programmed cell death is a physiological 
process that is responsible for elimination of unwanted, damaged, mutated and/or aged 
cells that might pose robust threats. Cell death is essential for life and must balance cell 
proliferation in the living body (Czabotar et al., 2014). The principe of apoptosis is the 
dismissal of damaged cells in a fashion that causes the least damage and inflammation. 
The primary morphological feature of apoptosis is shrinkage of nuclei, nuclear chromatin 
condensation, cytoplasmic shrinkage, dilated endoplasmic reticulum and membrane 
blebbing. The contents of the cell are then wrapped in apoptotic bodies which are 
recognised and engulfed by phagocytic cells and digested in lysosomes (Hotchkiss et al., 
2009). Apoptotic mechanisms are typically interlinked with other prominent pathways 
such as cell cycle, metabolism and receptor transduction pathways. Dysregulation of this 
pathway, either excessive or recessive is central to many diseases, cancer being one of 
them (Walsh, 2014).

1.3.1 Intrinsic mitochondria-mediated pathway 
	 Apoptosis is triggered by activation of caspase families via two distinct but 
congregating pathways known as the intrinsic and extrinsic pathways. The intrinsic or 
otherwise known as the stress or mitochondrial pathway is dominantly controlled by the 
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BCL2 family of proteins. This mitochondria-controlled cell death is firstly triggered by an 
increase in mitochondrial permeability, resulting in release of apoptogenic factors BAX 
and BAK through the outer membrane, disturbing the electrochemical gradient of the 
inner membrane. This change is detected by a multiprotein mitochondrial permeability 
transition complex that resides at the junction of inner and outer mitochondrial 
membranes. Secondly this mitochondrial dysfunction results in either the disturbance of 
plasma membrane integrity leading to necrosis and/or the activation of specific caspases 
by the mitochondrial protein cytochrome c leaking into the cytosol. Cytochrome c forms 
an apoptosome complex and one of its key constituents, apoptotic protease activating 
factor 1 (APAF-1) binds procaspase 9, activates effector caspases and induces 
apoptosis. The released protein second mitochondria-derived activator of caspases 
(SMAC) blocks the caspase inhibitor called X-linked inhibitor of apoptosis protein (XIAP). 
The intrinsic pathway could also be engaged and magnified when certain death receptor 
ligands in the extrinsic pathway, such as FAS and TNF signalling activate caspase-8 and 
generate tBID via FADD and TRADD. These two pathways subsequently congregate at 
the effector caspases-3, -6 and -7 (Zamzami and Kroemer, 2001).

1.3.2 Extrinsic receptor-mediated pathway 
	 Alternatively, activation of caspases is also brought about through death receptor 
(DR) signalling initiated at the cellular surface. This pathway is referred to as extrinsic or 
death receptor pathway. All DRs expressed on the cell membrane are characterised by 
the presence of a death domain (DD) that play a crucial role in the apoptotic signal 
transduction. So far, six members of the DR family have been recognised: TNF-R1, CD95 
(APO1/FAS), DR3, TRAIL-R1, TRAIL-R2 and DR6. The DRs are triggered following 
activation by death ligands, resulting in the formation of a death-inducing signalling 
complex (DISC). This DISC is comprised of oligomerised receptors: Fas-associated death 
domain, procaspase-8 (FLICE), procaspase-10 and the cellular FLICE inhibitory proteins 
(c-FLIP). Formation of DISC activates procaspase-8/-10 and initiates the proapoptoic 
cascade of caspases (Ashkenazi, 2002). 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FIG. 1.3 APOPTOSIS PATHWAYS 
a. The mitochondria-mediated intrinsic and b. death receptor-mediate extrinsic pathway. Adapted 
from Baig et al., 2016.

1.3.3 BCL2 protein family 
	 There are a total of 25 known genes of the BCL2 protein family and members are 
characterised by four conserved amphipathic α-helical regions designated BCL2 
homology (BH) 1-4 domains. Based on these domains, members could be broadly 
categorised into three subgroups: [1] pro-apoptotic multi-domain proteins BAX and BAK, 
[2] anti-apoptotic multi-domain proteins BCL2, BCLXL, BCLW, BFL1 and MCL1, and [3] 
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pro-apoptotic single domain BH3-only proteins BID, BIM, BAD, p53 unregulated 
controller of apoptosis (PUMA) and NOXA (Danial and Korsmeyer, 2004).

TABLE 1.1 BCL-2 PROTEIN FAMILY MEMBERS AND THEIR FUNCTION 
1.3.4 Inhibitor of apoptosis proteins 
	 Inhibitor of apoptosis proteins (IAPs) are a family of proteins that serve as 
endogenous inhibitors of apoptosis and all have a common domain of 70 amino-acid 
baculo-virus repeats (BIR) that suppress caspase function by facilitating protein-protein 
interactions. XIAP prevents caspase-3 processing in response to caspase-8 activation, 
inhibiting the extrinsic apoptotic signalling. The human IAP family consists of eight 
members: NAIP, XIAP, cIAP1, cIAP2, ILP2, survivin, livin and BRUCE (Lemke et al., 2014).

Bcl-2 family 
member
BH domain Proapoptotic Antiapoptotic Proapoptotic 
function
BCL BH 1-4 - Y -
BCLXL BH 1-4 - Y -
BCLW BH 1-4 - Y -
MCL1 BH 1-4 - Y -
BAX BH 1-3 Y - Effector
BAK BH 1-3 Y - Effector
BIM BH3-only Y - Activator
BID BH3-only Y - Activator
BAD BH3-only Y - Sensitiser
BIK BH3-only Y - Sensitiser
NOXA BH3-only Y - Sensitiser
PUMA BH3-only Y - Sensitiser
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1.4 Rho family of small GTPases in actin regulation and motility 
1.4.1 Rho GTPases and upstream regulation 
	 The Rho-family of p21 small GTPases are critical to the regulation of actin 
cytoskeleton and cell motility. Rho GTPases function as molecular switches and can 
interact with downstream effector molecules to propagate signal transduction when in 
their GTP-loaded “on” state (Bourne et al., 1991). Intrinsic phosphatase activity can 
hydrolyses the GTP to GDP, turning the Rho GTPase “off”. This process is accelerated by 
interactions with GTPase activating proteins (GAPs). The relative affinity difference for 
effector molecules from the GTP “on” versus GDP-loaded “off” states of the Rho GTPase 
can be as much as 100-fold, resulting in a highly specific signalling processes only in the 
GTP-bound activated state. Interaction with guanine-nucleotide exchange factors (GEFs) 
facilitates the exchange of GDP back to GTP (Rossman et al., 2005).

	 Binding of GAP or GEF interactions take place directly at the same effector binding 
interface of the Rho GTPase. The binding of GAP confers slight structural changes that 
act to insert a water molecule into the catalytic pocket of the Rho GTPase to facilitate the 
hydrolysis of GTP into GDP by a factor of almost 4000-fold greater than the rate of 
intrinsic phosphates. The binding of GEF displaces the Mg+2 and releases the bound 
GDP in exchange for GTP (Moon and Zheng, 2003). There exists mutant versions of Rho 
GTPase, either dominant negative or constitutively active and they can sequester 
upstream GAPs and GEFs.

	 Guanine-nucleotide dissociation inhibitors (GDIs) are another class of molecules 
that interact with Rho GTPases as they bind and inhibit the dissociation of the guanine 
nucleotide, preventing the activation of Rho GTPases. The N-terminal regulatory portion 
of GDI also interacts with the effector binding interface of the Rho GTPases, preventing 
binding with any of its effectors. Binding of GDI to Rho GTPases at the plasma membrane 
causes the bound complex to by pulled into the cytoplasm. The shuttling of the active 
fraction of Rho GTPase between membranes and the inactive fraction in the cytoplasm 
constitutes one of the major regulatory dynamics of Rho GTPases (DerMardirossian and 
Bokoch, 2005). Various upstream kinases target GDI and Rho GTPases including Src, 
PKC, PKA and specifically modulate the affinity of GDI towards members of the Rho 
GTPase family.
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	 Traditionally, the Rho family of GTPases, RhoA, Rac1 and Cdc42 have been 
primarily associated with cytoskeleton rearrangements. Microinjections of the activated 
mutants of Rho GTPases into starved and quiescent Swiss3T3 cells induced dramatic 
actin cytoskeletal rearrangements where RhoA caused stress fibre and adhesion 
formation, Rac1 induced sheet-like lamellipodial protrusions and Cdc42 produced 
filopodial protrusions (Bishop and Hall, 2000).

	 While it is easy to conclude that any one of the GTPases could have distinct and 
isolated effects on cell motility, it appears more likely these Rho GTPases exist in complex 
activation cascades. An example of this effect is the antagonism between Rac1 and RhoA 
and it has been observed that the protrusive phenotype driven by Rac1 must prevail at 
the leading edge and the contractile phenotype by RhoA primarily drives the tail retraction 
in locomoting cells (Rottner et al., 1999).

FIG. 1.4 FLUORESCENT BIOSENSOR DATA SHOWING ACTIVATION PATTERNS OF RHOA AT THE 
LEADING EDGE 
Figure adapted from Pertz et al., 2006.

1.4.2 Rho GTPase downstream targets 
	 The downstream Rho targets are well described and include kinases, formins, 
WASp proteins, and other scaffolding molecules. Of these major subclasses, the p21-
activated kinase (PAK), mammalian Diaphanous formin (mDia) and proteins of the WASp 
family including WASp, N-WASp and WAVE, all have direct effects on actin cytoskeleton 
rearrangements crucial to motility. RhoA, B and C activate the immediate downstream 
kinase target ROCK, which phosphorylate a number of actin cytoskeleton regulators 
including myosin light chain phosphatase and LIM kinase (LIMK). (Narumiya et al., 2009) 
Direct phosphorylation of myosin light chain or of myosin light chain phosphatase 
impacts on the level of phosphorylated myosin light chain, which contributes to 
contractility. Activation of LIMK by ROCK phospho-regulates ADF/cofilin, which is one of 
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the key regulators of actin severing, nucleation and capping within the protrusive 
machinery. Feeding directly into this pathway, Rac1 and Cdc42 activates p21-activated 
kinase1 (PAK1), which also activates LIMK (DesMarais et al., 2005). The Slingshot and 
Chronophin family of phosphatases activated by Rac1 can also dephosphorylate cofilin to 
activate it.

	 Another critical downstream effector of RhoA, B and C is the Formin family of 
proteins. Formins produce straight, unbranched actin fibres through the formin homology 
domain 2 (FH2). FH2 is associated with the tip of the growing actin filament and 
accelerates the incorporation of actin monomers. Formin homology 1 (FH1) delivers 
profilin-bound actin monomers to FH2. These actin fibres are typically evident in actin 
stress fibres, filopodia, actin cables and cytokinesis actin rings. Formins are typically 
activated by Rho GTPases which displaces the auto-inhibitory domain, relaxing the 
closed conformation, allowing for FH1/FH2 to process actin polymerisation (Goode and 
Eck, 2007).

	 Rac1 and Cdc42 activate Wiskott-Aldrich Syndrome family of proteins including, 
WASp, N-WASp and WAVE1/2. These molecules exist in an auto-inhibited, closed 
conformation where the C-terminal VCA motif binds to the GTPase binding domain 
(GBD). Activated Cdc42 or Rac 1 competes against this auto-inhibition, releasing the VCA 
from the GBD, which allows binding of Arp2/3 complex and subsequent activation of the 
Arp2/3 complex. Unlike WASp, WAVE proteins do not have a GBD domain and their 
activation requires binding of Rac1 to the adapter molecule IRSp53, followed by binding 
of this complex to the WAVE protein (LeClaire et al., 2008).



 33
Chapter 1: General Introduction
FIG. 1.5 DOWNSTREAM EFFECTOR TARGETS OF RHO FAMILY OF GTPASES 
Adapted from Spiering and Hodgson, 2011.

1.5 The NFkB signalling pathway 
	 NFkB-mediated transcription plays a critical role in the regulation of immune 
responses, apoptosis and cell survival, hence are centrally implicated as mediators of 
cancer initiation and progression. NFkB activation leads to the transcription of a wide 
range of genes encoding for inflammatory cytokines, cell-cycle modulators, survival 
signals, growth and angiogenic factors, all positive drivers in the tumour environment. The 
fine tuned balance between NFkB activation and control is lost during pathological 
conditions such as cancer and chronic inflammation (Grivennikov et al., 2010).

1.5.1 NFkB subunits 
	 The mammalian NFkB family consists of five subunits: p65 (RelA), RelB, c-Rel, p50 
(NFKB1) and p52 (NFKB2) (Fig. 1.6). Unlike other subunits, NFKB1 and NFKB2 are 
synthesised as precursors (p105 and p100) which are proteolytically cleaved to p50 and 
p52, respectively. The various NFkB subunits are capable of forming homo- and hetero-
dimers as they share structurally similar Rel homology domains (RHD) essential for 
dimerisation and cognate DNA interactions (May and Ghosh, 1997).

 34
Chapter 1: General Introduction
	 In most quiescent cells, these dimers are collectively held inactive in the cytoplasm 
by binding to inhibitor of kB proteins (IkB). These inhibitors are characterised by their 
ankryin repeat domains, which associate with the DNA-binding domains of the NFkB 
subunits, making them transcriptionally inactive. The precursors p105 and p100 contain 
ankyrin repeats which act as internal inhibitors prior to cleavage and maturation. In 
contrast to other NFkB subunits, p50 and p52 do not contain transactivation domains 
(Marienfeld et al., 2003). Consequently when p50 and p52 dimers bind to NFkB elements 
of gene promoters, they will be inactive and act as transcriptional repressors (Hayden and 
Ghosh, 2012). However, when p50 or p52 are bound to a subunit containing a 
transactivation domain, such as p65 or RelB, they will act as a transcriptional activator. 
One atypical member of the IkB family, Bcl-3 also contains transactivation domains and 
can complex p50 and p52 dimers, rendering them transcriptionally active (Fujita et al., 
1993). NFkB subunits also contain phosphorylation sites and other post-translational 
modifications that play a role in activation and/or crosstalk with other signalling pathways 
(Oeckinghaus and Ghosh, 2009).



FIG. 1.6 THE FIVE SUBUNITS OF THE MAMMALIAN NFKB FAMILY. 
Figure adapted from Hoesel and Schmid, 2013.

1.5.2 Mechanisms activating NFkB signalling pathways 
	 Typically, activation of NFkB subunits involves either the release from the IkB 
molecules or by cleavage of the p100 and p105 inhibitory ankyrin repeat domains. 
Proteasomal degradation of the IkB inhibitors requires prior polyubiquitination of the 
target molecules with lysine-48 linked ubiquitin chains. In order for the ubiquitination 
enzymes to carry out this process, it must first recognise a specific double 
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phosphorylation signature on the substrate. This is catalysed by a complex containing IkB 
kinases (IKKα and IKKβ) and at least one non-catalytic accessory protein (NEMO) (Fig. 
1.c) (Hayden and Ghosh, 2008). This IkB kinase (IKK) complex is able to bind additional 
components, respond to upstream signalling molecules and can be activated by a great 
variety of stimuli. The varying activation mechanisms guarantee that different stress 
situations can induce the catalytic activity of IKKs, leading to the liberation and activation 
of NFkB signalling.

	 The canonical activation pathway (Fig. 1.7a) involves excitatory signals mediated 
through toll-like receptors (TLRs), interleukin-1 receptor (IL1R), tumour necrosis factor 
receptor (TNFR) and antigen receptors. Typical molecules that stimulate signalling include 
tumour necrosis factor alpha (TNFα), lipopolysaccharides (LPS) and interleukin-1 beta 
(IL1B) (Perkins and Gilmore, 2006). Stimulation through these receptors leads to the 
activation of the IKK2 complex and subsequently phosphorylates IkBα. The non-
canonical activation pathway (Fig. 1.7b) signals through a different class of receptors 
including B-cell activation factor (BAFFR), lymphotoxin β-receptor (LTBR), CD40, receptor 
activator for nuclear factor kappa B (RANK), TNFR2 and Fn14 (Sun, 2011). This process 
results in the activation of the NFkB inducing kinase NIK, which phosphorylates and 
activates IKK1. IKK1 induces phosphorylation of p100 resulting in its ubiquitination and 
partial degradation to p52 (Xiao et al., 2001). In many cases, p100 is associated with 
RelB, so the proteolytic processing of p100 induces the formation of the transcriptionally 
active RelB-p52 complex. The atypical activation pathway (Fig. 1.7c) involves the 
activation of the IKK complex after genotoxic stress via the ATM checkpoint kinase, 
resulting in the ubiquitination of NEMO and subsequent NFkB signalling.

	 After NFkB dimers are liberated from the inhibitory IkB proteins, they localise to the 
nucleus and the RHDs are free to bind their cognate DNA-sequences in the enhancer 
elements of gene promoters. Depending on the accessibility determined by the epigenetic 
mechanism of the cell type, thousands of potential target genes could become 
transcriptionally activated upon NFkB pathway activation. Termination of NFkB 
transcriptional activity is primarily achieved through NFkB up-regulating its own inhibitors 
of the IkB family in a negative feedback loop, until complete inactivation back to 
background levels (Pahl, 1999).
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1.5.3 NFkB in cancer 
	 NFkB is constitutively active in many cancers and subsequently exerts a variety of 
pro-tumourigenic functions. The immune system appear to play a role in protecting 
against malignant cells with dysregulated NFkB as immune-suppressed individuals 
exhibit a higher risk of cancer (Smyth et al., 2006). NFkB activation has been associated 
with the up-regulation of anti-apoptotic genes, promotion of proliferation, as well as 
inducing the release of pro-inflammatory cytokines (Guttridge et al., 1999). It has been 
postulated that neutrophils of the innate immunity that release reactive oxygen species to 
kill invading pathogens could cause DNA-damage and promote genetic mutations that 
trigger tumour initiation as a side effect (Liou and Storz, 2010). Moreover, NFkB signalling 
has been shown to contribute towards cancer progression through mediating EMT and 
metastatic progression (Huber et al., 2004). Finally, NFkB can also control tumour 
angiogenesis via up-regulation of VEGF and its receptors (Yoshida et al., 1999).

	 Direct mutations of NFkB genes have been found in lymphoid malignancies with 
amplifications or point mutations of RelA in B-cell lymphomas, chromosomal truncations 
of the NFKB2 gene in other lymphomas (Neri et al., 1991). Furthermore, mutations of 
other members of the NFkB signalling pathway including Bcl-3 and c-Rel have also been 
detected in B-cell leukemias (Rayet and Gélinas, 1999). In solid tumours, direct mutations 
of NFkB are rarer, but transgenic mice studies have demonstrated direct contributions of 
the NFkB signalling pathway to the development of colorectal tumours (Greten et al., 
2004).

 37
Chapter 1: General Introduction
 
 38
FI
G.
 1
.7
 T
HE
 C
AN
ON
IC
AL
, N
ON
-N
ON
-C
AN
ON
IC
AL
 A
ND
 T
HE
 A
TY
PI
CA
L 
NF
KB
 S
IG
NA
LL
IN
G 
PA
TH
W
AY
S 
a.
 C
an
on
ica
l N
Fk
B 
sin
gl
ing
 in
ac
tiv
at
ed
 b
y L
PS
, T
NF
a,
 IL
1a
nd
 th
eir
 re
sp
ec
tiv
e 
re
ce
pt
or
s t
hr
ou
gh
 a
 w
id
e 
ra
ng
e 
of
 a
da
pt
er
 p
ro
te
ins
 a
nd
 k
ina
se
s, 
th
is 
lea
ds
 to
 th
e 
ac
tiv
at
io
n 
of
 IK
KB
 in
 th
e 
IK
K 
co
m
pl
ex
, w
hic
h 
in 
tu
rn
 p
ho
sp
ho
ry
lat
es
 Ik
Ba
 o
n 
se
r3
2 
an
d 
se
r3
6.
 T
his
 a
 p
re
re
qu
isi
te
 e
ve
nt
 fo
r 
po
lyu
bi
qu
itin
at
io
n,
 w
hic
h 
re
su
lts
 in
 th
e 
pr
ot
ea
so
m
al 
de
gr
ad
at
io
n 
of
 Ik
Ba
. N
Fk
B 
di
m
er
s c
an
 th
en
 b
e 
tra
ns
lo
ca
te
d 
to
 th
e 
nu
cle
us
 a
nd
 a
ct
iva
te
 
tra
ns
cr
ip
tio
n.
 b
. N
on
-c
an
on
ica
l N
Fk
B 
sig
na
llin
g 
ca
n 
be
 si
gn
all
ed
 th
ro
ug
h 
BA
FF
R,
 R
AN
K,
 LT
BR
, le
ad
ing
 to
 a
ct
iva
tio
n 
of
 IK
Ka
 b
y t
he
 N
IK
. I
KK
a 
ca
n 
th
en
 p
ho
sp
ho
ry
lat
e 
p1
00
 o
n 
se
r8
66
 a
nd
 se
r8
70
, w
hic
h 
lea
ds
 to
 p
ol
yu
bi
qu
itin
at
io
n 
of
 p
10
0 
an
d 
its
 su
bs
eq
ue
nt
 p
ro
te
as
om
al 
pr
oc
es
sin
g 
to
 
th
e 
ac
tiv
e 
fo
rm
 w
hic
h 
ca
n 
th
en
 a
ct
iva
te
 tr
an
sc
rip
tio
n.
 c
. A
ty
pi
ca
l N
Fk
B 
sig
na
llin
g 
is 
ac
tiv
at
ed
 b
y g
en
ot
ox
ic 
st
re
ss
 w
hic
h 
lea
ds
 to
 tr
an
slo
ca
tio
n 
of
 
NE
M
O 
to
 th
e 
nu
cle
us
 w
he
re
 it
 is
 su
m
oy
lat
ed
 a
nd
 th
en
 u
bi
qu
itin
at
ed
. T
his
 p
ro
ce
ss
 is
 m
ed
iat
ed
 b
y t
he
 A
TM
 c
he
ck
po
int
 k
ina
se
. N
EM
O 
an
d 
AT
M
 
ca
n 
th
en
 re
tu
rn
 to
 th
e 
cy
to
so
l w
he
re
 th
ey
 a
ct
iva
te
 IK
KB
. F
ig
ur
e 
ad
ap
te
d 
fro
m
 H
oe
se
l a
nd
 S
ch
m
id
, 2
01
3.
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1.6 B-cell lymphoma 3 (Bcl-3) 
	 Bcl-3 was first identified in cases of B-cell lymphocytic leukaemia as a 
translocation into the immunoglobulin alpha-locus on chromosome 19 (van Krieken et al., 
1990). It is an atypical member of the IkB family of proteins and despite being structurally 
similar to the other family members, it serves a separate function (Wulczyn et al., 1992). 
Both p50 and p52 dimers are transcriptionally inactive as they lack transactivation 
domains, however Bcl-3 is able to heterocomplex with these homodimers, providing two 
transactivation domains and subsequently drive transcription (Fujita et al., 1993). Bcl-3 
interacts with both p50 and p52 and is able to activate both the canonical and non-
canonical NF-κB pathways. Bcl-3 is able to cleave cytosolic inactive p105 and complex 
with active p50 homodimers and facilitate its translocation into the nucleus (Watanabe et 
al., 1997).

1.6.1 Bcl-3 interactions 
	 The physiological signalling cascades leading to activation of Bcl-3 has yet to be 
fully characterised, but its up-regulation has been reported in response to a number of 
cytokines including TNF-α (Heissmeyer et al., 1999), IL4 (Rebollo et al., 2000), IL1 (Elliott 
et al., 2002), IL6 (Brocke-Heidrich et al., 2006), IL10 (Kuwata et al., 2003), adiponectin 
(Folco et al., 2009) and IL12 (Valenzuela et al., 2005). These cytokines are all associated 
with the induction of diverse signalling pathways such as AP1 (Rebollo et al., 2000) and 
STAT3 (Maldonado et al., 2010). Similar to other members of the NFκB family, Bcl-3 is 
regulated by p50 as well as itself, generating an auto-regulatory loop to terminate its 
activity (Brasier et al., 2001). Deubiquitination of ubiquitin chains at lysine 63 by the 
cylindromatosis gene product, CYLD, is able to regulate and prevent accumulation of 
Bcl-3 in the nucleus (Wickström et al., 2010).

	 Although the state of Bcl-3 phosphorylation will not be investigated within the 
scopes of this project, it is nevertheless an important aspect to consider. Bcl-3 exists as a 
phospho-protein in many cancers (Viatour et al., 2004) and unphosphorylated Bcl-3 acts 
as a classical IkB-like inhibitor and removes p50/p52 from bound DNA (Fujita et al., 1993). 
A recent study showed that Akt, Erk2 and IKK1/2 phosphorylated Bcl-3 and 
phosphylation of Ser33 by Akt switched K48 ubiquitination to K63 ubiquitination and 
promoted Bcl-3 nuclear localisation and stabilisation. Phosphorylation by Erk2 and 
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IKK1/2 of Ser114 and Ser446 facilitated the recruitment of Bcl-3 to DNA by turning on its 
transcriptional coregulator capabilities and it was shown that phosphorylation of these 
serines were key to the maintenance of cellular proliferation and migration (Wang et al., 
2017). This study highlighted the importance of phospho-Bcl-3 and linked Akt and MAPK 
pathways to NFkB signalling through Bcl-3 (Fig.1.8) and provided some key mechanistic 
insight into how Bcl-3 functioned as an oncogene.

FIG. 1.8 MODEL OF BCL-3 ACTIVATION. 
In resting cells, Bcl-3 undergoes continuous degradation, but upon LPS stimulation, Akt is 
activated through the PI3K pathway and stabilises Bcl-3. Figure adapted from Wang et al., 2017.
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	 In additions to NFkB gene products, Bcl-3 has also been shown to associate with 
B3BP, a protein implicated in DNA damage responses (Watanabe et al., 2003), Lck, a 
tyrosine kinase expressed in haematological malignancies (Zhao et al., 2005), and 
ERRalpha and PGC-1alpha, proteins involved in metabolism (Yang et al., 2009). Recent 
studies have also reported interactions with CtBP1, a transcriptional repressor (Choi et 
al., 2010), IRS3, an insulin receptor substrate (Kabuta et al., 2010) and Bcl-10, a protein 
involved in apoptosis induction (Chan et al., 2010). All of these interactions and their 
physiological consequences have not been extensively studied, but highlights the 
widespread functions linked with Bcl-3 signalling.

1.6.2 Bcl-3 related malignancies 
	 Since the discovery of Bcl-3 involvement in B-cell chronic leukemias, it has been 
found to be translocated in other haematological malignancies such as small lymphocytic 
lymphoma, Burkitt-like lymphoma as well as diffuse large cell lymphoma (Au et al., 2002). 
Furthermore, its overexpression without translocation has been identified in multiple 
subtypes of both non-Hodgkin and Hodgkin lymphomas (Schlette et al., 2005). Its 
dysregulation has also been reported in a large number of solid tumours including breast 
cancer (Cogswell et al., 2000), nasopharyngeal carcinoma (Thornburg et al., 2003), and 
colorectal cancer (Choi et al., 2010) and has since been largely accepted as a proto-
oncogene. The most common alteration found in solid tumours is Bcl-3 overexpression 
and no translocations in the Bcl-3 locus has been found. This suggests the mechanism of 
deregulation is likely to be due to upstream activating signal cascades and/or epigenetic 
mechanisms. Since NFkB is commonly constitutively active in tumours it is likely Bcl-3 
dysregulation could be due to aberrant NFkB activation (Karin et al., 2002).

	 The underlying mechanism of its oncogenicity is not yet fully understood, however 
Bcl-3 in complex with p52 has been shown to promote cell proliferation and survival in 
vitro through cyclin D1 up-regulation (Westerheide et al., 2001). Bcl-3 has a reciprocal 
relationship with the tumour suppressor p53 and induction of p53 can result in cyclin D1 
inhibition resulting from reduced Bcl-3 levels. As previously mentioned, work done with 
human breast cancer MCF-7 cells showed that by overexpressing Bcl-3, it resulted in 
suppression of p53 induction following DNA damage, leading to a reduced apoptosis 
response (Kashatus et al., 2006).
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	 Elevated Bcl-3 levels is not only pathogenically specific to cancer and has been 
implicated in immune cell functions. Patients with inflammatory bowel disease have 
exhibited high Bcl-3 expression in colonic T cells and this correlated positively with 
disease manifestation. Mice with T-cell specific Bcl-3 overexpression developed severe 
colitis caused by pro-inflammatory immune infiltration attributed to defective Treg cell 
function and development (Reißig et al., 2017). Bcl-3 overexpression was also shown to 
be a novel regulator of non-alcoholic fatty liver disease or otherwise known as hepatic 
steatosis. Hepatocytes overexpressing Bcl-3 led to pronounced metabolic alterations, 
characterised by de novo lipogenesis and uptake, decreased hydrolysis and export of 
fatty acids. This was accompanied by an augmented inflammatory milieu, liver cell injury, 
as well as decreased insulin sensitivity (Gehrke et al., 2016). These recent studies 
highlighted the potential prognostic value of Bcl-3 not only in cancer, but also diseases 
such as colitis and non-alcoholic steatoheapatitis.

1.6.3 Bcl-3 in breast cancer  
	 Up-regulation of Bcl-3 in human breast cancer was first observed by Cogswell et 
al. when nuclear extracts of primary tumour samples, breast carcinoma cell lines and 
normal adjacent breast tissue were analysed for NFκB activation. RNA levels for NFκB-
regulated genes indicated Bcl-3, c-Rel, p50 and p52 were all elevated compared to 
adjacent non-tumourigenic tissue (Cogswell et al., 2000). Bcl-3 overexpression was also 
able to augment the development of an oestrogen-independent phenotype in vivo in an 
ER+ MCF-7 murine model. The same study also found elevated levels of Bcl-3 as well as 
activated NFκB signalling in oestrogen-independent MCF-7/LCC1 cells compared to 
oestrogen-dependent parental controls (Pratt et al., 2003). 

	 The C-terminal binding protein 1 (CtBP1) has been identified as a binding partner 
of Bcl-3 and it is a repressor of pro-apoptotic genes, such as p21 and NOXA. A strong 
positive correlation was found between Bcl-3 protein levels and CtBP1 in breast cancer 
patients. Binding of Bcl-3 to CtBP1 blocks its ubiquitination and prevents its degradation. 
It has also been shown that CtBP1 is able to stabilise Bcl-3 and further enhance its 
transrepressive functions (Keutgens et al., 2010). Aberrant overexpression of Bcl-3 
subsequently results in cells becoming resistant to apoptotic stimuli and helps to explain 
progression to cancer (Choi et al., 2010). 
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1.6.4 Bcl-3 as a therapeutic target for metastasis 
	 The metastatic process is multistep and fundamentally relies on the migration of 
tumour cells from the primary to secondary sites. Current standard of care for metastatic 
disease remains focusing on improving quality of life, but it has long been argued that 
existing therapies aimed at regressing primary tumours should be complemented with 
anti-metastatic agents aimed at preventing the initial or ongoing dissemination of disease 
(Sleeman and Steeg, 2010). However, to ensure successful translation into the clinic, such 
interventions must overcome the problems of non-selective toxicity and cellular plasticity, 
whereby tumours are able to evade inhibition of specific migration pathways by adopting 
alternative modes of migration (Gandalovicova et al., 2017). Despite some promising 
advances in this area, such as the next generation ROCK inhibitors (Sadok et al., 2015) 
and agents targeting the actin cytoskeleton (Zhang et al., 2012), ongoing issues of toxicity 
and efficacy justifies further search for novel targets of multi-modal migration.

	 Bcl-3 has shown early promise as a new anti-metastatic target in the pre-clinical 
setting and it has recently been implicated in progression and resistance to therapy in a 
number of solid tumour types (Legge et al., 2019). Its nuclear expression has been 
associated with colorectal cancer metastasis and high Bcl-3 expression has been 
correlated with reduced metastasis-free survival (Puvvada et al., 2010). Bcl-3 
suppression. In breast cancer, high expression has been attributed to a reduction in 
metastasis-free survival (Chen et al., 2016) and in a recent transgenic mouse study 
featuring HER2+ mammary tumours resulted in significant reductions in pulmonary 
metastasis without disruptions to regular cell homeostasis, highlighting Bcl-3 inhibition as 
a potential clinical therapeutic option (Wakefield et al., 2013). More importantly, complete 
deletion of Bcl-3 in these mouse models was well tolerated with only minor disruptions to 
the immunological compartments (Schwarz et al., 1997). While it has been previously 
shown that Bcl-3 inhibition was able to reduce metastatic migration in a TNBC cell line 
murine model and despite recent promising advances, the precise mechanisms detailing 
the oncogenicity of Bcl-3 has yet to be fully characterised. Therefore we set out to further 
investigate the roles of Bcl-3 in TNBC as an anti-metastatic target and determine its 
effects on tumour proliferation, amoeboid, collective and mesenchymal-like cell migration, 
as well as seeking to identify the underlying signalling pathways by performing global 
gene expression.
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1.6.5 Development of a small molecule inhibitor of Bcl-3 
	 We modelled the interaction of Bcl-3 with the NFkB subunits p50 and p52 to 
identify possible interaction areas on the surface of Bcl-3 that could be targeted by small 
molecules. A suitable novel binding pocket was identified between ANK6 and ANK7 
ankyrin repeats in the Bcl-3 backbone (Fig. 1.9). In silico screening was performed to 
identify small molecules that would bind to this area and 10 hit compounds were selected 
from the SPEC database. We tested these compounds in an indirect sandwich ELISA to 
determine which compound had the highest efficacy at inhibiting p50 and p52 binding to 
Bcl-3. Using this top hit as a structural scaffold for the activity relationship between 
subunits, we were able to design and synthesise a novel small molecule compound with 
equivalent or greater biological potency.

FIG. 1.9 BCL-3 SMALL MOLECULE BINDING SITES 
Molecular dynamics were assessed using Bcl-3/p50 heterodimers to identify suitable small 
molecule binding sites. The contact area positioned between the ANK6 and ANK7 domain of 
Bcl-3 was determined to be a unique binding motif and subsequently used for in silico screening 
of small molecule compounds (Adapted from Soukupova, 2013, unpublished).
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1.7 Project Aims 
Investigate the functional effects of both Bcl-3 suppression as well as up-regulation 
through ectopic protein overexpression in a panel of TNBC cell lines
TNBCs are an important clinical subtype and they do not respond effectively to 
traditional endocrine or targeted therapies. Bcl-3 is consider a proto-oncogene and its 
suppression has been postulated to be therapeutic in a number of solid cancers. Therefore 
is possible for Bcl-3 suppression to have potential therapeutic efficacy in TNBCs.
Confirm the in vitro and in vivo efficacy of novel small molecule Bcl-3 inhibitor 
compounds.
In vitro efficacy using our Bcl-3 inhibitors have been shown in a number of breast 
cancer cell lines. It is logical to demonstrate in vivo efficacy using luciferase xenograft 
models in athymic nude mice. Robust animal data is a vital prerequisite for adoption into 
human clinical trials. The Bcl-3 inhibitors have shown no significant cytotoxicity in animals 
and this is one advantage over traditional cytotoxic chemotherapies.
Investigate the transcriptional changes following Bcl-3 suppression to identify potential 
mechanisms of action.
Affymetrix DNA microarray analysis using GeneChip 2.1 was carried out on RNA 
from the TNBC cell line MDA-MB-231-Luc. The samples will be from Bcl-3 siRNA treated, 
as well as Bcl-3 inhibitor treated cells and their appropriate controls. This will hopefully 
give us a starting point for elucidating a possible transcriptional mechanism and it is 
hypothesised that there will be some mechanistic overlap between the two different 
methods of Bcl-3 suppression. 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2 Materials and Methods
2.1 Cell culture
2.1.1 Experimental cell lines
The human breast cancer cell lines used in this study were acquired from 
commercial sources and their descriptions are outlined below:
MDA-MB-231-Luc-D3H2LN (Caliper, Life Sciences)
This epithelial cell line was derived from pleural effusion of adenocarcinoma from a 
human patient with ER-, PR-, ERBB2- breast cancer. It overexpresses epidermal growth 
factor (EGF) receptors as well as transforming growth factor alpha (TGF alpha) receptors. 
It was passaged from a spontaneous lymph node metastasis from a D3H1 mammary fat 
pad tumour and transfected with pGL3 control red (SV40-luc) and pSV40/Zeo. It 
expresses in vitro bioluminescence of approximately 189-208 photos/sec/cell, subject to 
imaging and culturing conditions.
MDA-MB-231 (ATCC HTB-26)
This is a highly metastatic, human basal epithelial cell line isolated from an 
adenocarcinoma pleural effusion. The cells are triple-negative with a ER-, PR-, ERBB2- 
expression profile. It strongly overexpress EGFR.
MDA-MB-436 (ATCC HTB-130)
This epithelial cell line was derived from pleural effusion of adenocarcinoma from a 
human patient with ER-, PR-, ERBB2- breast cancer and has a BRCA1 5396 + 1G>A 
splice donor mutation in exon 20 site (Elstrodt et al., 2006).
SUM149PT (Asterand)
This epithelial cell line was derived from invasive ductal carcinoma from a human 
patient with ER-, PR-, ERBB2- inflammatory breast cancer. It over-expresses epidermal 
growth factor (EGF) receptors and carries the 2288delT mutations of BRCA1 (Elstrodt et 
al., 2006).
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MCF10a (ATCC CRL-10317)
This is a mammary epithelial cell line and has been considered as a model of non-
tumourigenic mammary cells. They were derived from mammary tissue from a 36-year old 
woman in good health and this immortalised cell line can grow in culture with a stable, 
near diploid karyotype with modest genetic modifications typical of culture adapted breast 
epithelial cells.
HCC1954 (ATCC CRL-2338)
This is an epithelial mammary cell line derived from a 61-year old female with TNM 
stage IIA, grade 3, ductal carcinoma disease. This cell lines is poorly differentiated and 
was initiated in 1995. It over-expresses HER2 and is negative for ER and PR.
2.1.2 Maintenance of cell lines
The following culture conditions were used for:
MDA-MB-231, MDA-MB-231-Luc-D3H2LN, MDA-MB-436, HCC1954
Cultured with Roswell Park Memorial Institute (RPMI) 1640 medium supplemented 
with GlutaMAX (ThermoFisher Scientific), and heat-inactivated Fetal Bovine Serum 
(Gibco) at a final concentration of 10%.
SUM149PT
Cultured with Ham’s F-12 (ThermoFisher) medium supplemented with heat-
inactivated Fetal Bovine Serum (Gibco) at a final concentration of 5%, HEPES (Gibco) at 
10mM, Hydrocortisone (Sigma-Aldrich) at 1ug/mL, and Insulin (Sigma-Aldrich) at 5ug/mL.
MCF10a
Cultured with Dulbecco’s modified Eagle’s medium nutrient mixture FG12 
(Invitrogen) supplemented with 5% Horse Serum (Sigma-Aldrich, Dorset, UK), Penicillin at 
50u/mL (Invitrogen), Epidermal Growth Factor at 20ng/mL (Sigma-Aldrich), Hydrocortisone 
at 0.5mg/mL (Sigma-Aldrich), Cholera Toxin at 100mg/mL (Sigma-Aldrich) and insulin at 10 
μg/mL (Sigma-Aldrich).
All cell lines were incubated at 37°C and 5% CO2 in T25 tissue culture flasks 
(Nunc) and were routinely passaged every 4-7 days at split ratios of 1:5-1:10 when they 
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became 90% confluent. Growth media was completely aspirated using a vacuum and cells 
gently washed with PBS. The PBS was removed and 1mL of 0.25% Trypsin/EDTA 
(ThermoFisher) was added to the flask followed by incubation at 37°C for 5-10mins. Once 
cells were detached, the appropriate split ratio was performed by discarding a set amount 
of cell suspension. The remaining volume of cell suspension was made up to 5mLs with 
complete growth medium.
2.1.3 Cell counting and seeding
Cells were trypsinised using 0.25% Trypsin/EDTA and counted using an automated 
Luna cell counter (LogosBiosystems). Single cells were counted by adding 10uL of cell 
suspension to the Luna cell counting slide, and inserted into the machine. Cells were then 
diluted with the appropriate amount of culture medium before being seeded into the 
specific culture plates depending on the assay being performed. 
2.1.4 Long term frozen storage of cell lines
A confluent T75 flask of cells were trypsinised and resuspended in 10mLs of 
complete medium and spun down at 1200RPM for 5 mins. The supernatant was then 
removed and cells resuspended in 5mLs of complete medium containing 10% DMSO 
(Sigma-Aldrich) before being aliquoted into 1mL cryotubes (Nunc) and transferred to a 
freezing container (ThermoFisher). This container was then stored at -80°C overnight and 
cryotubes subsequently transferred to liquid nitrogen for long term storage.
2.1.5 Raising cells lines from frozen storage
Cell lines were transferred from liquid nitrogen storage into dry ice before being 
thawed in a warm 37°C water bath until cells were defrosted. Cell suspension was then 
transferred into a 15mL falcon (Nunc) containing 4mL of complete growth medium and 
centrifuged at 1200RPM for 3 mins. The supernatant was aspirated, pellet resuspended in 
normal growth medium before being transferred into a T25 culture flask and incubated at 
the correct culturing conditions.
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2.2 Transfection and drug treatment of cell lines
2.2.1 Single siRNA transfection
Tubes containing 5nmol of siRNA were briefly centrifuged to collect the pellets at 
the bottom of the tubes. siRNA pellets were resuspended in 250uL of RNase-free 1x 
siRNA buffer to make up the desired final concentration of 20uM. The solutions were then 
placed on an orbital shaker for 30 mins at room temperature before being aliquoted and 
frozen at -20°C. The concentration of siRNA was verified using UV spectrophotometry at 
260nm and 5uM = 66.5 ng/uL.
Transfection of siRNA was performed on cells that reached 70% confluent using 
Lipofectamine 3000 (Invitrogen) and serum-free Opti-MEM (Invitrogen) medium. Different 
volumes of reagent were calculated depending on the total culture medium held by each 
different cell culture plate (Tab. 2.1). The correct volume of siRNA was diluted in Opti-MEM 
in a 1.5mL Eppendorf tube before Lipofectamine 3000 was added. The siRNA mixture was 
then vortexed for 5 seconds and left to incubate at RT for 5 mins. Lipofectamine-siRNA 
complexes were then added on top of adherent cells in the appropriate volume of growth 
medium to give a final siRNA concentration of 20nM (Tab. 2.2). Cells were cultured for 48h 
before harvest. Transfections were controlled for by using a pool of scrambled siRNA 
designed for minimal targeting of human genes, which allowed us to determine the 
baseline cellular response in RNAi experiments. Bcl-3 knockdown efficiency was 
measured by assessing both mRNA and proteins levels following transfection and the final 
siRNA concentration of 20nM resulted in consistent 90% reductions in Bcl-3 expression.
TABLE 2.1 TRANSFECTION CONCENTRATION FOR SIRNA
Tissue culture 
plate type
Culture 
medium
Opti-MEM 
medium
Final siRNA 
concentration
Volume of 
20uM siRNA
Lipofectamine 
3000
12-well 1.125mL 125uL 20nM 1.25uL 2.5uL
6-well 2.25mL 250uL 20nM 2.5uL 5uL
T25 flask 4.5mL 500uL 20nM 5uL 10uL
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TABLE 2.2 SEQUENCES OF SIRNA
2.2.2 Bcl-3 plasmid constructs
Plasmids containing either wild type (WT) Bcl-3 or the Bcl-3 ANK M123 (Fig. 4.1) 
non-binding mutant sequences contained within a FLAG-tagged pcDNA 3.1 backbone 
vector were gifted from Dr. Alain Chariot (Interdisciplinary Cluster for Applied 
Genoproteomics, University of Liège, Belgium).
2.2.3 Tranfection of NFkB reporter and Bcl-3 plasmids
For transfection of the NFkB luciferase reporter or Bcl-3 plasmids, 1 x 104 cells 
were seeded into 12-well plates (Costar) in normal growth media and left to settle 
overnight. Wells were transfected with either 900ng of 3x kB luciferase reporter plasmid 
and 100ng of pcDNA 3.1-LacZ plasmid or 500ng of Bcl-3 plasmid using the appropriate 
amounts of Lipofectamine 3000, p3000 reagent and Opti-MEM (Tab. 2.3).
TABLE 2.3 NFKB LUCIFERASE REPORTER ASSAY TRANSFECTION VOLUMES
2.2.4 Generation of stable overexpression clones
Stably transfected cells overexpressing either WT Bcl-3, the Bcl-3 ANK mutant or 
empty control pcDNA vector were selected by continuous addition of G418 (Sigma) to the 
culture medium. Under selective conditions, resistant cells that carry the plasmid vectors 
siRNA Target sequence (5’-3’) Catalogue Number
Human control ON-Target plus 
SMART pool
UGGUUUACAUGUCGACUAA
UGGUUUACAUGUUGUGUGA
UGGUUUACAUGUUUUCUGA
UGGUUUACAUGUUUUCCUA
D-001810-10 
Human Bcl-3 ON-Target plus 
SMART pool
UGGUUUACAUGUUUUCCUA 
UGGUUUACAUGUUUUCCUA 
GCGCAAAUGUACUCCGGCA 
GCCGGGAGCUCGACAUCUA 
L-003874-00-0005 
Transfection reagent NFkB Reporter WT Bcl-3/ANK/pcDNA plasmids
DNA plasmid 1000ng 500ng
Lipofectamine 3000 2uL 2uL
p3000 reagent 4uL 4uL
Opti-MEM 100uL 100uL
 51
Chapter 2: Materials & Methods
will outgrow the non-resistant cells, resulting in a stable polyclonal population of 
overexpression cells. 500ug/mL of G418 was used to select for resistant cells within the 
first 7 days and subsequently the stable cell lines were cultured in media with 250ug/mL of 
G418.
2.2.5 Drug treatments
Novel small molecule inhibitor compounds, JS6, 15F and CB1 were designed and 
synthesised to disrupt the interaction of Bcl-3 with p50 and p52 homodimers. They were 
synthesised by Cinzia Bordoni, Cardiff University and stored in powder form at RT. Each 
compound was diluted in an appropriate volume of fresh DMSO (Sigma) to a stock 
concentration of 100mM (Tab 2.4). Compounds were then aliquoted and frozen at -20°C 
until use and each compound was discarded following 2 freeze-thaw cycles. When treating 
cells, each compound was diluted in the appropriate volume of complete growth media to 
the required concentration, with DMSO being diluted at the same ration to act as blank 
vehicle controls.
TABLE 2.4 LIST OF NOVEL BCL-3 INHIBITORS
2.3 Cell based functional assays
2.3.1 Migration assays
2.3.1.1 Wound-healing assay
In order to assess collective migration in cancer cell lines, the wound-healing assay 
was performed. Cell were seeded at 1 x 105 cells/well in 12-well plates and left to settle 
overnight. Once cells have reached 70% confluence, they were transfected with Bcl-3 
siRNA and incubated for 48 hours. Two separate wounds were then created on the 
confluent cell monolayer using 200uL pipette tips (Anachem) before culture media was 
gently removed and cells washed with PBS. Fresh media was replaced before place 
Compound Molecular weight DMSO volume per mg Final concentration
JS6 371.41 26.9uL 100mM
CB1 401.43 24.9uL 100mM
15F 383.44 26.1uL 100mM
 52
Chapter 2: Materials & Methods
holder locations were marked on the bottom of the plate using a permanent marker to 
define areas to be recorded. Images were captured on an inverted microscope (Leica) at 
each of the different marks before cells were left to incubate for the appropriate length of 
time relevant for each experiment.
2.3.1.2 Fluoroblok migration assay
In order to assay amoeboid-like single cell migratory capacities of cancer cell lines, 
the Fluoroblok migration assay plate (Corning) was used. Following relevant experimental 
pre-treatment of cells defined by individual experiments, cells were harvested and 
suspended in phenol red free growth medium (Invitrogen) without FBS. Cells were diluted 
to a concentration of 1 x 105 cells/mL and 50uL per well of cells were seeded into the top 
chambers of the 96-well Fluoroblok assay plate. To stimulate chemotaxis migration across 
the pored membrane, 200uL of phenol red free growth medium with 10% FBS was added 
to the bottom chambers. After 24h incubation, the top and bottom chambers were 
detached and the growth medium removed from the bottom wells. The top chamber was 
then carefully reassembled and 200uL of 1uM Calcein AM (eBioscience) in PBS was 
added to the bottom chambers and incubated for 1 hour at 37°C. Post-incubation the 
fluorescence intensity of each well was read at 500nm from the bottom side using the 
Clariostar plate reader (BMG Labtech).
2.3.1.3 Single cell migration assay
In order to assess the mesenchymal-like single cell migratory capacities of cancer 
cell lines, the ability of singular cancer cells were monitor in real-time. Cells were seeded 
into 6-well plates at a density of 1 x 105 cells/well and left to settle overnight before being 
treated with siRNA for 48h. Cells were then removed, counted and re-seeded in Leibovitz’s 
L-15 medium (Invitrogen), at a low density of 5 x 104 cells/well into 12-well plates. Once 
cells have settled overnight, they were placed into a time-lapse incubation chamber (Leica) 
pre-warmed to 37°C with 5% CO2 and left to equilibrate for 1 hour. Each well was then 
located using the “mark and find” software tool, 4 different areas tracked and cells were 
monitored over a period of 18 hours with photos being taken every 10 minutes. The first 50 
images equating to 8 hours of elapsed time, was exported as a .tiff image sequence, which 
were then converted into an 8-bit grayscale image sequence using ImageJ. The sequence 
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was then opened in the CellTracker software and cell movement tracks for each cell 
quantified and analysed manually.
2.3.2 Colony formation assay
This assay tested the clonogenicity of individual cancer cells and assessed their 
ability to survive, proliferate and clonally expand into small colonies. Cells were seeded at 
the low density of 250 cells/mL in 6-well format in complete growth medium and incubated 
for 10 days. Quantification of colonies involved aspiration of culture media, washing the 
cells gently with PBS, followed by fixation of colonies with glutaraldehyde (6% v/v) and 
staining with crystal violet (0.5% w/v) for 15mins at RT. The crystal violet solution was then 
removed and cells were thoroughly washed under running tap water to completely remove 
excess staining. Colonies were then imaged and quantified using the GelCount plate 
reader.
2.3.3 CellTiter-Blue assay
The CellTiter-Blue cell viability assay (Promega) is a homogenous, fluorescence 
based method for assessing cell viability. This reagent assayed the ability of living cells to 
convert a redox dye, resazurin, into the fluorescent end product resorufin. Nonviable cells 
rapidly lose metabolic capacity and thus do not generate a fluorescent signal. The assay 
involved adding a single nontoxic reagent directly to the medium of cultured cells and after 
an incubation step of 1 hour at 37°C, viability data is recorded using a plate reader based 
on the intensity of fluorescence at 560/590nm. 20uL of reagent was added for every 100uL 
of growth medium.
2.3.4 Realtime-glo assay
The RealTime-Glo MT Cell Viability Assay (Promega) incorporates non-lytic 
NanoLuc Luciferase and MT Cell Viability substrates to cell media during time of plating. 
The assay reagents then diffused into cells where it was reduced to form a NanoLuc 
substrate, which exited the cells and was used by NanoLuc Luciferase in the media. This 
assay was used to quantify cell population growth because metabolically active cells could 
reduce the substrate and light produced was directly proportional to the number of viable 
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cells in culture. The non-lytic and rapid response of the assay allowed for accurate and 
continued measurements of cell proliferation over time.
2.3.5 NFkB luciferase reporter assay
The NFkB activity of cells was quantified using a luciferase reporter plasmid. Cells 
were transfected with the reporter using conditions previously mentioned (Refer to 2.2.2) 
following Bcl-3 siRNA knockdown or inhibitor treatment. Cells were seeded into clear 
bottom black walled 96-well plates (Corning Inc., Lowell, US) in antibiotic free culture 
media (1-2x105 cells/mL). After 24 hours, cells were transfected with reporter plasmids 
using Lipofectamine LTX reagent (Invitrogen) according to manufacturer’s protocol. The 
NFκB reporter plasmid pLTRX-Luc (10 ng/well) was used with pcDNA3.1-LacZ plasmid 
(10 ng/well) to normalize for transfection efficiency. For positive and negative controls 
respectively, 10ng of pGL3control or pGL3basic were transfected in place of the reporter 
plasmid.	After 48 hours post-transfection cell were lysed using Glo-lysis buffer and 
analysed using Beta-glo and Bright-glo according to manufacturer’s protocol (Promega).	
Luminescence relative to LacZ was read using a Flurostar Optima plate reader (BMG 
Labtech) and displayed as relative light units (RLU).
2.3.6 DAPI cell cycle assay via flow cytometry
In order to determine cell cycle progression, flow cytometry was used to sort based 
on the intensity of the nuclear DNA marker DAPI. This allows us to determine the total 
DNA content of each individual cell, and this data can be aggregated to calculate the 
stages of the cell cycle. Cells were harvested, counted and diluted in PBS to a 
concentration of 1 x 106 cells/mL, cells were then pelleted and resuspended in 5uL/mL 
DAPI solution (ThermoFisher Scientific) in 0.01% IGEPAL CA-630 (Sigma) in PBS and 
incubated for 5 mins at RT. Cells were stored on ice and shielded from light.
Before DAPI stained cells were analysed, each sample was filtered through a 40um 
cell strainer (BD Biosciences) into flow cytometry collection tubes (BD) to ensure a robust 
single cell suspension. Flow cytometry was carried out on the LSRFortessa flow cytometer 
(BD) and analysed using the FlowJo software. Cells were gated by FSC-area/SSC-area 
and by FSC-area/FSC-height in order to obtain a single cell population and remove 
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artefacts and doublets. Single cells were then analysed by plotting histograms using the 
DAPI-area curves to determine the DNA content of the cell.
2.3.7 Caspase-glo -3/-7 assay
	 The Caspase-Glo 3/7 assay (Promega) is a homogenous, luminescent assay that 
measured caspase-3 and -7 activities. The assay contained a pro-luminescent 
caspase-3/7 substrate with the tetrapeptide sequence DEVD, in a reagent optimised for 
caspase activity, luciferase activity and cell lysis. Cleavage of substrate released 
aminoluciferin and resulted in the production of light and luminescence was proportional 
to the amount of caspase activity present. Media was aspirated from wells of a 96-well 
plate and 50uL of caspase-glo was added per well, which lysed the cells and allowed 
luminescence representative of caspase activity to be measured using a plate reader.

2.3.8 Mammosphere assay
A reliable and cost efficient assay involving the formation of anoikis resistant 
mammospheres is able to demonstrate the presence of a stem-like cell population. 1 x 103 
cancer cells were disaggregated and transferred from an adherent monolayer setting into 
a non-adherent, serum-free epithelial growth medium (MEBM, Lonza, Slough, UK), 
supplemented with B27 (Invitrogen), 20 ng/ml EGF (Sigma), Insulin (Sigma), and 
hydrocortisone (Sigma), in a 96-well condition. After at least 7 days incubation, the number 
of mammospheres formed were imaged and quantified.
2.4 Protein analysis
2.4.1 Protein extraction from cells
Cell were chilled on ice, media was completely aspirated and an appropriate 
amount of ice-cold PBS was added. Cells were mechanically removed using a cell scraper 
and pelleted at 1200RPM at 4°C for 5 mins, supernatant was discarded. Cells were either 
stored at -80°C or protein extraction carried out immediately with the addition of an 
appropriate amount of RIPA buffer (150mM sodium chloride (Fisher Scientific), 1% v/v 
Nonidet-P40 (Roche), 0.5% w/v sodium deoxycholate (Sigma), 0.1% w/v sodium dodecyl 
sulphate (SDS; Sigma), 50mM Tris (Sigma), pH8) containing 1:100 protease and 
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phosphatase inhibitor cocktail (Cell Signalling Technologies, MA, USA) and incubated on 
ice for 30 minutes. Lysate was then centrifuged at 13k RPM for 15 minutes at 4°C to pellet 
cell debris and the protein supernatant was aliquoted into fresh tubes for protein 
quantification. 
For coIP: Adherent cell lines were cultured in 60mm dishes under normal conditions 
prior to protein harvest. Aspirate cell culture media, wash cells with ice cold PBS, discard 
PBS and repeat wash; keeping cells chilled on ice at all times. Add 1mL of PBS, scrap 
cells, transfer to 1.5mL micro-centrifuge tube and spin pellet cells at 4°C. Discard PBS and 
re-suspend cell pellet in 400uL of pre-chilled lysis buffer (20mM HEPES pH7.9, 100mM 
NaCl, 20% glycerol, 1mM MgCl2, 0.5mM EDTA, 0.1mM EGTA, 1% NP-40). Place on ice 
for 30-45 mins and pellet insoluble material by centrifugation at 13k RPM for 10 mins at 
4°C. Remove and store the total protein lysate supernatant at -80°C.
2.4.2 Nuclear and cytoplasmic protein extraction
Cell pellets were resuspended in 200uL of NEBA buffer (10mM HEPES pH7.9, 
10mM KCl, 0.1mM EDTA pH8, 0.1mM EGTA pH8) with protease inhibitors and incubated 
on ice for 15 mins. 10uL of 10% NP-40 were added and samples vortexed for 30 sec. 
Samples were then centrifuged at 10k RPM for 30 sec and the resulting supernatant is the 
cytoplasmic protein fraction. 100uL of NEBC buffer (10% glycerol, 20mM HEPES pH7.9, 
0.4M NaCl, 1mM EDTA pH8, 1mM EGTA pH8) was added to the resulting invisible protein 
pellet, vortexed and placed on ice for 30 mins. This was then spin at 13k RPM at 4°C for 5 
mins and resulting supernatant will be the nuclear protein fraction. Measure the protein 
concentration of the cytoplasmic protein fraction using the BCA assay and the nuclear 
protein fraction using the Bradford assay.
2.4.3 Quantification of protein
Protein concentrations were determined using the Pierce BCA protein assay kit 
(ThermoFisher Scientific) according to the manufacturers instructions. Protein standards 
were prepared by diluting 2mg/mL BSA in PBS to produce a range of 7 known 
concentrations (2mg/ml, 1mg/ml, 0.5mg/ml, 0.25mg/ml, 0.125mg/ml, 0.0625mg/ml, and 
0mg/ml) and 10μL of these standards or of sample were added to 100μL of solution 
containing BCA protein assay reagent A and BCA protein assay reagent B in a ratio of 50:1 
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in a 96 well plate. Samples were mixed and then incubated at 37°C for 30 minutes before 
being analysed on a Flurostar Optima plate reader (BMG Labtech, Bucks, UK) at 562nm. 
The standards were used to generate a standard curve from which the concentration of 
protein in each sample could be extrapolated.
2.4.4 Coimmunoprecipitation
Prepare 75mg protein A-sepharose bead (GE Healthcare Life Sciences) suspension 
in 50mL of water. Spin down at 13k RPM for 3 mins and repeat suspension-spin process 
once more. Resuspend beads in 2mL of water and store at 4°C. Pre-clear cell lysates by 
adding 100uL of bead suspension to 200uL of lysates; agitate at 4°C for 30-45 mins. Spin 
down at 13k RPM for 3 mins and transfer supernatant, discarding pelleted beads. Add 
10uL of Bcl-3 primary antibody and 5uL of p50 antibody to separate aliquots of 100uL 
lysate. Incubate overnight at 4°C under agitation.
Add 100uL of bead suspension to each lysate and incubate at 4°C under agitation 
for 2h. Spin down at 13k RPM for 3 mins and aspirate supernatant. Re-suspend beads in 
1mL of lysis buffer and re-spin down and aspirate supernatant. Repeat this wash 2 more 
times. After the final wash add the appropriate 5x Laemmli buffer, mix and boil at 95°C for 
5 mins.
2.4.5 Western Blotting
2.4.5.1 Protein sample preparation
25μg of protein was diluted in RIPA buffer to a final volume of 8μL. 2 μL of 5x 
laemmli buffer (0.125M Tris-HCL pH6.8, 4% w/v SDS, 40% v/v glycerol, 0.1% w/v 
bromophenol blue (Sigma), 6% v/v beta- mercaptoethanol (Sigma) in ddH20) was added 
to each sample. Prior to gel loading, the samples were heated to 95°C for 5 minutes to 
denature proteins. 
2.4.5.2 Gel electrophoresis
Precast gels were purchased from BioRAD (4–20% Mini-PROTEAN® TGXTM 
Precast Protein Gels) and placed in the Mini-Protean III (Bio-Rad) electrophoresis tank 
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and immersed in Tris-Glycine-SDS running buffer (Biorad). Protein molecular weight 
marker (PageRuler, ThermoFisher) was loaded into the first and last lane of each gel and 
prepared protein samples were loaded into the appropriate remaining wells. The samples 
were resolved down gels for approximately 45-60 minutes at 150V until the dye front 
reached the bottom of the gel. 
2.4.5.3 Membrane transfer
After electrophoresis, gels were removed carefully from plastic cassettes using a 
specific tool (BioRad). They were kept moist by dripping running buffer onto them and 
excess gel was trimmed. They were then placed into a membrane system purchased from 
BioRAD in the correct orientation (Trans- Blot® TurboTMPVDF, BioRAD) before being 
rolled to remove any air bubbles in Trans-Blot® TurboTM Transfer System (BioRAD) 
Cassettes. Cassettes were then placed in to the Trans-Blot® TurboTMSystem and run on 
a MIXED MW protocol for 7 minutes. 
2.4.5.4 Blocking and primary antibody incubation
Once Western transfer is completed, sandwiches were disassembled and 
membranes washed 3 x 5 mins in PBST (1 x PBS solution (Fisher): 5 tablets 500mL dH2O 
with 0.5mL Tween (Sigma)) before being incubated in blocking buffer (5% w/v non-fat milk 
powder (Marvel): 0.75g in 15 mL PBST per transfer membrane) with agitation for 1h. The 
membranes were then transferred to 30mL universal tubes (Fisher) containing 2mL of the 
desired primary antibody (Tab. 2.5) diluted in 5% w/v non-fat milk powder (Marvel) in 
PBST. Membranes were incubated in the primary antibody solution overnight at 4 C̊ on a 
roller. 
TABLE 2.5 PRIMARY ANTIBODIES USED IN WESTERN BLOTTING
Antibody Dilution Supplier Species Molecular Weight
Bcl-3 1:200 Proteintech (23959-1-AP) Rabbit Polyclonal 48-60kDa
p50 1:500 Cell Signalling #3035 Rabbit 50kDA active
120kDA precursor
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2.4.5.5 Detection and quantification
Membranes were then washed 3 x 5 mins in PBST and transferred to a 30mL tube 
containing 2mL of the appropriate rabbit horseradish peroxidise-conjugated secondary 
antibody (Dako) diluted 1:2000 in 5% BSA in PBST. Membranes were incubated in 
secondary antibody at room temperature for 1 hour on a roller. Finally, membranes were 
washed 3 x 5 mins in PBST. Antibody binding was detected using ECL prime detection 
reagent (Amersham) before being developed in a BioRad Chemidoc MP Imaging System. 
Digital images were then quantitated by densitometry using the program Image J.
2.4.6 Immunofluorescence
Cells were plated into wells of a 24-well plate atop an ethanol-UV sterilised glass 
coverslip and allowed to seed overnight. The culture media was then removed, cells gently 
rinsed with PBS before fixation with 500uL of warm PBS diluted 4% formaldehyde for 15 
mins at room temperature. The fixative was then aspirated and cells rinsed three times 
with PBS for 5 mins each time. Cells were then permeabilised and blocked in 300uL 1% 
BSA PBS/Triton 0.3% for 1h to minimise background staining. Following blocking, the 
blocking solution was replaced with 300uL of primary antibody (Tab. 2.6) made up in 
blocking buffer and incubated overnight at 4C on a rocker. The primary antibody was then 
aspirated and cells rinsed three times in PBS 5 mins each time. Cells were then incubated 
with 300uL fluorochrome-conjugated secondary antibody diluted in blocking buffer for 1-2h 
in the dark at room temperature. Following secondary incubation cells were rinsed once 
more with PBS for 5 mins and stained with DAPI (5uL/mL) diluted in PBS for 20 mins at 
room temperature. Cells were rinsed three times with PBS, coverslips were dip rinsed in 
water before being mounted onto glass slides on top of 2uL of Mowiol (Sigma-Aldrich) 
mounting solution.
TABLE 2.6 LIST OF ANTIBODIES USED FOR IMMUNOFLUORESCENCE
Antibody Dilution Species Origin
Ki67 1:200 Mouse monoclonal NCL-L-Ki67-MM1 (Leica Novocastra)
Phospho-Histone (Ser10) H3 1:400 Rabbit #9701 (Cell Signalling)
Anti-mouse 488 1:200 Goat Abcam
Anti-rabbit 488 1:200 Goat Abcam
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2.5 RNA analysis
2.5.1 RNA extraction
Harvested cells were pelleted at 1200RPM for 5 mins before being lysed in 350uL 
of RLT buffer (Qiagen) and placed on ice for immediate RNA extraction or stored frozen at 
-80°C. RNA extraction was performed using the Qiagen RNEasy kit following the exact 
manufacturer instructions. The concentration and purity of RNA was analysed using a 
nanodrop 3000 spectrophotometer (Thermo Scientific).
2.5.2 cDNA synthesis
Previously extracted RNA was synthesised into cDNA using the QuantiTect Reverse 
Transcription kit (Qiagen). Frozen RNA template was thawed on ice along with the gDNA 
Wipeout buffer, Quantiscript Reverse Transcriptase, Quantiscript RT buffer and RT primer 
mix. 1ug of RNA was diluted in 2uL of gDNA Wipeout buffer and RNase-free water to a 
total volume of 14uL and incubated for 2 mins at 42°C before being placed immediately on 
ice. The master mix (Tab 2.7) was used for each reaction and incubated for 30 mins at 
42°C followed by 3 mins at 95°C to inactivate the reverse transcriptase. The cDNA product 
was then either immediately used or stored at -20°C.
TABLE 2.7 CDNA SYNTHESIS MASTER MIX REAGENTS
2.5.3 Quantitative-real time-polymerase chain reaction (qRT-
PCR)
2.5.3.1 Primer acquisition
All primers were bought from ThermoFisher Scientific from their online inventoried 
TaqMan gene expression assay search tool and were selected to target human sequences 
(Tab. 2.8). Each primer was chosen to carry a FAM-reporter dye with the exception of 
Component Volume per 1ug reaction
Quantiscript Reverse Transcriptase 1uL
Quantiscript RT Buffer, 5x 4uL
RT Primer Mix 1uL
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ACTB controls, which carried the VIC-reporter dye, so multiplex PCR reactions could be 
performed.
TABLE 2.8 TAQMAN GENE EXPRESSION ASSAY PROBES
2.5.3.2 qRT-PCR reaction
All qRT-PCR reactions were designed to incorporate both the target gene probe as 
well as the ACTB control probe. This control was selected as a housekeeping gene and its 
expression levels are generally found to remain constant across different cell lines and can 
therefore be used to normalise target application based on the amount of cDNA added. A 
RNase-free water reaction with no templates was also run alongside to control for the 
presence of DNA contamination.
The TaqMan Universal Master Mix II, with UNG (ThermoFisher Scientific) was used 
in each experiment and this includes the AmpliTaq gold DNA polymerase, dNTPs (with 
dUTP), ROX passive reference dye, Uracil-N glycosylase (UNG) and optimised buffer 
components, The TaqMan master mix was added to the target and ACTB probes as well 
as enough RNase-free water to make up each individual target condition (Table 2.9). 
Either 18uL or 8uL of master mix was added to either 96 or 384-well plates before cDNA 
was added to each well.
Gene target Assay ID
Bcl-3 Hs00180403_m1
ACTB Hs99999903_m1
TNFA Hs00174128_m1
IL1B Hs01555410_m1
FOS Hs00171851_m1
EGR1 Hs00152928_m1
ESM1 Hs00199831_m1
IL6 Hs00985639_m1
CDH2 Hs00983056_m1
MDM2 Hs00540450_s1
IL10 Hs00961622_m1
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Once all components were added then the plates were sealed with Micro AMP 
optical adhesive film (Applied Biosystems) before being shaken for 30 seconds and spun 
down for 1 min at 1200RPM. Assay plates were then run on a QuantStudio 7 Real-Time 
PCR machine (Applied Biosystems) set to: initial denaturation at 95°C for 10 mins, 40 
cycles of 95°C for 15 seconds (denaturation), and 60°C for 1 minute (annealing/
elongation).
TABLE 2.9 QRT-PCR REACTION COMPONENT MIX
2.5.3.3 qRT-PCR data analysis
Data retrieve from the QuantStudio 7 can be directly uploaded to the Thermo cloud 
service which allows use to view relative gene expression quantification once a reference 
sample is selected. The target Ct values are subtracted from ACTB control Ct values for 
each individual well to create a ΔCt value, which is then averaged by the experimental 
triplicates for each sample. The relative value for the difference in transcription between 
samples can then be calculated as a difference between the ΔCt of samples and a 
reference sample, giving us the ΔΔCt value. This value is then calculated as 2-ΔΔCt to 
give us the relative fold change which can then be transformed to a log10 scale. Statistical 
significance is derived by assessing the overlap between the 95% confidence intervals.
2.6 Animal experiments
2.6.1 Licensing
All animal procedures were carried out in accordance with guidelines set by the UK 
Home Office in compliance with the Animals Scientific Procedures Act of 1986 under the 
UK HO personal licence number: I20ACBDE4
qRT-PCR component Volume per well for 96-well 
plate
Volume per well for 384-well 
plate
Target primer probe 20x (FAM) 1uL 0.5uL
ACTB primer probe 20x (VIC) 1uL 0.5uL
TaqMan master mix 2x 10uL 5uL
RNase-free water 6uL 3uL
cDNA 2uL 1uL
Total 20uL 10uL
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2.6.2 Animals
For immune-compromised animal xenograft experiments, Athymic Nude 
(Hsd:Athymic Nude-Foxn1nu) mice were obtained from Harlan Laboratories (Indianapolis, 
US). Animals were acquired at six to eight weeks of age and maintained in individually 
ventilated cages (Allentown Inc. NJ, US) with a 12hr day/night cycle. Mice received a 
Teklad global 19% protein extruded rodent diet (Harlan Laboratories) and water ad libitum. 
All food, drink, saw dust and water bottles were sterilised by autoclaving prior to use. All 
procedures and animal husbandry was performed within a laminar flow hood (Allentown). 
2.6.3 Experimental models
2.6.3.1 Subcutaneous orthotopic xenograft tumour model
Prior to transplantation, cells were either treated under the conditions of interest or 
grown to 70-80% confluency before being trypsinised and disaggregated into single cell 
suspension. Cells were washed in 5mLs RPMI media containing no additives (Invotrogen, 
Paisley, UK) and spun at 1200RPM for 5 minutes three times before being prepared at the 
required concentrations (1x106 cells in 100μl) in a mix of 50% RPMI with no additives and 
50% Matrigel (ThermoFisher) that had been thawed overnight at 4°C and kept on ice until 
transplantation. Cells were injected in the subcutaneous tissue bilaterally on the dorsum 
of mouse and allowed to grow.

2.6.3.2 Tail vein xenograft tumour model
	 Experimental metastases were established by intravenous injection of 2×105 MDA-
MD-231-Luc cells. Cells were suspended in 100 μL of RPMI media and injected via the 
tail vein of 8-week old female Hsd: Athymic Nude-Foxn 1nu mice (Harlan Laboratories) 
2.6.4 In vivo treatment of mice
For some experiments mice were treated in vivo with either JS6, 15F, CB1 or 
DMSO control. Mice were also treated with Bcl-3 inhibitors at a concentration of either 
3.5mg/kg via intraperitoneal injection or 20mg/kg via oral gavage. These dosing regimes 
were determined through outsourced pharmacokinetics experiments investigating the drug 
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concentration in circulating plasma over time. Drugs were prepared by diluting powdered 
compound in DMSO. The DMSO was controlled for by using the same concentration of 
DMSO injected into mice at the same time. Mice were weighed and drug dose determined 
by the relative animal weight (Tab. 2.10). 
TABLE 2.10 INJECTED DRUG VOLUME BASED ON ANIMAL WEIGHT FOR 3.5MG/KG
2.6.5 Tumour monitoring and measurements
Mice were inspected at least twice weekly for tumours via palpation and 
measurements were taken with digital calipers (Fisher Scientific, Loughborough, UK). The 
size of tumours was calculated as volume in mm3 using the formula: Volume = (Length x 
(Width2))/2.
2.6.6 Imaging of luciferase expressing tumour metastasis 
model
Metastatic progression to distal organs was assessed through bioluminescence 
imaging with the IVIS Spectrum In Vivo Imaging System (Perkin Elmer). Prior to imaging, 
an intraperitoneal injection of 100μL D-luciferin was administered to each animal. The mice 
were then anaesthetised with 2.5% isoflurane, oxygen mix and imaged with the charge-
coupled IVIS camera device selecting an exposure time of 2 minutes. Luminescence 
signal was measured through region of interest selection and quantified as total flux 
Mouse weight (g) Volume of CB1 (uL)
17 148
18 157
19 166
20 174
21 183
22 192
23 201
24 209
25 218
26 227
27 235
28 244
29 253
30 262
31 270
32 279
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(photon count) overlaying corresponding grayscale photographs (Fig. 5.10) and composite 
images were analysed using the Living Image software (Xenogen Bioscience Corp).
2.7 Affymetrix DNA Microarray GeneChip array analysis
Affymetrix Exon Expression experiment analysis was carried out in the GeneSpring 
GX Pathway Architect software. The ExonRMA summarisation algorithm was performed 
on all projects with the baseline set to the median of all samples. The samples were quality 
checked by assessing the PCA values to ensure appropriate clustering. Probe sets were 
filtered based on their signal intensity values and 43590 out of 48144 entities had values 
between 20 and 100 percentile for Bcl-3 knockdown experiment and 43889 out of 48144 
for CB-1 drug treatment experiment. The Benjamini and Hochberg False Discovery Rate 
multiple testing correction was performed to determine corrected p-values and entities 
were filtered based on a cut-off of p-value<0.05. 4229 out of 43590 entities satisfied the 
corrected p-value cut-off for Bcl-3 knockdown experiment and 127 out of 43889 for CB-1 
drug treatment experiment.
2.7.1 Gene function analysis with the PANTHER classification 
system
The PANTHER website was accessed at http://www.pantherdb.org. The input file 
was prepared as a simple text file (.txt) with gene symbols as the first column and log fold 
change values as the second column in order to use the statistical enrichment test. The 
gene list was uploaded to the PANTHER tool system and homo sapiens was selected as 
the list type. The appropriate test type was then selected and analysis carried out.
2.8 Statistical analysis
Error bars on all graphs represent standard error of the mean. Unpaired student’s T-
tests were performed within the GraphPad Prism software unless stated otherwise to 
query statistical significance for all normally distributed data sets. 
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3.1 Introduction 
	 B-cell lymphoma 3 (Bcl-3) is a proto-oncogene in the region adjacent to the 
t(14;19) (q32; q13) translocation first identified in a subset of patients with chronic 
lymphocytic leukaemia (CLL) (Ohno et al., 1990). Bcl-3 binds to p50 and p52 dimers on 
DNA, providing these complexes with a transactivation domain which subsequently drives 
transcription (Bours et al., 1993). Bcl-3 has been implicated in both innate and adaptive 
immunity (Zhang et al., 2007). In numerous hematopoietic and solid tumours, including 
breast cancer, Bcl-3 has been shown to be up-regulated and associated with tumour 
development and progression (Maldonado and Melendez-Zajgla, 2011).

	 Bcl-3 is often highlighted as an oncogene through its regulation of cell cycle or 
apoptosis at the gene expression or protein level during cancer development. The 
cylindromatosis (CYLD) protein binds and deubiquitinates Bcl-3 and prevents its nuclear 
accumulation. In cylindromas and other cancers featuring reduced CYLD, increased 
nuclear Bcl-3 accumulation induces transcription of genes such as cyclin D1 and N-
cadherin through interactions with p50 and p52 homodimers (Massoumi et al., 2009). 
Bcl-3 has also been shown to stabilise the c-Myc protein and promote colorectal cancer 
development by regulating ERK signalling (Liu et al., 2013). Bcl-3 was further reported to 
promote colorectal tumourigenesis through activation of AKT signalling (Urban et al., 
2016). These studies demonstrate the various novel roles Bcl-3 has in tumour 
development and progression by being a trans-activator or trans-repressor within NFkB 
signalling pathways. A recent study has demonstrated the ability of Bcl-3 to regulate 
metastasis of mouse mammary cancer cells. Bcl-3 knockout MMTV-Neu mice had 
significantly reduced secondary lung metastasis with no effect on primary tumour growth 
(Wakefield et al., 2013). This was supported by Chen et al., who confirmed that Bcl-3 
played a role in pulmonary metastasis in human breast cancer. Despite numerous studies 
highlighting the oncogenic properties of Bcl-3 up-regulation, and the identification of 
oncogenic pathways associated with Bcl-3 mediated oncogenesis (Chen et al., 2016), the 
underlying cellular mechanisms surrounding its oncogenicity remains largely unknown.

	 Triple-negative breast cancers (TNBC) are characterised by tumours that do not 
express oestrogen receptor (ER), progesterone receptor (PR), or HER2 receptors. They 
represent real clinical challenges, as these cancers do not respond well to traditional 
endocrine therapy or targeted agents. Typically, TNBCs feature earlier metastatic events 
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compared with other breast cancer subtypes, as well as a shorter period from the time of 
recurrence until death (Kim et al., 2009). This presents a hurdle for clinicians who are 
tasked with palliating an incurable disease and extending patient life when possible.

	 Given the previously published association between Bcl3 and metastatic breast 
cancer (Chen et al., 2016), the main aims in this chapter were to further explore and 
characterise the roles of Bcl-3 in human cancer progression, specifically in the context of 
TNBC, an aggressive, increasingly metastatic subtype of human breast cancers that often 
features poor clinical prognoses. We investigated the effects of Bcl-3 siRNA knockdown 
in a panel of four human triple negative breast cancer cell lines, contrasted with one 
nonmalignant human mammary epithelial cell line. Following Bcl-3 knockdown, we looked 
at the biological outcomes in a number of in vitro cell-based assays to quantify cell 
population change, proliferative markers, cell cycle, apoptosis, stemness, clonogenicity, 
migration and NFkB activity. We also carried out an in vivo xenograft experiment to 
assess the effect of Bcl-3 suppression in a mouse metastasis model. An Affymetrix 
microarray experiment was subsequently performed to profile global gene expression 
changes and help explain and piece together mechanisms pertaining to these biological 
outcomes. 

3.2 Bcl-3 expression in breast cancer cell lines 
	 A panel of triple negative breast cancer cell lines, MDA-MB-436, SUM149, MDA-
MB-231 and the highly metastatic MDA-MB-231 sub-line MDA-MB-231-Luc were 
selected and their relative Bcl-3 protein (Fig. 3.1a) and RNA (Fig. 3.1b) expression levels 
were profiled by western blotting and qRT-PCR. We chose these experimental cell lines as 
they are all extensively studied and well characterised in the current literature and 
provided good representation for modelling TNBCs. The HER2+ HCC1954 cell line which 
was found to features comparatively high Bcl-3 expression in our previous studies was 
used as a positive control. Within the triple negative cell lines, MDA-MB-436 expressed 
the highest Bcl-3 levels, followed by MDA-MB-231-Luc with just less than half Bcl-3 RNA 
levels, followed by MDA-MD-231 with another halving, and finally SUM149 have similar 
Bcl-3 levels to MDA-MD-231. The non-malignant MCF10a cell line expressed the lowest 
quantities of Bcl-3.
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3.3 Bcl-3 siRNA knockdown had no observable effects on bulk 
cellular monolayer morphology and knockdown was stable up 
to 96h 
	 We were interested in whether Bcl-3 knockdown had any discernible effects on the 
monolayer morphology of the cell lines through bright-field phase-contrast microscopy. It 
was also important to optimise and confirm the duration of Bcl-3 knockdown as siRNA 
only has a transient effect and wears off over time.

	 The five chosen breast cancer cell lines were each transfected with either Bcl-3 or 
scrambled control siRNA for 48h, 72h or 96h, before being imaged by bright-field 
microscopy and total cellular RNA was harvested (Fig. 3.2). qRT-PCR for Bcl-3 was then 
performed for each time-point and Bcl-3 expression was shown to be significantly 
lowered at all time-points up to 96h. Thus suppression of Bcl3 by siRNA was stable for up 
to 4 days. The time taken for levels to return to normal was not determined.

	 Each cell line exhibited distinct cellular morphologies. MDA-MB-436 cells (Fig. 
3.2a) appeared fibroblastic, displaying a mesenchymal-like morphology with hyper-
elongated cellular processes and an almost complete lack of cell-cell adhesion, traits 
which are associated with highly migratory cells. SUM149 cells (Fig. 3.2d) had a more 
‘cobblestone’-like appearance in confluency, similar to MCF10A (Fig. 3.2e), with clear 
evidence of cell-adhesions, while MDA-MB-231 subtypes (Fig. 3.2b&c) had an 
intermediate mesenchymal-like morphology. Bright-field images taken at 96h showed no 
significant cellular morphological differences between Bcl-3 knockdown and that of the 
scrambled control in any of the cell lines tested.
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FIG. 3.1 RELATIVE BCL-3 PROTEIN AND RNA EXPRESSION IN BREAST CANCER CELL LINES. 
a. Cell lines were cultured under standard conditions and total protein extraction and western 
blotting for Bcl-3 was carried out, using GAPDH as the loading control. Average relative 
densities are estimated. Image shown is representative of 3 independent westerns. b. Total 
cellular RNA was extracted and Bcl-3 expression quantified using Taqman qRT-PCR and relative 
gene expression normalised to beta-actin (ACTB). Error bars represent ±SEM of 3 independent 
experiments.
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FIG. 3.2 BCL-3 SIRNA KNOCKDOWN HAD NO EFFECTS ON BULK MONOLAYER MORPHOLOGY 
AND KNOCKDOWN WAS STABLE UP TO 96H 
Representative bright-field microscopy images following 96h knockdown with either Bcl-3 or 
scrambled control siRNA and qRT-PCR for Bcl-3 RNA expression following 48h, 72h or 96h 
knockdown for a. MDA-MB-436 b. MDA-MB-231-Luc c. MDA-MB-231 d. SUM149 e. MCF10a 
breast cancer cell lines. Error bars represent ±SEM of 3 independent experiments.
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3.4 Bcl-3 siRNA knockdown significantly reduced cell 
population growth in TNBC cell lines but not in the non-
malignant MCF10a cell line 
	 One of the primary characteristics of an oncogene is the ability to promote cell 
population growth and it is known that Bcl-3 positively drives proliferation in a number of 
different cancer types (Maldonado and Melendez-Zajgla, 2011). Therefore we 
hypothesised that knocking it down will inhibit growth in TNBCs.

	 The breast cancer cell line panel were transfected with either Bcl-3 or scrambled 
control siRNA for 48h, plated into assay plates and cell population growth measured 
using RealTime-Glo MT Cell Viability Assay (Promega). In this assay, non-lytic NanoLuc 
Luciferase and MT Cell Viability substrates were added to cell media during time of 
plating. The assay reagents then diffused into cells where it was reduced to form a 
NanoLuc substrate, which exited the cells and was used by NanoLuc Luciferase in the 
media. This assay was used to quantify cell population growth because metabolically 
active cells could reduce the substrate and light produced was directly proportional to the 
number of viable cells in culture. The non-lytic and rapid response of the assay allowed 
for accurate and continued measurements of cell proliferation over time.

	 By 72h all four TNBC cell lines showed a significant reduction in cell population 
growth following Bcl-3 siRNA knockdown (Fig 3.3a-d). This growth effect was most 
prominent in the MDA-MB-231 (Fig 3.3c) and MDA-MB-231-Luc (Fig 3.3b) cell lines as 
significant cell growth reductions could already be seen from 24h and 48h respectively. 
There was no growth reduction in the non-malignant MCF10a cell line following Bcl-3 
siRNA knockdown (Fig. 3.3e).
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FIG. 3.3 BCL-3 SIRNA KNOCKDOWN REDUCED CELL POPULATION FOLD CHANGE OVER TIME 
RELATIVE TO THE SCRNA CONTROL 
a. MDA-MB-436 b. MDA-MB-231-Luc c. MDA-MB-231 d. SUM149 e. MCF10a cell lines were 
knockdown with either Bcl-3 or scrambled control siRNA for 48h, plated into 96-well plates and 
cell population growth assayed using RealTime-Glo Assay. The results at each timepoint were 
normalised to their corresponding values at 0 hours and plotted as cell population fold change 
increases over time. f. Graph comparing cell population growth between different cell lines. Error 
bars represent ±SEM of 3 independent experiments. (T-test, *=p<0.05, **=p<0.01, ***=p<0.001)
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3.5 Bcl-3 siRNA knockdown significantly reduced Ki67 
expression in TNBC cell lines but not in the non-malignant 
MCF10a cell line 
	 To confirm whether the effects on growth seen in the cell viability assay manifested 
in a reduction in cell proliferation, we investigated the proportion of cells undergoing cell 
division. Ki67 is a nuclear protein associated with cellular proliferation and a commonly 
used proliferative marker (Scholzen and Gerdes, 2000). Ki67 is present during all active 
phases of the cell cycle (G1, S, G2, and mitosis), but is absent in resting or quiescent cells 
(G0) (Bruno and Darzynkiewicz, 1992). Cellular content of Ki67 protein markedly increases 
during cell progression through S phase (Darzynkiewicz et al., 2015).

	 The breast cancer cell line panel were transfected with either Bcl-3 or scrambled 
control siRNA for 48h, plated onto coverslips, PFA fixed and immunofluorescence staining 
for Ki67 was performed. Bcl-3 knockdown significantly reduced the fraction of Ki67 
positive cells in all TNBC cell lines but had no effect on the non-malignant MCF10a cell 
line, which comparatively had a much lower basal Ki67 expression (Fig 3.4f).
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FIG. 3.4 BCL-3 SIRNA KNOCKDOWN REDUCED KI67 EXPRESSION 
Representative immunofluorescence images of a. MDA-MB-436 b. MDA-MB-231-Luc c. MDA-
MB-231 d. SUM149 e. MCF10a cells were knockdown with either Bcl-3 or scrambled control 
siRNA for 48h, plated onto coverslips, PFA fixed and immunofluorescent-stained for Ki67. f. 
Graph comparing Ki67 expression between knockdowns and different cell lines. Error bars 
represent ±SEM of 3 independent experiments. (T-test, *=p<0.05, **=p<0.01, ***=p<0.001)
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3.6 Bcl-3 siRNA knockdown significantly reduced phosph-
Histone H3 (ser10) expression in TNBC cell lines but not in the 
non-malignant MCF10a cell line 
	 To compliment our Ki67 findings, phospho-histone H3 (pHH3) immunofluorescence 
staining was carried out. pHH3 is a recently described immuno-marker specific for cells 
undergoing mitosis. The phosphorylation of Histone H3 plays an important role in gene 
expression, chromatin remodelling, chromosome condensation and cell division (Hans 
and Dimitrov, 2001). Histone H3 phosphorylation is always heavily associated with 
metaphase, and H3 phosphorylation at serine 10 is coupled with mitotic chromosome 
segregation and condensation during both mitosis and meiosis (Hendzel et al., 1997). 
Upon exit of mitosis and meiosis global dephosphorylation of H3 takes place during 
anaphase (Dai et al., 2005). Due to the narrower window of expression in the cell cycle 
this marker detects a smaller proportion of cells than Ki-67.

	 The breast cancer cell line panel were transfected with either Bcl-3 or scrambled 
control siRNA for 48h, plated onto coverslips, PFA fixed and immunofluorescence staining 
for pHH3 was performed. Bcl-3 knockdown was able to significantly reduce the fraction 
of pHH3 positive cells in all TNBC cell lines but had no effect on the non-malignant 
MCF10a cell line, which comparatively had a much lower basal pHH3 expression (Fig 
3.5f).

 80
Chapter 3: Results
 
 81
M
DA
-M
B-
43
6
M
DA
-M
B-
23
1-
Lu
c
M
DA
-M
B-
23
1
a
b
c
scRNA Control Bcl-3 siRNA
Chapter 3: Results
 
 82
SU
M
14
9
M
CF
10
a
d
e
FIG. 3.5 BCL-3 SIRNA KNOCKDOWN REDUCED PHOSPHO-HISTONE H3 (SER10) EXPRESSION 
Representative immunofluorescence images of a. MDA-MB-436 b. MDA-MB-231-Luc c. MDA-
MB-231 d. SUM149 e. MCF10a cells were knockdown with either Bcl-3 or scrambled control 
siRNA for 48h, plated onto coverslips, PFA fixed and immunofluorescent-stained for phospho-
Histone H3. f. Graph comparing Ki67 expression between knockdowns and different cell lines. 
Error bars represent ±SEM of 3 independent experiments. (T-test, *=p<0.05, **=p<0.01, 
***=p<0.001)
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3.7 Effects of Bcl-3 siRNA knockdown on the cell cycle 
	 In order to further confirm and explain the effects seen on cell growth, we 
investigated the effects of Bcl-3 knockdown on stages of the cell cycle. A common 
approach for determining cell cycle stage is through measurement of cellular DNA 
content. This allows the discrimination of cells in the G0/G1, S, and G2/M phases of the 
cell cycle. DNA is stained with the fluorescent DAPI dye and cellular fluorescence is 
measured by flow cytometry. The intensity of integrated fluorescence for each cell is 
expected to be in stoichiometric relationship to DNA content and thereby can be used to 
determine cell cycle stage. The DNA content frequency histograms can be deconvoluted 
using FlowJo, a computer program used for single-cell flow cytometry analysis 
(Darzynkiewicz et al., 2001). Internucleosomal DNA fragmentation is one of the hallmarks 
of apoptosis as low molecular weight DNA fragments are extracted during cell staining in 
aqueous solution. This results in a subG1 peak as the apoptotic cells are identified on the 
DNA content frequency histograms as cells with fractional DNA content thus providing an 
additional assessment of Bcl3’s effects on cell viability (Kajstura et al., 2007).

	 MDA-MB-436 cells were transfected with either Bcl-3 or scrambled control siRNA 
for 48h before being permeabilised with NP-40 and stained with DAPI. Single-cell DNA 
content was measured using flow cytometry and cell cycle stages calculated. Bcl-3 
knockdown cells had a 25% significantly increased subG1 population, which was 
balanced by significant reductions in all other G0/G1, S and G2/M populations (Fig 3.6a). 

	 MDA-MB-231-Luc cells were transfected with either Bcl-3 or scrambled control 
siRNA for 48h before being permeabilised with NP-40 and stained with DAPI. Single-cell 
DNA content was measured using flow cytometry and cell cycle stages calculated. Bcl-3 
knockdown cells had a significantly decreased G2/M population (Fig 3.7a).

	 MDA-MB-231 cells were transfected with either Bcl-3 or scrambled control siRNA 
for 48h before being permeabilised with NP-40 and stained with DAPI. Single-cell DNA 
content was measured using flow cytometry and cell cycle stages calculated. Bcl-3 
knockdown cells had a significantly increased G0/G1 and decreased G2/M population 
(Fig 3.8a).
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	 SUM149 cells were transfected with either Bcl-3 or scrambled control siRNA for 
48h before being permeabilised with NP-40 and stained with DAPI. Single-cell DNA 
content was measured using flow cytometry and cell cycle stages calculated. Bcl-3 
knockdown cells had a significantly increased G0/G1 and decreased S, and G2/M 
populations (Fig 3.9a).

	 MCF10a cells were transfected with either Bcl-3 or scrambled control siRNA for 
48h before being permeabilised with NP-40 and stained with DAPI. Single-cell DNA 
content was measured using flow cytometry and cell cycle stages calculated. Bcl-3 
knockdown cells did not have significantly different cell cycle populations compared to 
control (Fig 3.10a).
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FIG. 3.6 BCL-3 SIRNA KNOCKDOWN IN MDA-MB-436 INCREASED THE SUBG1 POPULATION 
WHILE DECREASING THE G0/G1, S, AND G2/M POPULATIONS 
MDA-MB-436 cells were transfected with either Bcl-3 or scrambled control siRNA for 48h before 
being permeabilised with NP-40 and stained with DAPI. Single-cell DNA content was measured 
using flow cytometry and cell cycle stages calculated. a.&b. Percentage of cells in each cell 
cycle. c.&d. Representative histograms detailing cell cycle stage distribution. Error bars 
represent ±SEM of 3 independent experiments. (T-test, *=p<0.05, **=p<0.01, ***=p<0.001)
p=0.001
p=0.001
p=0.014
p=0.007
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FIG. 3.7 BCL-3 SIRNA KNOCKDOWN IN MDA-MB-231-LUC DECREASED THE G2/M POPULATION 
MDA-MB-231-Luc cells were transfected with either Bcl-3 or scrambled control siRNA for 48h 
before being permeabilised with NP-40 and stained with DAPI. Single-cell DNA content was 
measured using flow cytometry and cell cycle stages calculated. a.&b. Percentage of cells in 
each cell cycle. c.&d. Representative histograms detailing cell cycle stage distribution. Error 
bars represent ±SEM of 3 independent experiments. (T-test, *=p<0.05, **=p<0.01, ***=p<0.001)
p=0.032
Chapter 3: Results
 
 87
a
b
scRNA Controlc Bcl-3 siRNAd
FIG. 3.8 BCL-3 SIRNA KNOCKDOWN IN MDA-MB-231 INCREASED THE G0/G1 AND DECREASED 
THE G2/M POPULATIONS 
MDA-MB-231 cells were transfected with either Bcl-3 or scrambled control siRNA for 48h before 
being permeabilised with NP-40 and stained with DAPI. Single-cell DNA content was measured 
using flow cytometry and cell cycle stages calculated. a.&b. Percentage of cells in each cell 
cycle. c.&d. Representative histograms detailing cell cycle stage distribution. Error bars 
represent ±SEM of 3 independent experiments. (T-test, *=p<0.05, **=p<0.01, ***=p<0.001)
p=0.019
p=0.043
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FIG. 3.9 BCL-3 SIRNA KNOCKDOWN IN SUM149 INCREASED THE G0/G1 AND DECREASED THE S, 
AND G2/M POPULATIONS 
SUM149 cells were transfected with either Bcl-3 or scrambled control siRNA for 48h before 
being permeabilised with NP-40 and stained with DAPI. Single-cell DNA content was measured 
using flow cytometry and cell cycle stages calculated. a.&b. Percentage of cells in each cell 
cycle. c.&d. Representative histograms detailing cell cycle stage distribution. Error bars 
represent ±SEM of 3 independent experiments. (T-test, *=p<0.05, **=p<0.01, ***=p<0.001)
p=0.001
p=0.041
p=0.027
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FIG. 3.10 BCL-3 SIRNA KNOCKDOWN IN MCF10A DID NOT AFFECT THE CELL CYCLE 
MCF10a cells were transfected with either Bcl-3 or scrambled control siRNA for 48h before 
being permeabilised with NP-40 and stained with DAPI. Single-cell DNA content was measured 
using flow cytometry and cell cycle stages calculated. a.&b. Percentage of cells in each cell 
cycle. c.&d. Representative histograms detailing cell cycle stage distribution. Error bars 
represent ±SEM of 3 independent experiments. (T-test, *=p<0.05, **=p<0.01, ***=p<0.001)
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3.8 Bcl-3 siRNA knockdown significantly increased 
caspase-3/-7 activity in TNBC cell lines but not in the non-
malignant MCF10a cell line 
	 Apart from cellular proliferation another key contributor to overall cell population 
growth is the rate of cellular apoptosis or other forms of programmed cell death. In light of 
the results highlighting a high sub-G1 population in MDA-MB-436s, which is indicative of 
apoptotic bodies, we wanted to specifically assay the rate of apoptosis in our cell line 
panel. Cell lines were transfected with either Bcl-3 or scrambled control siRNA for 48h 
before being lysed and assayed for caspase-3/7 activity using the Caspase-Glo 3/7 assay 
(Promega). This is a homogenous, luminescent assay that measures caspase-3 and -7 
activities. These members of cysteine aspartic acid-specific protease (caspase) family 
plays key effector roles in apoptosis in mammalian cells (Thornberry and Lazebnik, 1998). 
The assay contains a pro-luminescent caspase-3/7 substrate with the tetrapeptide 
sequence DEVD, in a reagent optimised for caspase activity, luciferase activity and cell 
lysis. Cleavage of substrate releases aminoluciferin and results in the production of light 
and luminescence is proportional to the amount of caspase activity present.

	 Bcl-3 knockdown significantly increased caspase-3/7 activity in all TNBC cell lines 
(Fig 3.11). A 35% increase was observed in the MDA-MB-436, a 140% increase in the 
MDA-MB-231-Luc, a 110% increase in MDA-MB-231 and 160% increase in SUM149. 
There was no change in the caspase-3/7 activity of the non-malignant MCF10a cell line.
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FIG. 3.11 BCL-3 SIRNA KNOCKDOWN INCREASED CASPASE-3/7 ACTIVITY IN TNBC CELL LINES 
Cell lines were transfected with either Bcl-3 or scrambled control siRNA for 48h before being 
lysed and assayed for caspase-3/7 activity. Error bars represent ±SEM of 3 independent 
experiments. (T-test, *=p<0.05, **=p<0.01, ***=p<0.001)
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3.9 Bcl-3 siRNA knockdown did not affect mammosphere 
numbers but significantly reduced mammosphere size in TNBC 
cell lines 
	 Recent research has focused on a small population of tumour cells termed cancer 
stem-like cells (CSCs) for their characteristics of self-renewal and are associated with 
tumour initiation and development. Breast cancer recurrence rates are close to 40% and 
evidence suggests this could be due to remaining CSCs following either incomplete 
elimination of primary tumour, or through their inherent resistance to adjuvant therapy. 
The gold standard for CSC self-renewal is in vivo transplantation. However a reliable and 
cost efficient in vitro assay involving the formation of anoikis resistant mammospheres is 
also able to demonstrate the presence of a stem-like cell population (Shaw et al., 2012). 
We wanted to investigate whether Bcl-3 played any roles in promoting CSC formation or 
stem-like properties as this would certainly contribute to the increased tumourigenicity 
associated with an oncogene.

	 Cell lines were transfected with either Bcl-3 or scrambled control siRNA for 48h 
before being disaggregated into single cells and plated into non-adherent mammosphere 
plates, cultured for 10 days and total mammosphere numbers and size quantified. Bcl-3 
knockdown did not affect the number of spheres formed but for the MDA-MB-436, MDA-
MB-231-Luc and MDA-MB-231 cell lines average sphere sizes were significantly lower 
(Fig 3.12f). We did not carry out a second passage as sphere formation numbers were not 
affected in the primary passage, suggesting Bcl-3 did not act upon mechanisms 
pertaining to propagation of a stem-like population.
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FIG. 3.12 BCL-3 SIRNA KNOCKDOWN DID NOT AFFECT MAMMOSPHERE NUMBERS BUT 
SIGNIFICANTLY REDUCED MAMMOSPHERE SIZE 
Cell lines were transfected with either Bcl-3 or scrambled control siRNA for 48h before being 
disaggregated into single cells and plated into non-adherent mammosphere plates and cultured 
for 10 days. Representative bright-field microscopy images for a. MDA-MB-436 b. MDA-
MB-231-Luc c. MDA-MB-231 d. SUM149 e. MCF10a cell lines. f. Total mammosphere numbers 
and average mammosphere sizes for each cell line. Error bars represent ±SEM of 3 independent 
experiments. (T-test, *=p<0.05, **=p<0.01, ***=p<0.001)
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3.10 Bcl-3 siRNA knockdown significantly impaired clonogenic 
survival in TNBC cell lines but not the non-malignant MCF10a 
cell line 
	 Colony formation or otherwise known as clonogenic assay is an in vitro cell survival 
assay based on the ability of a single cell to grow into a colony. Colonies are defined as 
containing at least 50 cells and this assay tests the ability of every cell in the plated 
population to undergo unlimited division. This assay is typically used to determine cell 
reproductive death following treatment with ionising radiation or cytotoxic agents as only 
a fraction of seeded cells retain the capacity to produce colonies (Franken et al., 2006). 
As Bcl-3 knockdown appeared to affect cellular proliferation and promoted apoptosis, it 
made sense to also investigate its effect on clonogenicity.

	 Cell lines were transfected with either Bcl-3 or scrambled control siRNA for 48h 
before being plated at low densities and cultured for 10 days. Colonies were then fixed 
with glutaraldehyde (6% v/v), stained with crystal violet (0.5% w/v), imaged using a plate 
scanner and colonies quantified. Bcl-3 knockdown in all TNBC cell lines resulted in 
impaired clonogenic potential as there were significant reductions in both totally colony 
number as well as average colony size. There was no effects on clonogenicity in the non-
malignant MCF10a cell line. 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FIG. 3.13 BCL-3 SIRNA KNOCKDOWN SIGNIFICANTLY IMPAIRED CLONOGENIC SURVIVAL  
Clonogenic potential was tested by transfecting cell lines with either Bcl-3 or scrambled control 
siRNA for 48h before being plated at low density in a colony formation assay and cultured for 10 
days before being fixed and stained with crystal violet. Representative images, total colony 
number and average colony coverage for a. MDA-MB-436 b. MDA-MB-231-Luc c. MDA-
MB-231 d. SUM149 e. MCF10a cell lines. Error bars represent ±SEM of 3 independent 
experiments. (T-test, *=p<0.05, **=p<0.01, ***=p<0.001)
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3.11 Effects of Bcl-3 siRNA knockdown on cellular migration 
	 Recently it has been shown elevated Bcl-3 expression was associated with higher 
metastatic potential and reduced metastasis-free survival. Bcl-3 was linked to increased 
cell motility through regulation by TGF-β signalling and stabilisation of SMAD3 (Chen et 
al., 2016). Bcl-3 was also demonstrated to regulate the metastasis of mouse breast 
cancer cells (Wakefield et al., 2013). In light of the significance of Bcl-3 surrounding 
metastasis, we wanted to investigate its roles in several different forms of cellular 
migration. Three different assays were used to assess collective, amoeboid-like and 
mesenchymal-like single cell migration.

3.11.1 Bcl-3 siRNa knockdown significantly inhibited collective 
migration in wound-healing assay in TNBC cell lines but not 
the non-malignant MCF10a cell line 
	 The wound-healing assay is a simple, inexpensive, and one of the earliest 
developed methods to study directional collective in vitro cell migration. The basic steps 
involve creating a “wound” or scratch with a pipette tip in a confluent cell monolayer, 
capturing images at the beginning and at regular intervals during cell migration to close 
the wound, and comparing images to quantify the migration rate of cells (Rodriguez et al., 
2005). Cell lines was transfected with either Bcl-3 or scrambled control siRNA for 48h 
before a scratch was made on a confluent monolayer using a 200µL pipette tip and cells 
cultured for a further 48h. Bright-field microscopy images were captured at 12h, 24h, 36h 
and 48h time-points and percentage wound closure was calculated using ImageJ.

	 Bcl-3 siRNA knockdown significantly reduced the collective migratory capacity of 
this cell line at all time-points and by the final 48h time-point the knockdown wound 
closure was ~15% less than that of the control (Fig. 3.14c). Bcl-3 siRNA knockdown 
significantly reduced the collective migratory capacity of this cell line at all time-points 
and by the final 48h time-point the knockdown wound closure was ~60% less than that of 
the control (Fig. 3.15c). Bcl-3 siRNA knockdown significantly reduced the collective 
migratory capacity of this cell line at all time-points and by the final 48h time-point the 
knockdown wound closure was ~50% less than that of the control (Fig. 3.16c). Bcl-3 
siRNA knockdown significantly reduced the collective migratory capacity of this cell line 
at all time-points and by the final 48h time-point the knockdown wound closure was 
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~35% less than that of the control (Fig. 3.17c). Bcl-3 siRNA knockdown did not reduce 
the collective migratory capacity of this cell line at all time-points (Fig. 3.18c).
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FIG. 3.14 BCL-3 SIRNA KNOCKDOWN SIGNIFICANTLY INHIBITED COLLECTIVE MIGRATION IN 
MDA-MB-436 
The wound-healing assay was used to investigate collective migration in MDA-MB-436. The 
cell line was transfected with either Bcl-3 or scrambled control siRNA for 48h before a scratch 
was made on a confluent monolayer using a 200µL pipette tip and cells cultured for a further 
48h with images being taken every 12h. a. Representative images showing the scratch at 0h 
and 48h. b. Total scratch area quantified using ImageJ and % wound closure calculated for 
12h, 24h, 36h and 48h time-points. c. % wound closure at 48h time-point. Error bars represent 
±SEM of 3 independent experiments. (T-test, ***=p<0.001)
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FIG. 3.15 BCL-3 SIRNA KNOCKDOWN SIGNIFICANTLY INHIBITED COLLECTIVE MIGRATION IN 
MDA-MB-231-LUC 
The wound-healing assay was used to investigate collective migration in MDA-MB-231-Luc. The 
cell line was transfected with either Bcl-3 or scrambled control siRNA for 48h before a scratch 
was made on a confluent monolayer using a 200µL pipette tip and cells cultured for a further 
48h with images being taken every 12h. a. Representative images showing the scratch at 0h 
and 48h. b. Total scratch area quantified using ImageJ and % wound closure calculated for 12h, 
24h, 36h and 48h time-points. c. % wound closure at 48h time-point. Error bars represent ±SEM 
of 3 independent experiments. (T-test, ***=p<0.001)
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FIG. 3.16 BCL-3 SIRNA KNOCKDOWN SIGNIFICANTLY INHIBITED COLLECTIVE MIGRATION IN 
MDA-MB-231 
The wound-healing assay was used to investigate collective migration in MDA-MB-231. The cell 
line was transfected with either Bcl-3 or scrambled control siRNA for 48h before a scratch was 
made on a confluent monolayer using a 200µL pipette tip and cells cultured for a further 48h 
with images being taken every 12h. a. Representative images showing the scratch at 0h and 
48h. b. Total scratch area quantified using ImageJ and % wound closure calculated for 12h, 
24h, 36h and 48h time-points. c. % wound closure at 48h time-point. Error bars represent ±SEM 
of 3 independent experiments. (T-test, ***=p<0.001)
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FIG. 3.17 BCL-3 SIRNA KNOCKDOWN SIGNIFICANTLY INHIBITED COLLECTIVE MIGRATION IN 
SUM149 
The wound-healing assay was used to investigate collective migration in SUM149. The cell line 
was transfected with either Bcl-3 or scrambled control siRNA for 48h before a scratch was 
made on a confluent monolayer using a 200µL pipette tip and cells cultured for a further 48h 
with images being taken every 12h. a. Representative images showing the scratch at 0h and 
48h. b. Total scratch area quantified using ImageJ and % wound closure calculated for 12h, 
24h, 36h and 48h time-points. c. % wound closure at 48h time-point. Error bars represent ±SEM 
of 3 independent experiments. (T-test, ***=p<0.001)
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FIG. 3.18 BCL-3 SIRNA KNOCKDOWN DID NOT AFFECT COLLECTIVE MIGRATION IN MCF10A 
The wound-healing assay was used to investigate collective migration in MCF10a. The cell line 
was transfected with either Bcl-3 or scrambled control siRNA for 48h before a scratch was 
made on a confluent monolayer using a 200µL pipette tip and cells cultured for a further 48h 
with images being taken every 12h. a. Representative images showing the scratch at 0h and 
48h. b. Total scratch area quantified using ImageJ and % wound closure calculated for 12h, 
24h, 36h and 48h time-points. c. % wound closure at 48h time-point. Error bars represent ±SEM 
of 3 independent experiments.
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a
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3.11.2 Bcl-3 siRNA knockdown significantly inhibited 
amoeboid-like single cell migration in TNBC cell lines but not 
the non-malignant MCF10a cell line 
	 The hallmark of metastatic cells is their ability to invade through the basement 
membrane and migrate to other parts of the body. Using the BD FluoroBlok system we 
were able to look at chemotaxis, movement in response to a chemical gradient and 
amoeboid-like cell motility. It consists of a 96-well insert plate with 8.0 micron pore size 
polyethylene terephthalate (PET) membranes. Subsequent quantification of cell migration 
is achieved by labelling with the fluorescent dye calcein AM and measuring fluorescence 
of migrated cells. Since the BD FluoroBlok membrane effectively blocks the passage of 
light from 490-900nm at >99% efficiency, fluorescently labelled cells that have not 
migrated past the membrane are not detected by a bottom-reading plate reader.

	 Cell lines were transfected with Bcl-3 or scrambled control siRNA for 48h before 
being plated into the top well of a FluoroBlok assay plate and left to migrate for 24h 
across a chemotactic gradient. Bcl-3 knockdown was able to significantly inhibit 20-30% 
of the amoeboid-like migratory capacity of TNBC cell lines but had no effect in the non-
malignant MCF10a cell line (Fig. 3.19). 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3.11.3 Bcl-3 siRNA knockdown significantly inhibited 
mesenchymal-like single cell migration in TNBC cell lines but 
not the non-malignant MCF10a cell line 
	 In metastatic cancer, cells must be able to invade across physiological barriers and 
migrate effectively in a single cell mesenchymal manner. By seeding cells at low densities 
we were able to quantify single cell migration using a time-lapse incubator chamber over 
the course of 12h with images being taken every 10 min. Cell lines were transfected with 
Bcl-3 or scrambled control siRNA for 48h, plated into 12-well plates and imaged.

	 Bcl-3 siRNA knockdown significantly reduced the average distance travelled by 
single cells over the course of 12h in MDA-MB-436 by ~70%, MDA-MB-231-Luc by 
~45% and MDA-MB-231 by ~25% (Fig. 3.20e). Average distance travelled from origin at 
0h was also reduced by a comparable amount over the course of 12h (Fig. 3.20d).
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FIG. 3.19 BCL-3 SIRNA KNOCKDOWN SIGNIFICANTLY INHIBITED AMOEBOID-LIKE SINGLE CELL 
MIGRATION IN TNBC CELL LINES 
The FluoroBlok assay was used to investigate amoeboid-like migration of cell line panel. Cells 
were transfected with either Bcl-3 or scrambled control siRNA for 48h before being plated into 
the top well of a FluoroBlok assay plate and left to migrate for 24h across a chemotactic 
gradient. Cells were stained with calcein AM and fluorescence intensity at 500nm was quantified 
by a bottom-reading plate reader. Error bars represent ±SEM of 3 independent experiments. (T-
test, *=p<0.05, **=p<0.01, ***=p<0.001)
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FIG. 3.20 BCL-3 SIRNA KNOCKDOWN SIGNIFICANTLY INHIBITED MESENCHYMAL-LIKE SINGLE 
CELL MIGRATION IN TNBC CELL LINES 
The single cell migration assay was used to investigate the 2D motility of the cell line panel. 
Cells were transfected with either Bcl-3 or scrambled control siRNA for 48h before being plated 
low densities and single cell migration was quantified by tracking the motility path of each cell 
using a time-lapse incubator chamber over the course of 12h with images captured every 10 
min. Representative images of motility paths of single cells over 12h for Bcl-3 siRNA knockdown 
and scrambled control in a. MDA-MB-436 b. MDA-MB-231-Luc c. MDA-MB-231. d. Average 
distance travelled away from origin for Bcl-3 knockdown and control cells. e. Average distance 
travelled after 12h for Bcl-3 knockdown and control cells. Error bars represent ±SEM of 3 
independent experiments. (T-test, *=p<0.05, **=p<0.01, ***=p<0.001)
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3.12 Bcl-3 siRNA knockdown significantly inhibited NFkB 
activity 
	 The activity of NFkB signalling in cultured cells can be monitored using a luciferase 
NFkB reporter plasmid vector. This reporter contains a firefly luciferase gene under the 
control of multiple NFkB transcriptional responsive elements (TRE) located upstream of a 
minimal promoter. The nucleotide binding sequence for these NFkB TREs are 
GGGACTTTCC.

	 Cells were transfected with either Bcl-3 or scrambled control siRNA for 24h before 
being further transfected with the luciferase NFkB reporter plasmid, LacZ control plasmid 
and cultured for another 24h. Cells were then lysed and NFkB activity measured as 
luminescence using a plate reader. NFkB activity was then normalised to LacZ 
luminescence to control for transfection efficiency. Bcl-3 knockdown significantly 
inhibited NFkB activity in all cell lines (Fig. 3.21).  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FIG. 3.21 BCL-3 SIRNA KNOCKDOWN SIGNIFICANTLY INHIBITED NFKB ACTIVITY 
A luciferase NFkB reporter plasmid was used to quantify NFkB levels in the cell line panel. Cells 
were transfected with either Bcl-3 or scrambled control siRNA for 24h before being further 
transfected with the luciferase NFkB reporter plasmid, LacZ control plasmid and cultured for 
another 24h. Cells were then lysed and NFkB activity measured as luminescence using a plate 
reader. NFkB activity was then normalised to LacZ luminescence to control for transfection 
efficiency. Error bars represent ±SEM of 3 independent experiments. (T-test, *=p<0.05, 
**=p<0.01, ***=p<0.001)
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3.13 Bcl-3 knockdown reduced metastatic occurrence in a 
murine tail vein xenograft metastasis model 
	 Xenograft modelling has served as a robust method for researching genetic drivers 
of cancer and determining the potential efficacy of cancer therapies. The capacity to 
propagate human cancer cell lines and tissues in mice was first catalysed with the 
discovery of T-cell deficient athymic nude (nu/nu) mice and T- and B-cell deficient 
combined immunodeficient (scid/scid) mice (Flanagan, 1966; Bosma and Carroll, 1991). 
Since then many additional immunocompromised mouse models have become 
established such as the more recent NOD-scid IL2Rgamma(null) mice (otherwise known 
as NSG mice) (Shultz et al., 2005).

	 Direct injection of breast cancer cells via the tail vein (TV) vasculature provides a 
quick and easy method for studying the later stages of the metastatic process. This is 
especially the case for aggressive cell lines that proliferate rapidly and take long periods 
of time to metastasise, if at all from the orthotopic site. Although we skip some natural 
biological steps the primary tumour must take in order to produce distal metastases, it 
had been shown that TV tumours exhibited no gene profile differences to that of 
metastases generated by orthotopic tumours. Hence this is a relevant model for the study 
of breast cancer metastasis (Rashid et al., 2013).

	 MDA-MB-231 cells transfected with either Bcl-3 or scrambled control siRNA for 
48h were injected intravenously via the lateral tail vein (2x105 cells in 100μl of RPMI 
media) in 6 week old female Hsd: Athymic Nude-Foxn 1nu mice (Harlan Laboratories). 
Animals were culled and necropsy performed at 45 days post surgery. Xenograft tissue 
were fixed, embedded in paraffin blocks, serial sections cut and H&E slides generated for 
metastases quantification through histological analysis. (Fig. 3.22c) Bcl-3 knockdown 
significantly decreased the number of metastases identified in both the lungs and liver. 
(Fig. 3.22a) The average metastases size between the two conditions was not found to be 
significantly different (Fig. 3.22b). There were attempts to generate stably inducible 
shRNA Bcl-3 knockdown cell line clones, but theses cell attempts were unsuccessful.
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FIG. 3.22 BCL-3 KNOCKDOWN REDUCED METASTATIC OCCURRENCE IN A MURINE TAIL VEIN 
XENOGRAFT METASTASIS MODEL 
MDA-MB-231 cells transfected with either Bcl-3 or scrambled control siRNA for 48h were 
injected intravenously via the lateral tail vein (2x105 cells in 100μl) in 6 week old female Hsd: 
Athymic Nude-Foxn 1nu mice (Harlan Laboratories). Animals were culled and necropsy 
performed at 45 days post surgery. Xenograft tissue were fixed, embedded in paraffin blocks, 
serial sections cut and H&E slides generated for metastases quantification through histological 
analysis. a. Average metastasis count and b. Average metastasis size in the lung and liver for 
control siRNA cohort (n=4) and Bcl-3 siRNA cohort (n=4). Error bars represent ±SEM of 4 
independent mice. (T-test, *=p<0.05, **=p<0.01, ***=p<0.001) c. Haematoxylin and eosin (H&E) 
staining of mouse lung and liver sections with representative metastatic tumours. M = 
Metastasis, L = Normal lung parenchyma, Lv = Normal liver tissue.
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3.14 Affymetrix DNA microarray analysis of Bcl-3 siRNA 
knockdown 
	 We knew from our previous experiments that Bcl-3 knockdown led to a decrease in 
overall NFkB output. Building upon this knowledge, we carried out global gene 
expression profiling to further our understanding of Bcl-3 mediated transcriptional 
signalling. An Affymetrix DNA GeneChip microarray experiment was carried out using 
mRNA extracted from MDA-MD-231-Luc cells treated with either Bcl-3 or scrambled 
control siRNA for 48h. Experimental data were normalised and analysed using 
GeneSpring GX Pathway Architect software. Genes were filtered based on their corrected 
p-values and a statistical cut off of 0.05 was chosen. 4229 out of 43590 genes satisfied 
this cut off.

3.14.1 Gene function analysis of significantly up/down-
regulated genes following Bcl-3 siRNA knockdown using the 
PANTHER classification system 
	 The PANTHER (protein annotation through evolutionary relationship) classification 
system is designed as an online based platform for comprehensive analysis of gene 
function on genome-wide scale. The PANTHER system is composed of three functional 
modules. The core module is a large protein library that contains all protein-coding genes 
from 82 organisms, each annotated with ontology terms. The second is a pathways 
module with all pathways connected to individual proteins and linked to phylogenetic 
information and statistical models. The last module is a website tool suite that contains a 
collections of bioinformatic tools and software allowing users to visualise, analyse and 
interpret genome-wide experimental data (Mi et al., 2013).

	 Using the gene analysis tool that can be accessed directly from the PANTHER 
home page we can input a list of genes and quantitative data for analysis. The PANTHER 
data recognises a number of identifiers and in our case we used the gene symbol and log 
fold change data. The gene list can be analysed in a number of ways. The functional 
classification tool analyses input genes, stratifies them by biological processes, molecular 
functions, cellular components, pathways and displays them in either a gene list or pie 
chart. The statistical overrepresentation tool compares the input genes to a reference 
gene list and determines whether a particular ontology class or pathway of genes is over 
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or underrepresented. The statistical enrichment test uses the Mann-Whitney test to 
consider the numerical values associated with each gene to determine whether there are 
trends within an ontology class or pathway. It looks for significant coordinated effects 
across all the relevant ratios to test whether an up- or down-regulation is unlikely to be 
accounted for by random chance. PANTHER functional classification, statistical 
overrepresentation and statistical enrichment analyses were carried out on the 4229 
significant gene hits and stratified by biological process, pathways, molecular function 
and cellular components. (Fig.3.23)

 114
Chapter 3: Results
 
 115
PANTHER Biological Processes
72, 1.1%
572, 9.1%
522, 8.3%
1875, 29.9%
338, 5.4%
5, 0.1%
92, 1.5%
473, 7.5%
57, 0.9%
1468, 23.4%
269, 4.3%
46, 0.7%
484, 7.7%
a
1, 0.1%
3, 0.1%
PANTHER Molecular Function
8, 0.3%
1091, 38.9%
1111, 39.6%
5, 0.2%
126, 4.5%
118, 4.2% 22, 0.8%
211, 7.5%
111, 4%
b
Chapter 3: Results
 116
PANTHER Cellular Components
33, 0.9%
1384, 39.6%
25, 0.7%
100, 2.9%
492, 14.1%
471, 13.5%
964, 27.6%
24, 0.7%c
FIG. 3.23 PANTHER FUNCTIONAL CLASSIFICATION TOOL FOR BCL-3 SIRNA KNOCKDOWN 
Genes found to be significantly up/down-regulated (p-value<0.05) in the MDA-MB-231-Luc, 48h 
Bcl-3 siRNA knockdown Affymetrix microarray experiment were used to perform PANTHER 
functional classification. Result of analyses are visualised as pie charts with information within 
each wedge detailing the number of genes and percent of genes against total hits for a. 
PANTHER biological processes b. PANTHER Molecular Function c. PANTHER Cellular 
Components.
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PANTHER	Biological	Processes H.Sapiens	Ref	List
Bcl3	
siRNA Expected
Fold	
Enrichment FDR<0.05
cellular	process 8247 1875 1657.47 1.13 1.79E-08
cell	cycle 723 182 145.31 1.25 3.37E-02
cytokinesis 138 55 27.74 1.98 4.44E-04
apoptoEc	process 336 92 67.53 1.36 4.92E-02
metabolic	process 5878 1468 1181.35 1.24 6.05E-16
nitrogen	compound	metabolic	
process 2524 614 507.27 1.21 1.17E-04
biosyntheBc	process 1745 452 350.71 1.29 1.70E-05
catabolic	process 1176 302 236.35 1.28 1.13E-03
carbohydrate	metabolic	process 320 96 64.31 1.49 5.86E-03
protein	glycosylaBon 105 36 21.1 1.71 4.27E-02
cellular	component	organisaEon	
or	biogenesis 2099 522 421.85 1.24 9.93E-05
cellular	component	
morphogenesis 423 119 85.01 1.4 8.74E-03
cytoskeleton	organisaBon 404 119 81.2 1.47 2.88E-03
localisaEon 2012 473 404.37 1.17 8.66E-03
protein	transport 736 186 147.92 1.26 2.93E-02
anion	transport 241 70 48.44 1.45 3.70E-02
nucleobase-containing	compound	
metabolic	process 2797 662 562.14 1.18 5.87E-04
RNA	metabolic	process 1570 389 315.54 1.23 1.40E-03
transcripBon	from	RNA	
polymerase	II	promoter 774 206 155.56 1.32 2.86E-03
phosphate-containing	compound	
metabolic	process 1595 439 320.56 1.37 8.35E-08
intracellular	signal	transducEon 1071 272 215.25 1.26 3.77E-03
immune	system	process 669 92 134.45 0.68 2.85E-03
complement	acBvaBon 94 2 18.89 0.11 1.03E-04
B	cell	mediated	immunity 94 1 18.89 0.05 2.04E-05
G-protein	coupled	receptor	
signaling	pathway 456 44 91.65 0.48 6.40E-06
single-mulEcellular	organism	
process 1665 268 334.63 0.80 2.81E-03
cell	recogniBon 105 4 21.10 0.19 4.96E-04
system	process 1020 150 205.00 0.73 1.63E-03
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PANTHER	Molecular	FuncEon H.Sapiens	Ref	List
Bcl3	
siRNA Expected
Fold	
Enrichment FDR<0.05
nucleic	acid	binding 1625 390 326.59 1.19 1.29E-02
transcripBon	factor	binding	
transcripBon	factor	acBvity 236 71 47.43 1.5 2.86E-02
binding 4911 1091 987.01 1.11 7.45E-03
cytoskeletal	protein	binding 320 101 64.31 1.57 1.85E-03
acBn	binding 139 48 27.94 1.72 1.95E-02
ligase	acEvity 227 74 45.62 1.62 5.75E-03
ubiquiBn-protein	ligase	acBvity 80 30 16.08 1.87 3.76E-02
transferase	acEvity 1325 400 266.3 1.5 8.80E-11
kinase	acBvity 625 210 125.61 1.67 1.46E-08
enzyme	regulator	acBvity 405 114 81.4 1.4 1.97E-02
catalyEc	acEvity 4217 1111 847.53 1.31 1.57E-16
hydrolase	acBvity 1844 463 370.61 1.25 2.39E-04
pyrophosphatase	acBvity 663 173 133.25 1.3 2.21E-02
phosphatase	acBvity 201 74 40.4 1.83 3.91E-04
receptor	acEvity 1128 126 226.70 0.56 3.27E-10
G-protein	coupled	receptor	acBvity 309 33 62.10 0.53 3.38E-03
signal	transducer	acEvity 960 118 192.94 0.61 1.48E-06
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PANTHER	Cellular	Component H.Sapiens	Ref	List
Bcl3	
siRNA Expected
Fold	
Enrichment FDR<0.05
organelle 3910 964 785.83 1.23 6.33E-09
endosome 132 45 26.53 1.7 1.86E-02
vacuole 196 64 39.39 1.62 7.64E-03
cytoskeleton 600 156 120.59 1.29 1.90E-02
acBn	cytoskeleton 203 63 40.8 1.54 1.97E-02
nucleus 1943 498 390.5 1.28 6.23E-06
nucleoplasm 392 115 78.78 1.46 3.80E-03
endoplasmic	reEculum 412 113 82.8 1.36 1.85E-02
intracellular 5262 1335 1057.55 1.26 1.75E-16
cytoplasm 3171 817 637.3 1.28 2.23E-10
protein	complex 1796 422 360.96 1.17 1.85E-02
extracellular	region 673 100 135.26 0.74 1.75E-02
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PANTHER	Pathways H.Sapiens	Ref	List
Bcl3	
siRNA Expected
Fold	
Enrichment FDR<0.05
p53	pathway	feedback	loops	2 51 25 10.25 2.44 0.011
VEGF	signalling	pathway 68 33 13.67 2.41 0.004
p53	pathway 89 39 17.89 2.18 0.005
Apoptosis	signalling	pathway 120 52 24.12 2.16 0.001
TGF-beta	signalling	pathway 97 39 19.49 2 0.013
Integrin	signalling	pathway 190 67 38.19 1.75 0.005
Angiogenesis 173 60 34.77 1.73 0.012
Gonadotropin-releasing	
hormone	receptor	pathway 237 72 47.63 1.51 0.049
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TAB. 3.1 PANTHER STATISTSICAL OVERREPRESENTATION TEST FOR BCL-3 SIRNA KNOCKDOWN 
Genes found to be significantly up/dow-regulated (p-value<0.05) in the MDA-MB-231-Luc 48h 
Bcl-3 siRNA knockdown Affymetrix microarray experiment were used to perform the PANTHER 
Statistical Overrepresentation test. The Bcl-3 knockdown gene list was compared to a reference 
human gene list and whether a particular biological process, pathway, molecular function or 
cellular component is over or underrepresented is determined and fold enrichment calculated. 
Tables represent broad categories from the enriched or depleted biological processes, molecular 
functions, cellular components and pathways. Fisher’s Exact test with FDR multiple test 
correction is used to determine statistical significance and only those with FDR of <0.05 is 
shown.
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3.14.1 PANTHER statistical overrepresentation analysis 
	 Numerous genes associated with biological processes were both significantly over 
and underrepresented following Bcl-3 siRNA knockdown (Tab 3.1). The enriched subsets 
include genes involved in cell cycle, cytokinesis, apoptosis, cellular metabolism, 
catabolism, protein glycosylation, cellular component biogenesis, cytoskeleton 
organisation, localisation of proteins and anions, transcription associated metabolism, 
phosphate-containing compound metabolism and intracellular signal transduction. The 
depleted subsets include genes involved in immune process such as complement 
activation and B-cell mediated immunity, G-protein coupled receptor signalling pathways, 
various system processes such as cell recognition.

	 Numerous genes associated with molecular functions were both significantly over 
and underrepresented following Bcl-3 siRNA knockdown (Tab 3.1). The enriched subsets 
include genes involved in transcription factor binding, actin and cytoskeletal protein 
binding, ubiquitin-protein ligase activity, transferase activity, catalytic activity including 
phosphatases and hydrolase. The depleted subsets include genes involved in the activity 
G-protein coupled receptors and signal transducers.

	 Numerous genes associated with cellular components were both significantly over 
and underrepresented following Bcl-3 siRNA knockdown (Tab 3.1). The enriched subsets 
include genes associated with the nucleoplasm, actin cytoskeleton, vacuoles, 
endosomes, endoplasmic reticulum, intracellular cytoplasm, and protein complexes. 
Genes associated with the extracellular region were depleted.

	 Numerous pathways were both significantly overrepresented following Bcl-3 siRNA 
knockdown (Tab 3.1). The enriched subsets include genes associated p53, apoptosis, 
VEGF signalling, TGF-beta signalling, integrin signalling, angiogenesis and gonadotropin-
releasing hormone receptor pathways.

3.14.2 PANTHER statistical enrichment analysis 
	 Following statistical enrichment analysis the following genes associated with 
biological processes were found to be significantly down-regulated: multicellular 
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organismal processes, system development, signal transduction and cell 
communications. (Tab 3.2)

	 Following statistical enrichment analysis the following genes associated with 
molecular functions were found to be significantly down-regulated, activity of structural 
molecules, motor activity and cytoskeletal protein binding. (Tab 3.2)

	 Following statistical enrichment analysis genes associated with the cytoskeleton 
were found to be significantly down-regulated. (Tab 3.2)

	 Following statistical enrichment analysis genes associated with apoptosis 
signalling, purine metabolism and activin beta signalling pathways were significantly up-
regulated. Genes associated with pyridoxal-5-phosphate biosynthesis, 5-HT degradation 
and cytoskeletal regulation by Rho GTPase pathways were significantly down-regulated. 
(Tab 3.2) 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PANTHER	Biological	Process # +/- P	value
269 - 0.004
93 - 0.024
482 - 0.011
555 - 0.023
 signal	transducBon	(GO:0007165)
 system	development	(GO:0048731)
 mulBcellular	organismal	process	(GO:0032501)
 cell	communicaBon	(GO:0007154)
PANTHER	Molecular	FuncEon # +/- P	value
structural	molecule	acBvity	(GO:0005198) 111 - 0.013
motor	acBvity	(GO:0003774) 26 - 0.002
cytoskeletal	protein	binding	(GO:0008092) 101 - 0.001
PANTHER	Cell	Component # +/- P	value
cytoskeleton	(GO:0005856) 156 - 0.004
PANTHER	Pathway # +/- P	value
Apoptosis	signalling	pathway	(P00006) 52 + 0.006
Purine	metabolism	(P02769) 3 + 0.008
Pyridoxal-5-phosphate	biosynthesis	(P02759) 2 - 0.032
AcBvin	beta	signalling	pathway	(P06210) 2 + 0.039
5-Hydroxytryptamine	degradaBon	(P04372) 8 - 0.043
Cytoskeletal	regulaBon	by	Rho	GTPase	(P00016) 27 - 0.045
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TAB. 3.2 PANTHER STATISTSICAL ENRICHMENT TEST FOR BCL-3 SIRNA KNOCKDOWN 
Genes found to be significantly up/dow-regulated (p-value<0.05) in the MDA-MB-231-Luc 48h 
Bcl-3 siRNA knockdown Affymetrix microarray experiment were used to perform the PANTHER 
Statistical Enrichment test. This tests uses the Mann-Whitney test to consider the Log fold-
change associated with each gene to determine whether there are trends within an ontology 
class or pathway. It looks for significant coordinated effects across all the relevant ratios to test 
whether an up- or down-regulation is unlikely to be accounted for by random chance.Tables 
represent classes from enriched biological processes, molecular functions, cellular components 
and pathways with a p-value of <0.05.
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3.15 Discussion 
	 Bcl-3 is generally accepted to be a putative proto-oncogene and its up-regulation 
has been identified and associated with many solid tumours, including breast cancer. We 
tested four triple negative breast cancer (TNBC) cell lines and found they all expressed 
significantly higher Bcl-3 than a nonmalignant human mammary epithelial cell line, 
MCF10a (Fig. 3.1). We wanted to investigate how Bcl-3 knockdown affected the cellular 
characteristics of these TNBCs and whether it influenced oncogenic or metastatic 
potential. We optimised conditions to robustly suppress its expression using siRNA for at 
least 96h. There were no observable effects on bulk monolayer cellular morphology over 
this time course (Fig. 3.2).

3.15.1 Bcl-3 regulated cellular proliferation through modulation 
of the cell cycle 
	 Following Bcl-3 knockdown we observed changes in a number of cellular 
phenotypic outputs. There were significant reductions in cell population turnover and we 
saw reduced growth rates in all four TNBC cell lines following ectopic suppression of 
Bcl-3. Despite this predicted effect on proliferation when Bcl-3 was ectopically 
suppressed, interestingly the baseline growth or proliferation rates for TNBCs inversely 
correlated with endogenous Bcl-3 levels (Fig. 3.3f). MDA-MB-436s expressed the highest 
Bcl-3 yet had the slowest growth, while MDA-MB-231s and SUM149s had comparatively 
low Bcl-3, but proliferated almost 2.5-fold faster over the course of 96h. If Bcl-3 was a 
classically dominant oncogene, simplistically we would expect to correlate higher 
expression with increased growth rates. However these results suggest there are other 
dominant factors contributing to overall cell growth. Grow rates of the nonmalignant 
MCF10a cell line was not affected by Bcl-3 knockdown.

	 Ki67 is a commonly used proliferative marker and is present during all active cell 
cycle phases. Phospho-histone H3 (ser10) is a cell marker specific for mitosis. Bcl-3 
knockdown was able to significantly reduce expression of both Ki67 and pHH3 in all four 
TNBC cell lines, but not in MCF10a (Fig. 3.4f + 3.5f). This supports the notion that Bcl-3 
influences proliferation by modulating aspects of the cell cycle and helps explain the 
growth suppression effects previously seen. However if we compared Ki67 and pHH3 
expression with relative growth rate between the controls, there was a seemingly inverse 
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correlation. MDA-MB-436s expressed the highest Ki67 and pHH3 but exhibited the 
slowest growth, while MDA-MB-231s grew the fastest but had the lowest comparative 
Ki67 and pHH3. Nevertheless endogenous Ki67 and pHH3 expression of these TNBCs 
did positively correlate with endogenous Bcl-3 levels. Similarly to Bcl-3, higher fractions 
of Ki67-positive cells can often correlate with a worsening clinical course of breast cancer 
and serve as a prognostic indicator for survival and tumour recurrence (Yerushalmi et al., 
2010). pHH3 expression has also been reported to be of prognostic significance in many 
breast cancers (Skaland et al., 2007). These results supported the hypothesis of Bcl-3 
acting as an oncogene as we were able to pair its higher expression with increased 
proliferative markers. However the underlying mechanism for the inverse relationship seen 
between proliferation and overall cell growth is addressed further below.

	 By staining and measuring cellular DNA content, we were able to determine 
snapshots of cell cycle stages and discriminate between cell fractions in the G0/G1, S 
and G2/M phases. Following Bcl-3 knockdown, all TNBC cell lines apart from MDA-
MB-436 saw reduced in S and G2/M phases and increased G0/G1 phases. This 
suggested the slow down in proliferation previously seen is likely due to the shift in 
balance between the increased G0/G1 resting cell fraction and decreased S and G2/M 
dividing cell fractions. In MDA-MB-436, we observed an atypically high subG1 cell 
fraction (Fig. 3.6a). This is indicative of internucleosomal DNA fragmentations and a 
hallmark of an apoptotic population. Bcl-3 knockdown resulted in not only a reduction of 
G2/M and S, but also G0/G1, which was balanced by a drastic increase in the subG1 
apoptotic cell fraction. This indicated Bcl-3 knockdown not only negatively regulated cell 
population change through a shift towards the resting G0/G1 population, but also through 
increasing the rate of apoptosis. The cell cycle of the nonmalignant MCF10a cell line was 
not affected by Bcl-3 knockdown.

	 PANTHER analyses of the knockdown Affymetrix data highlighted many 
statistically enriched and overrepresented genes associated with integrin signalling 
pathways (Tab. 3.1). Integrins are transmembrane receptors that facilitate cell to 
extracellular matrix adhesion and upon ligand binding they activate signal transduction 
pathways that mediate the cell cycle and also potentially apoptosis (Giancotti and 
Ruoslahti, 1999). These downstream signalling implications following Bcl-3 knockdown 
could provide potential mechanistic explanations for the observed changes to the cell 
cycle.
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3.15.2 Bcl-3 regulated apoptosis signalling pathways 
	 By directly assaying caspase-3/-7 activity we were able to show that Bcl-3 
knockdown significantly increased their activation in all TNBC cell lines but not in 
MCF10a (Fig. 3.11). On top of this, MDA-MB-436 by far expressed the highest 
endogenous caspase activity when compared with the other cell lines. Hence when 
considering the overall rate of cell growth, one must consider the overall cell-turnover, the 
combined rate of proliferation and rate of cell death, this might help explain why MDA-
MB-436 had the slowest cell growth rate despite having the highest Ki67 and pHH3 
expression among the TNBCs. Interestingly, despite significantly increased of 
caspase-3/-7 activity in all TNBC cell lines following Bcl-3 knockdown, we only saw an 
increased subG1 apoptotic cell fraction in the MDA-MB-436. This could be explained by 
the presence of a time lag between when apoptosis signalling is first triggered following 
Bcl-3 suppression and the subsequent phenotype of accumulated cellular DNA 
fragmentation required to identify a subG1 population. It will be interesting to assess the 
effects on the cell cycle phases with time-points longer than 48h when Bcl-3 suppression 
is sustained.

	 PANTHER statistical enrichment analysis of the Affymtrix knockdown experiment 
revealed a total of 52 significantly altered genes falling within the apoptosis signalling 
pathway. The overall pathway genotype was up-regulation and this correlated with the 
increased apoptotic phenotypes seen within the triple negative cell line experiments. As 
expected, Caspase-3 (CASP3) and-7 (CASP7) were shown to be up-regulated 1.27-fold 
and 1.36-fold respectively. These members of the cysteine-aspartic acid protease family 
have central roles in the execution of apoptosis. Although caspase-9 (CASP9) was down-
regulated 0.89-fold, it is unclear whether this was the active isoform 1 or isoform 2, a 
dominant-negative inhibitor of caspase-9, helping explain the increased downstream 
activation of caspase-3 and -7 (Li et al., 2017).

3.15.2.1 Bcl-3 protected against intrinsic mitochondria-
mediated apoptosis 
	 The expression of a wide number of Bcl-2 family proteins were altered following 
Bcl-3 knockdown. Bcl-2 apoptosis regulator (BCL2) and Bcl-2 like 1 (BCL2L1) were both 
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down-regulated 0.70-fold and 0.73-fold. These encode integral outer mitochondrial 
membrane proteins that antagonises apoptosis through regulation of mitochondrial 
membrane permeability (Delbridge et al., 2016). Bcl-2 interacting killer (BIK) was up-
regulated 1.46-fold and this protein acts to sensitise and accelerate apoptosis. Pro-
apoptotic protein BAK (BAK1) was up-regulated 1.34-fold and it induces apoptosis by 
opening mitochondrion voltage-dependent anion channels, and release of cytochrome c. 
Bcl-2 associate X apoptosis regulator (BAX) was up-regulated 1.19-fold and it 
heterodimerises with Bcl-2, antagonising its apoptosis repressing functions. Bcl-2 related 
ovarian killer (BOK) was up-regulated 1.18-fold and positively regulate intrinsic apoptosis 
through both TP53-, BAX-, BAK1-dependent and independent manners. Bcl-2 family 
apoptosis regulator (MCL1) was up-regulated 1.32-fold and is involved in the regulation of 
survival and apoptosis. The longest MCL1 isoform 1 is anti-apoptotic, but the alternatively 
spliced shorter isoform 2 and 3 promotes apoptosis and are death-inducing (Yang-Yen et 
al., 2015). Tumour protein P53 (TP53) was up-regulated 1.07-fold and encodes a potent 
tumour suppressor mediating apoptosis through stimulation of BAX and FAS or 
repression of Bcl-2 (Kastenhuber and Lowe, 2017).

	 Mitogen-activated protein kinase kinase 3 (MAP2K3), mitogen-activated protein 
kinase kinase 4 (MAP2K4), mitogen-activated protein kinase kinase kinase kinase 4 
(MAP4K4) and mitogen-activated protein kinase kinase 7 (MAP2K7) were all up-regulated 
1.20-fold, 1.17-fold, 1.23-fold and 1.09-fold respectively. These encode kinases that 
activate MKK/JNK signalling pathways involved in mitochondrial death signalling (Otto et 
al., 2012). Apoptotic peptidase activating factor 1 (APAF1) was up-regulated 1.28-fold and 
it encodes a protein component of the oligomeric apoptosome which activates caspase-9 
stimulating the caspase cascade that executes apoptosis (Shakeri et al., 2017). Mitogen-
activated protein kinase 1 (MAPK1) was up-regulated 1.03-fold and mitogen-activated 
protein kinase 3 (MAPK3) was down-regulated 0.81-fold. These encode essential serine/
threonine kinase components of the MAPK/ERK signal transduction pathway which 
mediate diverse biological functions including apoptosis (Upadhya et al., 2013).

	 A recent study investigating the pathogenesis of gliomas found elevated Bcl-3 
levels compared to normal brain tissues. Bcl-3 silencing in U251 cells saw prominent 
reductions in proliferation, cell cycle arrest in G1 phase, increased apoptosis and 
inhibition of in vivo tumour growth. Mechanistically it was found Bcl-3 positively 
associated with an abundance of STAT3, p-STAT3 and downstream targets of the STAT3 
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pathways including BCL2, MCL1 and cyclin D1. When they knocked down STAT3, the 
oncogenic effects mediated by Bcl-3 was found to be abolished. Their findings suggest 
that Bcl-3 oncogenicity seem to be mediated through STAT3 signalling pathways in 
gliomas (Wu et al., 2016). In light of the gene changes linked to the intrinsic apoptosis 
pathways in our TNBC cell line, it would be interesting to investigate STAT3 pathways to 
see if there are shared mechanistic links. Taken together with all of the pro-apoptotic gene 
changes seen relating to the Bcl-2 family of proteins, we propose that the effect of Bcl-3 
knockdown in TNBCs is at least in part driven, or augmented by the intrinsic 
mitochondria-mediated apoptosis pathway. These results seem to indicate that Bcl-3 
plays a critical role in protecting TNBCs against activation of this particular pathway.

3.15.2.2 Bcl-3 protected against stress induced apoptosis 
	 Various genes implicated in the cellular stress response were found to be altered 
following Bcl-3 knockdown. Heat shock 70kDA protein 1A (HSPA1A), 1B (HSPA1B) and 2 
(HSPA2) were all down-regulated 0.75-fold, 0.75-fold and 0.82-fold. These encode 
molecular chaperones involved in the protection of the proteome from stress induced 
apoptosis (Daugaard et al., 2007). Activating transcription factor 6 (ATF6) and 6 beta 
(ATF6B) were up-regulated 1.10-fold and 1.22-fold. These encode atypical transcription 
factors that act as transmembrane proteins embedded in the ER involved in the unfolded 
protein response (UFR) pathway following ER stress (Thuerauf et al., 2007).

	 These gene changes suggest that Bcl-3 is involved in regulation of the cellular 
stress threshold required to trigger an apoptotic cascade. It is possible knockdown led to 
the lowering of this threshold and primed the cancer cells for apoptosis in response to 
existing environmental stressors. Further experiments will have to be carried out to 
investigate whether this is the case. It will be interesting to assay cell viability and the 
proportion of cells that undergo apoptosis following varied culturing conditions, such as 
changes in temperature, oxygen or carbon dioxide content or even chemotherapeutics.

3.15.2.3 Bcl-3 and the extrinsic receptor-mediated apoptosis 
pathways 
	 Although the most conclusive changes following Bcl-3 knockdown were 
associated with the intrinsic mitochondria-mediated apoptosis pathway, a number of 
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interesting changes in genes associated with the extrinsic receptor-mediated pathways 
were also observed. TNF receptor superfamily member 10a (TNFRSF10A), 10b 
(TNFRSF10B) and 10d (TNFRSF10D) were all up-regulated 1.21-fold, 1.21-fold and 1.60-
fold respectively. These encode apoptosis inducing receptors activated by the tumour 
necrosis factor-related apoptosis inducing ligand (TRAIL). Their up-regulation hints at 
perhaps a sensitisation for endogenous TRAIL-mediated apoptosis. TNF receptor 
superfamily member 10c (TNFRSF10C) was down-regulated 0.78-fold. This encodes a 
receptor containing an extracellular and transmembrane TRAIL-binding domain but no 
cytoplasmic death domain. Subsequently this receptor is not capable of inducing 
apoptosis and is thought to function as a competitive antagonistic receptor protecting 
cells from TRAIL-induced apoptosis (Micheau, 2018). Its down-regulation further suggests 
at an increased sensitivity for TRAIL-mediated apoptosis.

	 MAP kinase activating death domain (MADD) was down-regulated 0.89-fold and it 
encodes a death domain-containing adaptor protein that interacts with the death domain 
of TNF-alpha receptor 1 to activate mitogen-activated protein kinase (MAPK) and 
propagate apoptosis. Depending on alternative mRNA splicing, MADD can serve different 
regulatory roles. For example, isoform 1 and 2 induces apoptosis and decreases 
proliferation while isoform 5 increases proliferation and confers apoptosis resistance. 
Down-regulation of the anti-apoptotic isoforms could help explain the increase in 
apoptosis signalling, but further investigation is required before any conclusions can be 
drawn (Al-Zoubi et al., 2001). Receptor-interacting protein kinase 1 (RIPK1) was up-
regulated 1.28-fold and encodes a protein that mediates both apoptosis and necroptosis 
through the TNF-alpha signalling pathway (Shan et al., 2018). Protein kinase C epsilon 
(PRKCE) and gamma (PRKCG) were down-regulated 0.87-fold and 0.72-fold. These 
encode PKC isoforms associated with up-regulation of NFkB signalling, enhanced 
apoptosis (Körner et al., 2013), and radiotherapy and chemotherapy resistance (Lu et al., 
2014).

	 Despite the aforementioned pro-apoptotic gene changes seen following Bcl-3 
knockdown, there are some key anti-apoptotic gene changes that may counteract their 
effectiveness. Activating transcription factor 7 (ATF7) was up-regulated 1.16-fold and 
plays important functions in early cell signalling by forming activatory heterodimers with 
JUN or FOS. Proto-oncogene c-jun (JUN) and c-fos (FOS) were both up-regulated 1.14-
fold and 1.23-fold respectively and encodes nuclear phosphoproteins that forms 
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complexes with the JUN/AP-1 transcription factor. JUN and FOS are typically seen as 
survival factors and promoters of proliferation, though in some cases they have been 
shown to be associated with apoptosis (Durchdewald et al., 2009).

	 CASP8 and FADD like apoptosis regulator (CFLAR) was up-regulated 1.11-fold. 
This encodes a regulator of apoptosis that is structurally similar to caspase-8 and acts as 
an inhibitor of TNFRSF6 mediated apoptosis. Death domain containing protein CRADD 
(CRADD) was down-regulated 0.84-fold, this gene encodes an apoptotic adaptor 
molecule specific for caspase-2 and the FASL/TNF receptor-interacting protein RIP. In the 
presence of RIP and TRADD, CRADD recruits caspase-2 to the TNFR-1 signalling 
complex activating apoptosis (Fulda, 2013). AKT serine/threonine kinase 2 (AKT2) was 
up-regulated by 1.10-fold and this protein inhibits apoptosis by phosphorylation of 
MAP3K5 (Riggio et al., 2017). While it is clear Bcl-3 does play some roles in mediating 
extrinsic apoptosis, mixed changes in both pro- and anti-apoptotic genes suggested a 
more complex regulatory pathway.

3.15.3 Bcl-3 implicated in NFkB signalling 
	 Using a NFkB reporter vector we were able to show that Bcl-3 knockdown led to a 
global reduction in pan-NFkB signalling in all cell lines (Fig. 3.21). This made sense as 
Bcl-3 plays an important role as a transactivator within NFkB signalling and we would 
expect its down-regulation to result in decreased p50 and p52 complex-mediated 
transcription. NFkB signalling is also closely linked with cellular processes such as 
proliferation and reduced pathway activities could help explain the slow down in 
proliferation seen previously following Bcl-3 suppression.

	 We were able to tease from the microarray analyses a few specific changes 
pertaining to the NFkB signalling pathway following Bcl-3 knockdown. Nuclear factor 
kappa B subunit 2 (NFKB2) and transcription factor RelB (RELB) were up-regulated 1.18-
fold and 1.13-fold. These encode pleiotropic transcription factors involved in regulation of 
a wide range of biological processes including but not limited to apoptosis. A recent 
study found that RelB was consistently linked with Bcl-3 expression in colorectal cancers. 
NFkB2 and RelB complexes were shown to be able to bind directly to the promoter 
region of the Bcl-3 gene and upregulate its transcription (Tao et al., 2018). This could help 
explain the up-regulation of these two subunits following Bcl-3 knockdown as it could 
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perhaps be an attempted cellular feedback response to restore endogenous Bcl-3 
balance.

	 Inhibitor of NFkB Kinase subunit beta (IKBKB) was down-regulated 0.79-fold and 
this encodes a protein that phosphorylates inhibitors of NFkB. These modifications allow 
polyubiquitination of the inhibitors, subsequent proteasomal degradation and activation of 
NFkB signalling (Schmid and Birbach, 2008). Inhibitor of NFkB kinase subunit (CHUK) 
was up-regulated by 1.25-fold and this encodes a member of the serine/threonine protein 
kinase family that acts as an inhibitor of of NFkB transcription (Solt and May, 2008). NFkB 
inducing kinase (MAP3K14) was down-regulated 0.81-fold and encodes the serine/
threonine mitogen-activated protein kinase kinase kinase 14. This is involved in the 
activation of non-canonical NFkB transcriptional activity (Malinin et al., 1997). It is clear 
from these findings that Bcl-3 is intricately tied to the balance of many different arms of 
NFkB signalling and the knockdown phenotype is the a result of many shifted 
downstream outputs.

3.15.4 Bcl-3 did not regulate cancer cell stemness but affected 
clonogenic survival 
	 When we assayed for self-renewal and cancer stem-like cells, Bcl-3 knockdown 
did not affect the number of mammospheres formed in any of the TNBC cell lines. 
However the average mammosphere size in all cell lines apart from SUM149 and MCF10a 
were significantly smaller (Fig. 3.12). This suggested Bcl-3 is not specifically implicated in 
conferring anoikis resistance, nor the survival of a stem-like cell population. Smaller 
sphere sizes following knockdown is likely a carried forward effect of the growth reduction 
phenotype previously seen. We would have expected SUM149 spheres to be smaller, but 
it is possible for this cell line to have a stem population resistant to the growth impairing 
effects of Bcl-3 knockdown. MCF10a does not seem to be affected by Bcl-3 knockdown 
so it was unsurprising for their sphere numbers and size to also remain unchanged.

	 When clonogenic survival capabilities were assayed we saw a marked reduction in 
both the number of colonies formed as well as their size following Bcl-3 knockdown in all 
cell lines apart from MCF10a (Fig. 3.13). These effects can partly be explained by the 
reduced cell growth and increased apoptosis seen within the knockdown cell populations. 
Following knockdown, a greater proportion of cells plated into the colony formation assay 
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were apoptotic compared to controls, and the surviving clonal populations proliferated 
slower. Furthermore, the low cell plating density conditions of this assay appeared to 
further sensitise these effects, leading to an overall significant impairment of clonogenicity 
within the Bcl-3 knockdown cells. The nonmalignant MCF10a cell line did not exhibit any 
reduced clonogenicity.

3.15.5 Bcl-3 regulated various modes of migration potentially 
through Rho GTPases 
	 The effects of Bcl-3 knockdown on three different migratory outputs were 
characterised in our panel of cell lines. We tested collective migration using the wound 
healing assay, amoeboid-like migration using the fluoroblok assay and mesenchymal-like 
migration using the single cell assay. In all TNBC cell lines, Bcl-3 knockdown was able to 
significantly inhibit all three forms of migration when compared to the scrambled control. 
The migratory phenotypes of the nonmalignant MCF10a cell line was not affected by 
Bcl-3 knockdown (Fig. 3.14-3.20).

	 PANTHER statistical enrichment analysis revealed 27 significantly altered genes 
falling within the cytoskeletal regulation by Rho GTPase pathway following Bcl-3 siRNA 
knockdown. This signalling pathway is primarily associated with cellular actin 
restructuring linked to cell motility. The general genotype following Bcl-3 knockdown was 
inhibitory and this correlates with the decreased migratory phenotype seen in the triple 
negative cell line experiments. In the next section we will discuss the significance and 
roles of the various altered genes within this signalling pathway following Bcl-3 
knockdown (Fig. 3.24).

	 The Rho-related GTP-binding protein RhoB (RHOB) was up-regulated 1.32-fold. 
RhoB encodes a major member of the Rho GTPase family, it shares about 85% amino 
acid identity with RhoA and RhoC, but plays very biologically different roles. It has been 
well established in numerous studies that RhoA and RhoC are pro-tumourigenic in almost 
all cancers. However RhoB has unique post-translational modifications distinctive from 
RhoA and RhoC, contributing to a more dualistic role in cancer. While RhoA and RhoC 
can only be palmitoylated, RhoB can also undergo farnesylation (RhoB-F) or 
geranylgeranylation (RhoB-GG) and its pernylation state determines its function 
(Zandvakili et al., 2017). Farnesylated RhoB localises to the plasma membrane, promoting 
 131
Chapter 3: Results
cell growth, mediating effects of Ras actin cytoskeleton and activating NFkB. In contrast 
geranylgeranylated RhoB localises to endosomes and induces apoptosis (Ju and Gilkes, 
2018).

	 RhoB has been shown to “switch-off” EGF mitogenic signals by targeting activated 
EGF receptors to the lysosome (Gampel et al., 1999). It has also been shown to exert a 
negative regulatory influence on TGF-β-induced transcriptional activation (Engel et al., 
1998) and this signalling pathway was one that was found to be statistically 
overrepresented following Bcl-3 knockdown. RhoB promoter activity was detected 
following genotoxic treatments indicating its role in the cellular response to DNA damage 
(Fritz and Kaina, 2000). Some studies have also shown that Ras actually down-regulates 
RhoB via EGFR, ErbB2 and AKT/PKB pathways (Jiang et al., 2004). Numerous 
subsequent studies began to reveal emerging evidence for a cancer suppressor role of 
RhoB by inhibiting in vitro cell proliferation, survival, invasion and metastasis and backed 
up by in vivo findings that RhoB depleted cells formed tumours less efficiently than cells 
expressing RhoB (Liu et al., 2001). RhoB depletion promoted 2D cell migration by altering 
β1 integration expression and hence focal adhesion dynamics and distribution (Ridley, 
2013). In breast tumourigenesis it was shown that RhoB acted as a tumour suppressor 
until the tumour vasculature was established, in which then its angiogenic tumour 
promoter functions overrode the negative impact it had in tumour cells (Kazerounian et 
al., 2013).

	 Rho-related GTP-bind protein RhoJ (RHOJ) was down-regulated 0.70-fold and it 
has been associated with formation of f-actin rich structures and focal adhesions (Wilson 
et al., 2014). RHOJ is activated by VEGF, a signalling pathway found to be statistically 
overrepresented following Bcl-3 knockdown and also shown to be implicated in 
angiogenesis regulation (Kim et al., 2014). RhoJ depletion was able to attenuate hypoxia 
induced EMT (Liu et al., 2018).

	 The genes Diaphanous-related formin-1 (DIAPH1) and Diaphanous-related 
formin-3 (DIAPH3), members of the diaphanous subfamily of the formin family were 
down-regulated 0.75-fold and 0.74-fold respectively. DIAPH1 encodes a protein 
controlling cell shape, assembly of f-actin structures and stabilising microtubules. DIAPH3 
is implicated in formin-dependent TGF-β signalling for EMT (Rana et al., 2018). Silencing 
of DIAPH3 was shown to destabilise microtubules and increased prostate and breast 
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cancer sensitivity to taxanes (Morley et al., 2015). Tubulin beta-4A chain (TUBB4A) was 
down-regulated 0.70-fold and Tubulin beta-6 chain (TUBB6) up-regulated 1.13-fold. 
These proteins encode members of the tubulin family which are major constituents of 
microtubules. They are likely downstream effectors of DIAPH1 and DIAPH3 signalling 
(Nami and Wang, 2018).

	 Rho-associated protein kinase 1 (ROCK1) was down-regulated 0.88-fold. It 
encodes a serine/threonine kinase regulated by upstream Rho GTPases and modulates 
cytoskeletal rearrangements processes including focal adhesion formation, cell motility 
and tumour cell invasion (Julian and Olson, 2014). Downstream of ROCK1 is LIM domain 
kinase 1 (LIMK1), which was down-regulated 0.83-fold. This is another serine/threonine 
kinase that regulates actin polymerisation via phosphorylation and inactivation of cofilin, 
preventing the cleavage of f-actin and stabilising the actin cytoskeleton. In this way 
LIMK1 regulates several actin-dependent biological processes including cell motility, cell 
cycle progression, and differentiation (Gorovoy et al., 2005). Following LIMK1 down-
regulation, Cofilin 2 (CFL2) was found to be up-regulated 1.16-fold. Cofilin is a major 
component of intra-nuclear and cytoplasmic actin rods and reversibly controls actin 
polymerisation and depolymerisation. Slingshot protein phosphatase 2 (SSH2) which 
encodes a protein tyrosine phosphatase that dephosphorylates and activates cofilin, 
promoting actin filament depolymerisation was up-regulated 1.09-fold. Slingshot protein 
phosphatase 3 (SSH3), another member of the slingshot phosphatase family was found 
to be down-regulated 0.77-fold and it is likely to have inhibitory effects on cofilin 
activation (Kanellos and Frame, 2016).

	 Protein enabled homolog/MENA (ENAH) was found to be down-regulated 0.77-
fold. It encodes an actin regulatory protein involved in a range of processes dependent on 
cytoskeleton remodelling and lamellipodial and filopodial dynamics in migrating cells. In 
invasive migratory tumour cells, ENAH imparts increased sensitivity to EGF and both 
invasive and protrusive capabilities are up-regulated (Gertler and Condeelis, 2011). 
Myosin heavy chain 9 (MYH9) was down-regulated 0.72-fold. This gene encodes a 
conventional non-muscle cytoplasmic myosin involved in cytokinesis, cell motility, cell 
shape, focal contact formation and lamellipodial retraction (Pecci et al., 2018).

	 Cell division control protein 42 homolog (CDC42) was down-regulated 0.66-fold 
following Bcl-3 knockdown. It is a major Rho GTPase family member upstream of many 
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actin polymerisation processes and commonly associated with promoting filopodial 
protrusions. However both Rho GTPase activating protein 1 (ARHGAP1) and Rho GTPase 
activating protein 8 (ARHGAP8) were down-regulated 0.90-fold and 0.81-fold respectively. 
These encode a family of proteins that activate Rho GTPase metabolising enzymes, 
converting Rho GTPase family proteins into the putatively inactive GDP-bound state. The 
down-regulation of these specific GAP proteins might be a feedback response due to the 
inhibitory affects of Bcl-3 knockdown and could help explain why we did not observe a 
significant down-regulation of other major Rho GTPase family members such as Rac1 or 
RhoA (J. Li et al., 2017).

	 p21-activated kinase 1 (PAK1) and p21-activated kinase 6 (PAK6) were both down-
regulated 0.86-fold and 0.95-fold respectively. They encode serine/threonine p-21-
activating kinases PAK protein family members which are effector proteins for CDC42. 
PAK1 and PAK6 signalling are important for cytoskeleton dynamics, cell adhesion, 
migration and vesicle-mediated transport processes. They are also involved in a wide 
range of other cellular functions and facilitates the full activation of Ras/RAF/MEK/ERK, 
PI3K/Akt/mTOR, MAPK and Wnt signalling pathways, which are implicated in cell cycle 
progression, cell survival, differentiation and proliferation. They can phosphorylate BAD 
and protect against apoptosis (Pérez-Yépez et al., 2018).

	 Despite CDC42 down-regulation, Neural Wiskott-Aldich syndrome protein/N-
WASP (WASL) was found to be up-regulated 1.10-fold. WASL is a scaffold protein that 
typically bind CDC42 and transduce signals from the cell surface to activate ARP2/3 
complexes leading to actin nucleation, polymerisation and is involved in mitosis and 
cytokinesis. Actin-related protein 2/3 complex subunit 1A (ARPC1A), 1B (ARPC1B), and 4 
(ARPC4), were up-regulated 1.18-fold, 1.24-fold and 1.11-fold respectively. Actin-related 
protein 2/3 complex subunit 3 (ARPC3) was down-regulated 0.87-fold. These changes in 
genes encoding subunits of the Arp2/3 protein complex are likely downstream effects of 
WASL signalling (Abella et al., 2016). Even though CDC42 was shown to be down-
regulated following Bcl-3 knockdown, it is possible that Bcl-3 has an inhibitory effect on 
WASL signalling independent of CDC42 altering the cellular migration phenotype.

	 Profilin-2 (PFN2), down-regulated 0.90-fold, encodes an actin binding protein 
belonging to the profilin family which regulates actin polymerisation. PFN2 has been 
shown to enhance TGF-β1-induced EMT and production of the angiogenic VEGF and 
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drive lung cancer growth and metastasis (Tang et al., 2015). These are both pathways 
found to be statistically overrepresented following Bcl-3 knockdown. PFN2 has also been 
shown to promote metastatic potential and stemless of HT29 colorectal cancer cells by 
regulating EMT and stemness related proteins (Kim et al., 2015). Myosin light chain kinase 
(MYLK), down-regulated 0.90-fold, encodes a calcium/calmodulin depended enzyme that 
phosphorylates myosin regulatory light chains to facilitate interactions with actin filaments 
to produce contractile activity (Shen et al., 2015). Beta-actin-like protein 2 (ACTBL2) 
down-regulated 0.79-fold, is an isomer of beta-actin and this was identified as a novel up-
regulated protein in colorectal cancer (Ghazanfar et al., 2017). Actin, gamma-enteric 
smooth muscle (ACTG2), down-regulated 0.90-fold, is a component of the cytoskeleton, 
acts as mediators of internal cell motility and has also been shown to be involved in small 
intestinal neuroendocrine tumourigenesis (Edfeldt et al., 2016).

	 It is worth noting these changes in Rho GTPase signalling was derived from 
experimental Affymetrix microarray analysis of Bcl-3 siRNA knockdown in the MDA-
MB-231-Luc cell line and other triple negative cell lines may respond differently. However 
the other TNBC cell lines used within this project had comparable experimental 
phenotypes following Bcl-3 knockdown so it is likely this analysis is at least somewhat 
representative, highlighting important mechanistic elements. Regardless, it is still 
important to confirm and validate whether there are similar genotypic responses following 
Bcl-3 knockdown in other TNBCs in future studies. 
 135
Chapter 3: Results
 
 136
RHOB
DIAPH1/
DIAPH3 ROCK1
Microtubule 
Stabilisation, EMT, 
Cell Shape
LIMK1
CFL2
SSH2
Actin 
DepolymerisationSSH3
BCL3
Down-regulated
Up-regulated
RHOJ
Actin Structures, 
Angiogenesis, EMT
Tumour 
Suppressor, 
Angiogenesis
CDC42
Lamellipodial/
Filopodial 
Protrusive 
Dynamics
BCL3
ARHGAP1/
ARHGAP2
ENAH
PAK1/
PAK6
Cell Migration, 
Protection from 
Apoptosis
WASL
Actin 
Polymerisation 
via ARP2/3 
complexes
MYH9
PFN2
Actin 
Polymerisation, 
EMT, 
Angiogenesis, 
FIG. 3.24 BCL-3 REGULATES RHO GTPASES SIGNALLING PATHWAYS WHICH POTENTIALLY 
IMPACTS ON MIGRATION 
Following Bcl-3 knockdown, numerous changes in Rho GTPase signalling pathways were 
observed. This figure plots out signalling pathway diagrams highlighting the interlinked 
downstream interactions associated with Bcl-3 and describes the main roles of each pathway.
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3.15.6 Bcl-3 knockdown reduced metastatic occurrence in a 
murine tail vein xenograft metastasis model 
	 In order to derive eventual clinical relevance it was important to investigate the 
effects of Bcl-3 knockdown in the context of an in vivo model. We chose a xenograft tail 
vein model as this was an effective technique at rapidly producing tumours that featured 
similar genetic profiles to metastases generated from orthotropic lesions (Rashid et al., 
2013). It was found that when Bcl-3 knockdown cells were injected via the tail vein 
vasculature, significantly less total metastatic occurrences were found at point of 
necropsy. The total number of distinct tumours in both the lungs and liver were 
significantly lower compared to the control siRNA cell line.

	 Although there was no significant difference between the average tumour size 
between the two conditions, it is worth noting this does not necessarily disprove the 
efficacy of Bcl-3 knockdown. Firstly the effects of siRNA knockdown is only transient and 
Bcl-3 levels within tumours would have returned to endogenous levels over the course of 
the experiment. We did not hypothesise Bcl-3 suppression to lead to tumour regression, 
hence the seeded metastases would have continued to expand at varying rates. 
Depending on the timeframe of the experiment there might be a more optimal endpoint 
than 45 days in order to see a significant difference between the Bcl-3 knockdown and 
control tumours. For future in vivo studies it will prove more informative to use luciferase 
expressing tumour cell lines to enable us to image and measure tumour growth 
longitudinally without the need to cull and perform necropsy at a chosen experimental 
endpoint.

	 All in all these results supports the effects seen in the in vitro experiments as 
suppressing Bcl-3 had been shown to impair viability, clonogenicity, and migratory 
capabilities. Taken together these expected downstream effect all contributed towards 
and helped explain the reduction in metastatic occurrence. In vivo efficacy further 
highlights Bcl-3 as a promising therapeutic target.
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3.15.7 Bcl-3 knockdown and other downstream implications 
	 Aside from apoptosis and migration linked Rho GTPase signalling pathways, 
PANTHER analyses of the Affymetrix microarray data highlighted a number of other 
interesting outputs worthy of further investigation. Among the altered genes a higher than 
expected proportion belonged to those associated with metabolic processes such as 
nitrogen, purine and carbohydrate metabolism, protein glycosylation, and biosynthetic 
and catabolic processes. Bcl-3 dysregulation had been shown in a recent study to disrupt 
hepatocyte metabolism and contribute to liver steatosis (Gehrke et al., 2016). Changes in 
cellular metabolism could also have contributed some of the phenotype shifts we 
observed in the TNBC cell lines.

	 Various angiogenesis related genes, specifically those related to VEGF were also 
found to be significantly overrepresented. This data preliminarily suggests Bcl-3 may be 
implicated in this physiological process by acting through vascular endothelial growth 
factor (VEGF) signalling. VEGF is a protein involved in both vasculogenesis and 
angiogenesis and is a part of the system that provides oxygen to tissues under hypoxic 
conditions. The capability of tumours to recruit the formation of new blood vessels is a 
critical transitional step towards aggressive disease. Cancers that express VEGF are able 
to continue to grow and metastasise (Palmer and Clegg, 2014).

	 Altered genes pertaining to the TGF-beta signalling pathways were also found to 
be highly enriched and overrepresented, this included the significantly up-regulated 
activin-beta signalling pathway which belongs to the TGF-beta superfamily. TGF-beta in 
breast cancer is selectively associated with pulmonary metastasis and a recent paper 
demonstrated the role of Bcl-3 to serve as a critical regulator. Bcl-3 knockdown was 
shown to enhance degradation of Smad3 but not Smad2 following TGF-beta treatment 
and Bcl-3 was able to bind to Smad3 to prevent its ubiquitination and degradation (Chen 
et al., 2016). This study and the changes seen in our microarray experiment emphasises 
the importance of further investigating the diverse roles and mechanisms of Bcl-3 within 
metastatic breast cancers.
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3.15.8 Concluding remarks 
	 It was evident from the experimental results generated in this chapter that siRNA 
knockdown of Bcl-3 profoundly suppressed oncogenic outputs within TNBC cell lines. We 
saw reductions in overall cell population turnover, characterised by reduced proliferation 
as well as increased apoptosis, mostly likely mediated through the intrinsic mitochondria-
associated signalling pathways. We demonstrated the effects of Bcl-3 on the various 
modes of cellular migration and microarray analysis associated this reduced motility with 
Rho GTPase signalling pathways. Furthermore none of the above mentioned effects were 
seen in the control non-tumourigenic MCF10a breast cancer cell line, suggesting the 
effects were likely specific to TNBC. Bcl-3 knockdown was also able to reduce in vivo 
metastatic occurrences in a murine tail vein xenograft model. Altogether our findings 
highlight Bcl-3 as an important contributor toward human TNBC progression, especially 
within the roles of metastasis and outline some interesting mechanistic pathways worthy 
of further study. 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Chapter 4: Results
4.1 Introduction 
	 Bcl-3 is generally accepted in the literature as a proto-oncogene and its 
overexpression has been implicated in a wide range of solid tumours and haematological 
malignancies (Maldonado and Melendez-Zajgla, 2011). Breast cancers were one of the 
first to be associated with deregulated Bcl-3 as when compared with normal adjacent 
tissues, p52 and Bcl-3 were found to be significantly up-regulated (Cogswell et al., 2000). 
Although mechanisms of Bcl-3 oncogenicity have not yet been fully described, its up-
regulation has often been linked with promotion of cellular proliferation and survival, as 
well as suppression of apoptosis. These processes have been shown to act through a 
number of pathways, such as promotion of cyclin D1 (Westerheide et al., 2001), 
suppression of the p53 response to DNA damage (Kashatus et al., 2006), as well as 
stabilisation of CtBP1 (Choi et al., 2010).

	 In the previous chapter we established the cellular effects of Bcl-3 suppression in a 
panel of TNBC cell lines. Here, we wanted to investigate the physiological effects of the 
opposite - ectopic overexpression. We hypothesised that if Bcl-3 were to act as a 
classical oncogene then its overexpression in the same panel of cell lines should have 
opposing effects to those seen with siRNA knockdown. Plasmid vectors containing wild 
type (WT) Bcl-3 constructs were generated by Dr. Alain Chariot’s group (Interdisciplinary 
Cluster for Applied Genoproteomics, University of Liège, Belgium). Plasmids containing 
Bcl-3 binding mutant constructs, termed Bcl-3 ANK mutants were generated through 
mutagenesis of the second Bcl-3 ankyrin repeat (Fig. 4.1). The integrity of this structure is 
required for binding to p50 and p52, hence Bcl-3 proteins containing these mutations 
have disrupted Bcl-3-p50 and Bcl-3-p52 binding (Keutgens et al., 2010b). Overexpression 
of this Bcl-3 binding mutant was expected to lead to inhibition of Bcl-3 signalling as 
dimerisation of the ANK mutant with endogenous Bcl-3 would prevent the formation of 
transcriptionally active p50-/p52-Bcl-3 complexes. Our understanding of Bcl-3 structural 
interactions allows us to explore the effects of Bcl-3 inhibition through a different 
mechanism of suppression compared to the excision of Bcl-3 protein with siRNA in the 
previous chapter.

	 The main aims of this chapter were to generate TNBC cell lines stably 
overexpressing WT Bcl-3, as well as the non-binding ANK mutant and assess their effects 
on overall cellular phenotype. We used the same range of in vitro cell-based assays (fully 
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described in the previous chapter) to quantify cell population change, proliferative 
markers, cell cycle, apoptosis, stemness, clonogenicity, migration and NFkB activity. In 
vivo xenograft experiments were also carried out to assess the affects of Bcl-3 
overexpression in mouse models. We hoped the results would further inform and progress 
our understanding of the role of Bcl-3 in the context of human TNBC.

4.2 Generation of TNBC cell lines overexpressing ectopic Bcl-3 
	 MDA-MB-231-Luc and MDA-MB-436 cell lines were transfected with the 
previously described WT Bcl-3 and Bcl-3 ANK mutant constructs as well as an empty 
pcDNA3.1 control vector. 24h post transfection the culture media for these lines were 
supplemented with Geneticin (G418) in order to select for plasmid expression. These 
newly generated recombinant cell lines were subsequently expanded and cultured under 
selection conditions for 1 week. Total protein (Fig. 4.2a) and RNA (Fig. 4.2b) were then 
extracted, western blotting and qRT-PCR carried out to characterise Bcl-3 expression. We 
observed expected increases in both Bcl-3 protein and RNA levels compared to pcDNA 
controls in both WT and ANK cell lines. For MDA-MB-231-Luc cells we saw a 5-6 fold 
overexpression of Bcl-3 and in MDA-MB-436 cells we saw a 9-16 fold overexpression.

WT Bcl-3 161    N      N      L      R      Q      T       P      L      H      L       A      V      I      T    174
        AAC AAC CTA CGG CAG ACA CCG CTC CAC CTG GCT GTG ATC ACC
Bcl-3 ANK 
Mutant
161   N      N      L      R      Q      T       P      A      H       A      A      V      A       T   174
       AAC AAC CTA CGG CAG ACA CCG GCC CAC GCC GCT GTG GCC ACC
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FIG. 4.1 BCL-3 CONSTRUCTS 
a. Figure showing the position of the mutated region located at second Bcl-3 ankyrin repeat 
where a triple mutation is carried out to generate the ANK mutant construct. b. Table showing 
the corresponding Leucine (position 168), Leucine (position 170) and Isoleucine (position 173) in 
WT Bcl-3 being mutated into Alanines in the ANK mutant.
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	 Bcl-3 is thought to be predominantly active within the nucleus. In order to check 
the cellular localisation of our ectopic Bcl-3 constructs, cellular protein was separated 
into cytoplasmic and nuclear fractions. The cytoplasmic marker α-Tublin and nuclear 
marker Lamin A/C were used to control for protein prep purity. By blotting for Bcl-3 in 
both fractions we can see both WT and ANK constructs were equally overexpressed in 
both cytoplasmic and nuclear compartments for both MDA-MB-231-Luc and MDA-
MB-436 cell lines (Fig. 4.2c). These cell lines were cultured and maintained in G418 
selection media and Bcl-3 levels were periodically checked every 5 passages by western 
blotting to confirm stability of overexpression.
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FIG. 4.2 RELATIVE BCL-3 PROTEIN RNA EXPRESSION AND CELLULAR LOCALISATION IN BREAST 
CANCER CELL LINES. 
a. Cell lines were cultured under standard conditions, total protein was extracted and western 
blotting for Bcl-3 carried out, loading control = GAPDH. Relative densities estimated. b. Total 
cellular RNA was extracted and Bcl-3 expression quantified using Taqman qRT-PCR and relative 
gene expression normalised to beta-actin (ACTB). Error bars represent ±SEM of 3 independent 
experiments. c. Cellular protein was separated into cytoplasmic and nuclear protein fractions 
and WB for Bcl-3 carried out, cytoplasmic marker = α-Tublin, nuclear marker = Lamin A/C. 
Images representative of 3 independent WBs. 
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4.3 Ectopic WT Bcl-3 overexpression reduced cell population 
growth 
	 Due to the widely accepted oncogenic attributes of Bcl-3, we hypothesised that its 
ectopic overexpression would lead to accelerated cell population growth. MDA-MB-436 
and MDA-MB-231-Luc cell lines stably expressing either WT Bcl-3, ANK mutant or 
control pcDNA constructs were plated into 96-well plates and cell population growth 
assayed using RealTime-Glo Assay (previously described in chapter 3.4) over the course 
of 96h. Surprisingly both TNBC cell lines overexpressing WT Bcl-3 exhibited a slow down 
in their cell population growth. Overexpression of the ANK Bcl-3 binding mutant also 
resulted in reduced cell growth for both of the TNBC cell lines (Fig. 4.3).
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FIG. 4.3 ECTOPIC OVEREXPRESSION OF BCL-3 CONSTRUCTS REDUCED CELL POPULATION 
GROWTH 
a. MDA-MB-436 b. MDA-MB-231-Luc cell lines stably expressing either WT Bcl-3, ANK mutant 
or pcDNA control constructs were plated into 96-well plates and cell population growth assayed 
using RealTime-Glo Assay. Error bars represent ±SEM of 3 independent experiments.
* p=0.035

* p=0.017
* p=0.044
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4.4 Ectopic WT Bcl-3 overexpression increased Ki67 
expression in -231-luc cells 
	 To confirm whether the effects of reduced cell growth following overexpression as 
determined by the metabolism based viability assay was a result of reduced proliferation 
we stained for the proportion of cells undergoing cell division. Following 
immunofluorescent staining for the proliferative marker Ki67, overexpression of WT Bcl-3 
resulted in a significant increase in the Ki67 population in MDA-MB-231-Luc cells. There 
were no significant changes in the MDA-MB-436 cell line though there was a slight trend 
for increased expression (p=0.132). Overexpression of the ANK mutant resulted in 
significant reductions of the Ki67 populations in both cell lines (Fig. 4.4).

4.5 Ectopic WT Bcl-3 overexpression increased pHH3 
expression 
	 To compliment our Ki67 results we also stained for phospho-histone H3 which 
specifically marks cells undergoing mitosis. This marker detects a smaller proportion of 
proliferating cells by targeting a narrower window within the cell cycle. Following 
immunofluorescent staining for the mitosis marker pHH3, overexpression of WT Bcl-3 
resulted in an increase in the pHH3 population in both MDA-MB-231-Luc and MDA-
MB-436 cell lines. Similarly to Ki67 expression in both of these TNBC cell lines, 
overexpression of the ANK binding mutant resulted in significantly reduced pHH3 
expressions (Fig. 4.5).
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FIG. 4.4 ECTOPIC WT BCL-3 OVEREXPRESSION INCREASED KI67 EXPRESSION IN -231-LUC 
Representative immunofluorescence images of a. MDA-MB-436 and MDA-MB-231-Luc cells 
stably expression WT Bcl-3, ANK mutant or pcDNA constructs were plated onto coverslips, PFA 
fixed and immunofluorescent-stained for Ki67. b. Graph comparing Ki67 expression between 
different cell lines and overexpression constructs. Error bars represent ±SEM of 3 independent 
experiments. (T-test, *=p<0.05, **=p<0.01, ***=p<0.001)
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FIG. 4.5 ECTOPIC WT BCL-3 OVEREXPRESSION INCREASED PHH3 EXPRESSION 
Representative immunofluorescence images of a. MDA-MB-436 and MDA-MB-231-Luc cells 
stably expression WT Bcl-3, ANK mutant or control pcDNA constructs were plated onto 
coverslips, PFA fixed and immunofluorescent-stained for pHH3. b. Graph comparing pHH3 
expression between different cell lines and overexpression constructs. Error bars represent 
±SEM of 3 independent experiments. (T-test, *=p<0.05, **=p<0.01, ***=p<0.001)
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4.6 Effect of ectopic WT Bcl-3 overexpression on the cell cycle 
	 By staining with fluorescent DAPI and quantifying total cellular DNA content we 
were able to discriminate between the different phases of the cell cycle. This provided us 
with additional information regarding the effect of Bcl-3 overexpression on the overall 
structure of the cell cycle. MDA-MB-436 and MDA-MB-231-Luc cells stably expressing 
WT Bcl-3, ANK mutant or control pcDNA constructs were permeabilised with NP-40 and 
stained with DAPI. Single-cell DNA content was measured using flow cytometry and cell 
cycle stages calculated. We were able to calculate a cell turnover index (CTI) reflective of 
the overall rate of cell growth as the ratio between the proliferative G2/M population to the 
apoptotic subG1 population.

4.6.1 Ectopic WT Bcl-3 overexpression in MDA-MB-436 
increased the subG1 population and decreased the G0/G1 
population 
	 Overexpression of WT Bcl-3 in MDA-MB-436 resulted in a significant increase in 
the subG1 population which was balanced by a proportional reduction in the G0/G1 
population. There was a trend of an increased G2/M population but the results were not 
significant (p=0.140). The CTI was calculated to be 0.688-fold significantly reduced 
compared to control (p=0.0376)). Overexpression of the ANK mutant saw an increased 
subG1 population and decreased G0/G1 and G2/M populations. The CTI was calculated 
to be 0.372-fold significantly reduced compared to control (p=0.001) (Fig. 4.6).

4.6.2 Ectopic WT Bcl-3 overexpression in MDA-MB-231-Luc 
increased the subG1 population and decreased the G0/G1 
population 
	 Overexpression of WT Bcl-3 in MDA-MB-231-Luc resulted in a significant increase 
in the subG1 and G2/M populations which was balanced by a reduction in the G0/G1 
population. The CTI was calculated to be 0.328-fold significantly reduced compared to 
control (p=0.009). Overexpression of the ANK mutant also resulted in an increased subG1 
population and decreased G0/G1 and S populations. There was a trend of decreased G2/
M but the results were not significant (p=0.211). The CTI was calculated to be 0.188-fold 
significantly reduced compared to control (p=0.004) (Fig. 4.7). 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FIG. 4.6 ECTOPIC WT BCL-3 OVEREXPRESSION IN MDA-MB-436 INCREASED THE SUBG1 
POPULATION AND DECREASED THE G0/G1 POPULATION 
MDA-MB-436 cells stably expressing WT Bcl-3, ANK mutant or control pcDNA constructs were 
permeabilised with NP-40 and stained with DAPI. Single-cell DNA content was measured using 
flow cytometry and cell cycle stages calculated. a.&b. Percentage of cells in each cell cycle. 
c.&d.&e. Representative histograms detailing cell cycle stage distribution. f. Cell turnover index 
(CTI) calculated as the ratio of the proliferative G2/M population to the apoptotic subG1 
population. Error bars represent ±SEM of 3 independent experiments. (T-test, *=p<0.05, 
**=p<0.01, ***=p<0.001)
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FIG. 4.7 ECTOPIC WT BCL-3 OVEREXPRESSION IN MDA-MB-231-LUC INCREASED THE SUBG1 
AND G2/M POPULATIONS AND DECREASED THE G0/G1 POPULATION 
MDA-MB-231-Luc cells stably expressing WT Bcl-3, ANK mutant or control pcDNA constructs 
were permeabilised with NP-40 and stained with DAPI. Single-cell DNA content was measured 
using flow cytometry and cell cycle stages calculated. a.&b. Percentage of cells in each cell 
cycle. c.&d.&e. Representative histograms detailing cell cycle stage distribution. f. Cell turnover 
index (CTI) calculated as the ratio of the proliferative G2/M population to the apoptotic subG1 
population. Error bars represent ±SEM of 3 independent experiments. (T-test, *=p<0.05, 
**=p<0.01, ***=p<0.001)
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4.7 Ectopic Bcl-3 overexpression increased caspase-3/7 
activity 
	 The presence of subG1 cell cycle populations is indicative of apoptotic bodies and 
we wanted another to quantify and validate the increased rate of apoptosis. MDA-
MB-436 and MDA-MB-231-Luc cells stably expressing WT Bcl-3, ANK mutant or control 
pcDNA constructs were lysed and assayed for caspase-3/7 activity using the Caspase-
Glo 3/7 assay (previously described in chapter 3.8). Ectopic overexpression of both WT 
Bcl-3 and the ANK mutant resulted in increased caspase 3/7 activity of roughly 1.5-fold 
for both MDA-MB-436 and MDA-MB-231-Luc cell lines (Fig. 4.8).
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FIG. 4.8 ECTOPIC BCL-3 OVEREXPRESSION INCREASED CASPASE-3/7 ACTIVITY 
MDA-MB-436 and MDA-MB-231-Luc cells stably expressing WT Bcl-3, ANK mutant or control 
pcDNA constructs were lysed and assayed for caspase-3/7 activity. Error bars represent ±SEM 
of 3 independent experiments. (T-test, *=p<0.05, **=p<0.01, ***=p<0.001)
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4.8 Ectopic Bcl-3 overexpression did not affect total 
mammosphere numbers but significantly reduced 
mammosphere size 
	 We wanted to assess the whether Bcl-3 upregulation was able to promote anoikis 
resistance and increase the survival of a stem-like population as this attribute is 
commonly associated with oncogenicity. MDA-MB-436 and MDA-MB-231-Luc cells 
stably expressing WT Bcl-3, ANK mutant or control pcDNA constructs were 
disaggregated into single cells and plated into non-adherent mammosphere plates and 
cultured for 10 days and total mammosphere numbers and size quantified. 
Overexpression of both WT Bcl-3 and the ANK mutant in both TNBC cell lines did not 
affect total mammosphere numbers but resulted in significant reductions in average 
mammosphere size (Fig. 4.9).

4.9 Ectopic Bcl-3 overexpression significantly impaired 
clonogenic survival  
	 Clonogenic potential was tested by plating either MDA-MB-436 or MDA-MB-231-
Luc cells stably expressing WT Bcl-3, ANK mutant or control pcDNA constructs at low 
density in a colony formation assay and cultured for 10 days. Colonies were then fixed 
with glutaraldehyde (6% v/v), stained with crystal violet (0.5% w/v), imaged using a plate 
scanner and colonies quantified. Overexpression of both WT Bcl-3 and the ANK mutant in 
both TNBC cell lines resulted in impaired clonogenic potential. There were significant 
reductions in both totally colony number, as well as average colony size with the effect 
being more pronounced in the ANK mutant (Fig. 4.10).
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FIG. 4.9 ECTOPIC BCL-3 OVEREXPRESSION DID NOT AFFECT TOTAL MAMMOSPHERE NUMBERS 
BUT SIGNIFICANTLY REDUCED MAMMOSPHERE SIZE 
MDA-MB-436 and MDA-MB-231-Luc cells stably expressing WT Bcl-3, ANK mutant or control 
pcDNA constructs were disaggregated into single cells and plated into non-adherent 
mammosphere plates and cultured for 10 days. Representative bright-field images for a. MDA-
MB-436 b. MDA-MB-231-Luc c. Total mammosphere number. d. Average mammosphere size. 
Error bars represent ±SEM of 3 independent experiments. (T-test, *=p<0.05, **=p<0.01, 
***=p<0.001)
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FIG. 4.10 ECTOPIC BCL-3 OVEREXPRESSION SIGNIFICANTLY IMPAIRED CLONOGENIC SURVIVAL  
Clonogenic potential was tested by plating either MDA-MB-436 or MDA-MB-231-Luc cells 
stably expressing WT Bcl-3, ANK mutant or control pcDNA constructs at low density in a colony 
formation assay and cultured for 10 days before being fixed and stained with crystal violet. 
Representative images, total colony number and average colony coverage for a. MDA-MB-436 
b. MDA-MB-231-Luc. Error bars represent ±SEM of 3 independent experiments. (T-test, 
*=p<0.05, **=p<0.01, ***=p<0.001)
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4.10 Effect of ectopic Bcl-3 overexpression on cellular 
migration 
	 Similarly to the previous chapter 3.11, three different assays were used to assess 
the effect of Bcl-3 overexpression on collective, amoeboid-like and mesenchymal-like 
single cell migration in two TNBC cell lines.

4.10.1 Ectopic Bcl-3 overexpression significantly inhibited 
collective migration 
	 The wound-healing assay was used to investigate collective migration in MDA-
MB-436 and MDA-MB-231-Luc cells stably expressing WT Bcl-3, ANK mutant or control 
pcDNA constructs. Cells were cultured and a scratch was made on a confluent monolayer 
using a 200µL pipette tip and cells cultured for a further 48h. Bright-field microscopy 
images were captured at 12h, 24h, 36h and 48h time-points and percentage wound 
closure was calculated using ImageJ.

4.10.1.1 Ectopic Bcl-3 overexpression significantly inhibited 
collective migration in MDA-MB-436 
	 Overexpression of both WT Bcl-3 and the ANK mutant resulted in an inhibition of 
collective migration over the course of 48h. The WT Bcl-3 and ANK mutant 
overexpression cell lines saw a 50% and 30% reduction respectively in wound closure 
capabilities by 48h (Fig. 4.11).

4.10.1.2 Ectopic Bcl-3 overexpression significantly inhibited 
collective migration in MDA-MB-231-Luc 
	 Overexpression of both WT Bcl-3 and the ANK mutant resulted in an inhibition of 
collective migration over the course of 48h. The WT Bcl-3 and ANK mutant 
overexpression cell lines saw a 50% and 65% reduction respectively in wound closure 
capabilities by 48h (Fig. 4.12). 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FIG. 4.11 ECTOPIC BCL-3 OVEREXPRESSION SIGNIFICANTLY INHIBITED COLLECTIVE 
MIGRATION IN MDA-MB-436 
The wound-healing assay was used to investigate collective migration in MDA-MB-436 cells 
stably expressing WT Bcl-3, ANK mutant or control pcDNA constructs. A scratch was made on 
a confluent monolayer using a 200µL pipette tip and cells cultured for 48h with images being 
taken every 12h. a. Representative images showing the scratch at 0h and 48h. b. Total scratch 
area quantified using ImageJ and % wound closure calculated for 12h, 24h, 36h and 48h time-
points. c. % wound closure at 48h time-point. Error bars represent ±SEM of 3 independent 
experiments. (T-test, *=p<0.05, **=p<0.01, ***=p<0.001)
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FIG. 4.12 ECTOPIC BCL-3 OVEREXPRESSION SIGNIFICANTLY INHIBITED COLLECTIVE 
MIGRATION IN MDA-MB-231-LUC 
The wound-healing assay was used to investigate collective migration in MDA-MB-231-Luc cells 
stably expressing WT Bcl-3, ANK mutant or control pcDNA constructs. A scratch was made on 
a confluent monolayer using a 200µL pipette tip and cells cultured for 48h with images being 
taken every 12h. a. Representative images showing the scratch at 0h and 48h. b. Total scratch 
area quantified using ImageJ and % wound closure calculated for 12h, 24h, 36h and 48h time-
points. c. % wound closure at 48h time-point. Error bars represent ±SEM of 3 independent 
experiments. (T-test, *=p<0.05, **=p<0.01, ***=p<0.001)
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4.10.2 Ectopic WT Bcl-3 overexpression increased amoeboid-
like single cell migration 
	 The FluoroBlok assay (described in chapter 3.11.2) was used to investigate 
amoeboid-like migration of MDA-MB-436 and MDA-MB-231-Luc cells stably expressing 
WT Bcl-3, ANK mutant or control pcDNA constructs. Cells were plated into the top well of 
a FluoroBlok assay plate and left to migrate for 24h across a chemotactic gradient. Cells 
were then stained with calcein AM and fluorescence intensity at 500nm was quantified by 
a bottom-reading plate reader. Overexpression of WT Bcl-3 resulted in a 20-30% increase 
in fluorescence intensity while the ANK mutant resulted in a 25-40% reduction (Fig. 4.13).
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FIG. 4.13 ECTOPIC WT BCL-3 OVEREXPRESSION INCREASED AMOEBOID-LIKE SINGLE CELL 
MIGRATION 
The FluoroBlok assay was used to investigate amoeboid-like migration of cell line panel. MDA-
MB-436 and MDA-MB-231-Luc cells stably expressing WT Bcl-3, ANK mutant or control pcDNA 
constructs were plated into the top well of a FluoroBlok assay plate and left to migrate for 24h 
across a chemotactic gradient. Cells were stained with calcein AM and fluorescence intensity at 
500nm was quantified by a bottom-reading plate reader. Error bars represent ±SEM of 3 
independent experiments. (T-test, *=p<0.05, **=p<0.01, ***=p<0.001)
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4.10.3 Ectopic Bcl-3 overexpression significantly increased 
mesenchymal-like single cell migration in the -231-Luc cell line 
	 The single cell migration assay was used to investigate 2D motility of MDA-MB-436 
and MDA-MB-231-Luc cells stably expressing WT Bcl-3, ANK mutant or control pcDNA 
constructs. Cells were plated at low densities and single cell migration quantified by 
tracking the motility path of each cell using a time-lapse incubator chamber over the 
course of 12h with images captured every 10 min. Overexpression of WT Bcl-3 resulted in 
a 15% increase in average distance travelled over the course of 12h in the -231-luc cell 
line, while the ANK mutant resulted in a 40-50% reduction in average distance travelled 
for both TNBC cell lines (Fig. 4.14d).
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FIG. 4.14 ECTOPIC BCL-3 OVEREXPRESSION SIGNIFICANTLY INCREASED MESENCHYMAL-LIKE 
SINGLE CELL MIGRATION IN THE -231-LUC CELL LINE 
The single cell migration assay was used to investigate 2D motility of MDA-MB-436 and MDA-
MB-231-Luc cells stably expressing WT Bcl-3, ANK mutant or control pcDNA constructs. Cells 
were plated at low densities and single cell migration quantified using a time-lapse incubator 
chamber over the course of 12h with images captured every 10 min. Representative images of 
motility paths of single cells over 12h for a. MDA-MB-436 and b. MDA-MB-231-Luc cell lines. c. 
Average distance travelled away from origin. d. Average distance travelled after 12h. Error bars 
represent ±SEM of 3 independent experiments. (T-test, *=p<0.05, **=p<0.01, ***=p<0.001)
c
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4.11 Ectopic overexpression of WT Bcl-3 increased NFkB 
activity 
	 Since Bcl-3 is known to act through NFkB pathways (Bours et al., 1993) we wanted 
to verify the effect of overexpression on NFkB transcription activity. A luciferase NFkB 
reporter plasmid was used to quantify NFkB levels in MDA-MB-436 and MDA-MB-231-
Luc cells stably expressing WT Bcl-3, ANK mutant or control pcDNA constructs. Cells 
were transfected with the reporter plasmid, LacZ control plasmid and cultured for 24h. 
Cells were then lysed and NFkB activity measured as luminescence readout using a plate 
reader. NFkB activity was then normalised to LacZ luminescence to control for 
transfection efficiency. Overexpression of WT Bcl-3 resulted a 20% increase in NFkB 
activity in both TNBC cell lines, while the ANK mutant resulted in a 30-40% decrease in 
NFkB activity (Fig. 4.15).
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FIG. 4.15 ECTOPIC OVEREXPRESSION OF WT BCL-3 INCREASED NFKB ACTIVITY 
A luciferase NFkB reporter plasmid was used to quantify NFkB levels in MDA-MB-436 and 
MDA-MB-231-Luc cells stably expressing WT Bcl-3, ANK mutant or control pcDNA constructs. 
Cells were transfected with the luciferase NFkB reporter plasmid, LacZ control plasmid and 
cultured for 24h. Cells were then lysed and NFkB activity measured as luminescence readout 
using a plate reader. NFkB activity was then normalised to LacZ luminescence to control for 
transfection efficiency. Error bars represent ±SEM of 3 independent experiments. (T-test, 
*=p<0.05, **=p<0.01, ***=p<0.001)
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4.12 Effect of ectopic Bcl-3 overexpression in murine xenograft 
metastasis models 
	 Several options were considered when developing relevant xenograft models 
including the site of injection and implantation. Orthotopic xenografts offers a 
complementary stromal microenvironment. Injecting into the mammary fat pad is a 
relatively simple procedure and allows for visible and measurable growth of our TNBC cell 
lines. But it is always worth noting there are distinct differences between the human and 
rodent mammary stroma and hormonal environments.

	 MDA-MB-231 cells stably expressing WT Bcl-3, ANK mutant or control pcDNA 
constructs were injected either orthotopicaly into both abdominal mammary fat pads 
bilaterally (1x106 cells in 100μl) or intravenously via the lateral tail vein (2x105 cells in 
100μl) in 6 week old female Hsd: Athymic Nude-Foxn 1nu mice (Harlan Laboratories). 
Orthotopic tumour growth was measured by palpation over 42 days and intravenous 
xenograft recipients were culled and necropsy performed at 45 days post surgery. 
Harvested xenograft tissue was then formalin fixed, embedded in paraffin blocks and H&E 
slides generated for histological analysis.

4.12.1 Ectopic overexpression of Bcl-3 exhibited a trend of 
reduced growth rates at the orthotopic site 
	 Quantification of orthotopic MDA-MB-231 tumours revealed that overexpression of 
both WT Bcl-3 and the ANK mutant resulted in a trend of reduced growth rates compared 
to the pcDNA control over the course of 42 days. Final average tumour volumes for 
pcDNA control was 848mm3, WT Bcl-3 was 458mm3 and ANK mutant was 524mm3 (Fig. 
4.16). The latency of tumour formation was noted by the first day post-surgery a palpable 
tumour was detectable and measured was found to be day 12 for the pcDNA control, day 
14 for the WT Bcl-3 and day 17 for the ANK mutant.
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4.12.2 Ectopic overexpression of WT Bcl-3 increased 
metastases to distal organs but significantly reduced average 
tumour size 
	 Histological analysis of H&E stained serial sections of distal organs harvested from 
mice injected with MDA-MB-231 cells stably expressing control pcDNA, WT Bcl-3 or ANK 
mutant was carried out. The number of metastases on each section was counted and 
total area for each metastasis quantified. Overexpression of WT Bcl-3 resulted in a 
significant increase in the average number of metastases identified in the lungs, however 
the average size of these metastases were significantly smaller. Overexpression of the 
ANK mutant resulted in significantly less metastases in the lungs and a near significant 
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FIG. 4.16 ECTOPIC OVEREXPRESSION OF BCL-3 EXHIBITED A TREND OF REDUCED GROWTH 
RATES AT THE ORTHOTOPIC SITE 
MDA-MB-231 cells stably expressing WT Bcl-3, ANK mutant or control pcDNA constructs were 
injected orthotopicaly into both abdominal mammary fat pads bilaterally (1x106 cells in 100μl) of 
6 week old female Hsd: Athymic Nude-Foxn 1nu mice (Harlan Laboratories). Orthotopic tumour 
growth was measured by palpation. Graph showing the growth rate of each cell line detailing 
average tumour volume over the course of 42 days. Error bars represent ±SEM of 8 tumours in 4 
independent mice per cohort.
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reduction in average metastases size (p=0.11) (Fig. 4.17). Only a few metastases were 
found across all liver sections so there was insufficient data to plot anything statistically 
conclusive. Interestingly within the WT Bcl-3 overexpression cohort, we found distal 
metastases established in the heart, mammary gland and bone marrow (femur) in addition 
to the lungs and liver (Fig. 4.17c). No tumours at these locations were identified within the 
control and ANK mutant cohorts. 
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FIG. 4.17 ECTOPIC OVEREXPRESSION OF WT BCL-3 INCREASED METASTASES TO DISTAL 
ORGANS 
MDA-MB-231 cells stably expressing WT Bcl-3, ANK mutant or control pcDNA constructs were 
injected intravenously via the lateral tail vein (2x105 cells in 100μl) in 6 week old female Hsd: 
Athymic Nude-Foxn 1nu mice (Harlan Laboratories). Animals were culled and necropsy 
performed at 45 days post surgery. Xenograft tissue were fixed, embedded in paraffin blocks, 
serial sections cut and H&E slides generated for metastases quantification through histological 
analysis. a. Average metastasis count in the lung and liver, b. average metastasis size in lung for 
control pcDNA cohort (n=5), WT cohort (n=5) and ANK cohort (n=5). Error bars represent ±SEM 
of 5 independent mice. (T-test, *=p<0.05, **=p<0.01, ***=p<0.001) c. Representative 
haematoxylin and eosin (H&E) staining of mouse lung, liver, heart, femur and mammary gland 
sections with metastatic tumours marked as M.
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4.13 Discussion 
	 Bcl-3 is widely regarded as an oncogene and in the previous chapter we were able 
to demonstrate its knockdown led to a range of tumour suppressive phenotypes. 
Following those findings, we wanted to investigate the effects of Bcl-3 up-regulation by 
generating human TNBC cell lines stably overexpressing either WT Bcl-3 or a non-binding 
ANK mutant Bcl-3. This allowed us to address the hypothesis of whether up-regulated 
Bcl-3 is associated with increased tumourigenicity in TNBC cell lines, as commonly seen 
in many solid cancers (Maldonado and Melendez-Zajgla, 2011). Additionally the ANK non-
binding mutant gave us a way to validate effects seen with siRNA knockdown because 
when overexpressed, unpublished studies within our group showed it effectively acted as 
a dominantly negative Bcl-3 inhibitor.

4.13.1 Overexpression of WT Bcl-3 reduced cell turnover 
	 Contrary to our original expectations, up-regulation of Bcl-3 in both MDA-MB-231-
Luc and MDA-MB-436 cell lines amounted to overall reductions in the expansion of cell 
population as quantified by the metabolism based viability assay (Fig. 4.3). Though 
interestingly when we dissected the different components of cell population growth, Bcl-3 
overexpression actually resulted in an increase in cellular proliferation, highlighted by 
increased Ki67 and pHH3 (Fig. 4.4 & 4.5), as well as larger G2/M populations in the cell 
cycle phases (Fig. 4.6 & 4.7). Mechanistically, studies often found elevated Bcl-3 to up-
regulate cyclin D1, leading to increased proliferation (Tu et al., 2016). However, both of our 
TNBC cell lines also featured elevated subG1 populations indicative of increased 
apoptosis. Up-regulated apoptosis was confirmed by the Caspase-Glo assay and the 
Bcl-3 overexpressing cell lines had roughly 1.5-fold increased caspase-3/-7 activities (Fig. 
4.8). Taken together, these results allowed us to calculated the CTI as the ratio of 
proliferating cells to those undergoing apoptosis and Bcl-3 overexpression in both cell 
lines resulted in significantly reduced cell turnover (Fig. 4.6f & 4.7f). 

	 There are many examples in the literature demonstrating the pro-proliferative 
natures of up-regulated Bcl-3 (Maldonado and Melendez-Zajgla, 2011), however it is rarer 
for its overexpression to be associated with increased apoptosis. A recent study showed 
that Bcl-3 overexpression in hepatocytes attenuated in vivo hepatocarcinogenesis. Mice 
with hepatocytes overexpressing Bcl-3 featured smaller hepatocellular carcinomas, 
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decreased cell growth, as well as a higher rate of apoptotic cell death. Activation of JNK 
and ERK signalling was reduced and the number of activated intrahepatic macrophages, 
CD8+ T cells and activated B cells were all reduced in tumours with elevated Bcl-3 
(Gehrke et al., 2017). It is formally possible that similar pro-apoptotic mechanisms exist in 
the TNBC cells we tested.

	 A study using a dextran sulphate sodium induced mouse colon tumourigenesis 
model found elevated Bcl-3 to suppress colorectal tumour formation (Tang et al., 2016). 
Tumour burden was dependent on tumour necrosis factor-α, a NFkB-mediated pathway 
dampened by Bcl-3 (Walker et al., 2013). These findings suggest that depending on the 
cellular and environmental context, Bcl-3 can function either as a tumour promoter or 
have tumour-suppressive roles. It is likely for this atypical NFkB family member to have 
varied mechanisms of action, perhaps acting as a fine-tuned permissive regulator in some 
cancers, while acting as a classical proto-oncogene in others.

4.13.2 Overexpression of WT Bcl-3 did not affect 
mammosphere numbers but impaired clonogenicity 
	 There were no observable differences in anoikis-resistant cancer mammoshpere 
population following Bcl-3 up-regulation, though the average mammosphere sizes were 
smaller (Fig. 4.9). Taking into consideration that Bcl-3 overexpression reduced cell 
growth, it made sense for sphere sizes to be smaller as a subsequent carried forward 
effect. Although continued serial passage of mammospheres were not carried out, hence 
we cannot conclude on the self-renewal population. Though Bcl-3 is most likely not 
specifically implicated in promoting the selective survival of a stem-like population in 
TNBC based on previous findings with siRNA. When testing clonogenicity, the 
overexpressing cell lines exhibited reduced colony numbers as well as size (Fig. 4.10) and 
this could also be explained by the downstream result of reduced cell turnover.

	 A recent study showed that ectopic Bcl-3 overexpression was able to significantly 
reduce both proliferation and self-renewal in mouse embryonic stem cells. Interestingly 
knockdown of Bcl-3 also resulted in similarly reduced proliferation and loss of self-
renewal. In this case Bcl-3 was found to be a transcriptional repressor of Nanog 
expression and a sufficiently optimal concentration of Bcl-3 was critical for the 
maintenance of normal functions (Kang et al., 2018). In our TNBC cell lines, both 
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overexpression and suppression of Bcl-3 resulted in up-regulated apoptosis. It is perhaps 
possible for different cancers to have different optimal Bcl-3 concentrations where its 
oncogenic properties are best balanced to promote tumourigenicity without triggering 
transcriptional imbalances that might promote apoptosis. This is reminiscent of the 
Goldilocks or ‘just right’ model of WNT signalling in cancer, where not the highest levels 
of activation, but rather a specific increase in WNT was able to support tumour formation 
(Albuquerque et al., 2002).

4.13.3 Overexpression of WT Bcl-3 enhanced metastatic 
capacity 
	 When assessing the effects of Bcl-3 overexpression on cellular migration, we saw 
significant reductions in collective migration (Fig. 4.11 & 4.12).Although it is worth 
considering the characteristics of the wound healing assay as it is sensitive to changes in 
the rate of cell growth and to better represent this data, perhaps it would have been wise 
to normalise for apoptosis. We saw significantly increased amoeboid-like single cell 
migratory capabilities (Fig. 4.13). It is also worth considering that a higher proportion of 
cells overexpressing Bcl-3 plated into the Fluroblok assay would have been apoptotic, 
meaning these results may in fact be under-representative of the true effect. Time-lapse 
tracking of single cells, which is by definition independent of cell growth or death in the 
cell population, highlighted an increase in mesenchymal-like migration in the MDA-
MB-231-Luc Bcl-3 overexpressing cell line which further supported the role of Bcl-3 in 
contributing to increased single cell motility (Fig. 4.14c&d). In the light of gene expression 
analysis following Bcl-3 knockdown in the previous chapter, it is possible that 
overexpression of Bcl3 acted through similar migration pathways, potentially also through 
Rho GTPase signalling (Fig. 3.24).

4.13.4 Overexpression of WT Bcl-3 increased NFkB activity 
	 In line with the role of Bcl-3 as a transactivator of p50/p52-mediated transcription, 
we saw a significant increase in NFkB activity following overexpression (Fig. 4.15). This 
supports the notion that Bcl-3 is transcriptionally active as ectopic up-regulation was able 
to drive NFkB signalling. It may be informative to perform global gene expression analysis 
in the future, contrasting the differences between the overexpression cell lines with 
controls. This will also gives us a chance to integrate results from the prior Bcl-3 
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knockdown affymetrix experiment, allowing further refinement of our knowledge regarding 
the signalling pathways involved.

4.13.5 Overexpression of WT Bcl-3 increased in vivo metastatic 
seeding but tumours had reduced growth rates 
	 When we transplanted MDA-MB-231 cells overexpressing Bcl-3 into an orthotopic 
xenograft mouse model, the tumours grew significantly slower (Fig. 4.16). By the end of 
the experiment at day 42 these tumours were only around half the size of the controls. 
This confirmed our in vitro cell growth reduction observations following Bcl-3 
overexpression also held true for the in vivo setting. The complementary normal mouse 
stromal microenvironment was not able to rescue or promote any increased tumour 
growth commonly associated with Bcl-3 up-regulation. Interestingly, following necropsy 
of animals injected with cells through the tail vein, it was found that Bcl-3 overexpression 
greatly increased the number of distinct metastases in the lungs, even if each individual 
metastasis was smaller in size (Fig. 4.17a&b). Increased Bcl-3 also drove tumours to seed 
at additional sites such as the heart, mammary gland and bone marrow (femur) (Fig. 
4.17c). This finding appeared to support our in vitro migration observations as despite the 
slowdown in cell growth, Bcl-3 up-regulation seemed to enhance metastatic capabilities 
allowing cells to seed more effectively and also in varying microenvironments.

	 A recent study showed that Bcl-3 promoted pulmonary metastasis of breast 
cancer cells through transforming growth factor beta (TGFβ) signalling. Bcl-3 was found 
to bind to Smad3, preventing its ubiquitination and subsequent protein degradation (Chen 
et al., 2016). This mechanism could help explain the increased in vivo metastatic potential 
seen in our xenograft model, as overexpressing Bcl-3 could have resulted increased 
Smad3 stability and promotion of metastasis through TGFβ signalling. It might prove 
informative to investigate the binding status of Bcl-3 and Smad3, as well as other 
downstream TGFβ activated genes, in our overexpression lines through co-
immunoprecipitation experiments.

4.13.6 Overexpression of Bcl-3 ANK mutant in TNBC cell lines 
mimicked Bcl-3 suppression with siRNA 
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	 The Bcl-3 ANK mutant construct was designed to serve as a non-binding control 
vector. It featured three mutations within the second ankyrin (ANK) repeat domain (Fig. 
4.1) and this structure is important in facilitating binding interactions with p50 and p52. 
We hypothesised that overexpressing this Bcl-3 binding mutant would lead to dominant 
negative inhibition of Bcl-3 signalling as the ANK mutant would dimerise with endogenous 
Bcl-3, preventing the normal formation of p50-/p52-Bcl-3 complexes.

	 We ran MDA-MB-231-Luc and MDA-MB-436 TNBC cell lines stably expressing the 
Bcl-3 ANK mutant along side all of the assays investigating WT Bcl-3 overexpression. The 
Bcl-3 ANK cell lines exhibited slowdowns in cell population growth, reduced proliferative 
marker expression, increased apoptosis, reduced clonogenicity, impaired migration, 
reduced NFkB signalling, and decreased tumour growth and metastatic burden in 
xenograft models. These results entirely mimicked those seen with siRNA knockdown of 
Bcl-3 in the previous chapter, demonstrating the ANK mutant construct was able to act as 
an effective way of suppressing Bcl-3. These findings suggest that the protein-protein 
interactions between Bcl-3 and p50/p52 could be a viable target for inhibition and may 
serve as an attractive therapeutic option in TNBC.

4.13.7 Concluding remarks 
	 We showed in this chapter that although ectopic Bcl-3 overexpression in two 
TNBC cell lines increased cellular proliferation it also promoted apoptosis, resulting in 
lower overall cell turnover. Despite reduced tumour growth, elevated Bcl-3 also promoted 
an enhanced single-cell migratory phenotype, allowing for improved in vivo metastatic 
seeding in xenograft mouse models. Though it worth considering the limitations of 
drawing conclusions from overexpression in only two TNBC cell lines. This may not be a 
true representation of the effects of Bcl-3 up-regulation within TNBC. Within the scopes 
of this chapter, we attempted overexpression in the other cell lines previous investigated 
in our panel, however these attempts failed to produce stable clones as cells rapidly died 
following transfection. Further elucidation of the cause of this lethality following ectopic 
overexpression could prove interesting. But considering the results within the two tested 
cell lines, it suggested that although Bcl-3 has many dominant oncogenic properties, 
depending on the cellular context its up-regulation can be tumour suppressive. 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5.1 Introduction 
	 We know Bcl-3 is able to regulate NFkB signalling through interactions with both 
p50 and p52 proteins (Bours et al., 1993). In the previous chapters we showed that 
suppression of Bcl-3 through both siRNA and overexpression of a dominantly negative 
Bcl-3 ANK mutant resulted in tumour suppressive phenotypes. This highlighted the 
therapeutic potential of inhibiting Bcl-3 and in collaboration with the Cardiff School of 
Pharmacy, spurred the development of small molecule inhibitors targeting the Bcl-3-p50 
and Bcl-3-p52 protein-protein interactions.

	 The Bcl-3 inhibitor design process began with generation of computational models 
of Bcl-3-p50 and Bcl-3-p52 protein complexes. This allowed for a structure based virtual 
screening approach for commercial available pharmacophores from a large database, 
resulting in the compilation of a ranked list of suitable known compounds that best 
matched specific chemical features pertaining to the interacting residues in the protein 
binding sites. Ultimately a small number of compounds were selected following further 
stringent visual inspection. These compounds were subsequently biologically evaluated 
and a lead molecule, JS6, was selected based its effectiveness at disrupting Bcl-3 
protein-protein binding, suppressing NFkB signalling and inhibiting cellular migration. 
Working off the known chemical structure of this selected lead compound, structural 
analogues were synthesised to determine structure-activity relationships and investigate 
the importance of individual functional groups. With this information, we were able to 
design and synthesise completely novel Bcl-3 inhibitor analogues with the ultimate goal 
of establishing a new lead that is more efficacious at lower drug concentrations. This led 
to the subsequent synthesis of CB1, a structurally novel Bcl-3 inhibitor analogue 
compound (Clarkson, Unpublished).

	 The main aims of this chapter were to evaluate the biological effects of JS6 and 
CB1 in context of TNBC and determine whether small molecule inhibition of Bcl-3 could 
be clinically viable. We investigated the ability of the inhibitors to disrupt Bcl-3 protein-
protein binding, as well as their effects on cell viability, stemness, clonogenicity, NFkB 
signalling and the global gene expression profile. Following on from our in vitro findings, 
we set up a number of in vivo xenograft models designed to assess the effectiveness of 
our inhibitors at treating different aspects of metastatic disease. These experiments will 
be effective at assessing a range of potential cellular outputs in response to our drugs. 
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We hoped to generate promising preclinical data to showcase our novel Bcl-3 inhibitors 
as effective therapeutics and pave the way for future clinical trials.

5.2 JS6 and CB1 disrupted Bcl-3-p50 protein-protein binding 
	 In order to test whether both Bcl-3 inhibitors had the ability to disrupt Bcl-3-p50 
protein-protein binding and evaluate their effectiveness, we carried out some 
coimmunoprecipitation (coIP) experiments. Immunoprecipitation is a commonly used 
method used for antigen purification, whereby an antibody against a specific protein is 
allowed to form an immune complex with that target in a sample. This immune complex is 
then captured by an antibody binding protein, such as sepharose protein A or G 
immobilised on a beaded support, and any proteins not precipitated on the beads are 
washed away. CoIP builds upon the potential of IP reactions to capture and purify a 
primary target as well as any other interacting proteins that are bound by native 
interactions. Once captured, both the primary and secondary proteins can be eluted from 
the support beads and analysed through western blotting (Phizicky and Fields, 1995).

	 Total cellular protein from MDA-MB-231-Luc cells overexpressing WT Bcl-3 was 
extracted following treatment with either 30 minutes or 2 hours of JS6, CB1 or control 
DMSO at a concentration of 50μM. We also extracted protein from the pcDNA control 
MDA-MB-231-Luc cells, as well as MDA-MB-231-Luc cells overexpressing the non-
binding ANK Bcl-3 mutant. Bcl-3 and p50 protein complexes were then 
immunoprecipitated by centrifugation using the respective antibodies immobilised to 
sepharose protein A beads. Unbound proteins were washed away from these beads and 
the target Bcl-3 and p50 protein complexes were denatured and eluted through boiling. 
The secondary complexed component for each coimmunoprecipitant was quantified by 
western blotting and normalised to the total content of the primary protein 
immunoprecipitant (Fig. 5.1a&b).

	 Both JS6 and CB1 compounds were able to inhibit the protein-protein binding of 
Bcl-3 with p50. Following 30 minutes treatment with JS6, we saw a roughly 30% 
decrease in binding and after 2 hours treatment, this inhibition increase to roughly 45%. 
CB1 was found to be more effective inhibitor, with 30 minutes treatment resulting in 
55-75% binding inhibition and 2 hours treatment resulting in 80-95% inhibition (Fig. 
5.1c&d). The MDA-MB-231-Luc cell line expressing the empty control pcDNA vector 
 178
Chapter 5: Results
featured 30-40% reduced protein binding and the MDA-MB-231-Luc cell line 
overexpressing the ANK Bcl-3 mutant featured around 75% reduced complex binding.

5.3 48h JS6 and CB1 treatment reduced cell viability at higher 
drug concentrations 
	 Our results from previous chapters have demonstrated Bcl-3 suppression to have 
suppressive effects upon overall cell turnover in TNBC cell lines. Therefore we wanted to 
test our Bcl-3 inhibitor compounds and assess whether they have any potential cell 
cytotoxic effects. We used the CellTiter-Blue cell viability assay (Promega), a 
homogenous, fluorescence based method for assessing cell viability. This reagent 
assayed the ability of living cells to convert a redox dye, resazurin, into the fluorescent 
end product resorufin. Nonviable cells rapidly lose metabolic capacity and thus do not 
generate a fluorescent signal. The assay involved adding a single nontoxic reagent 
directly to the medium of cultured cells and after an incubation step of 1 hour, viability 
data is recorded using a plate reader based on the intensity of fluorescence.

	 Three TNBC cell lines and the non-tumourigenic MCF10a cell line were plated into 
96-well assay plates and treated with three different concentrations of JS6, CB1 or DMSO 
control. Cells were incubated for 48 hours before CellTiter-Blue reagent was added and 
viability assessed. JS6 significantly reduced cell viabilities by about 15% only at the 
highest 100μM concentration in the MDA-MB-436 and MDA-MB-231-Luc cell lines (Fig. 
5.2a&b). CB1 significantly reduced cell viabilities by around 20% at the highest 100μM 
concentration in all TNBC cell lines and about 15% at 10μM in MDA-MB-436 and MDA-
MB-231-Luc cells (Fig. 5.2a-c). MCF10a cells were not significantly affected by the Bcl-3 
inhibitors (Fig. 5.2d). 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FIG. 5.1 JS6 AND CB1 DISRUPTED BCL-3-P50 PROTEIN-PROTEIN BINDING  
The abilities of both compounds to disrupt Bcl-3-p50 protein binding was tested using 
coimmunoprecipitation (coIP) assays. Protein from MDA-MB-231-Luc cells overexpressing WT 
Bcl-3 was extracted following treatment with either 30min or 2h of JS6, CB1 or control DMSO at 
a concentration of 50μM. Protein from the pcDNA control MDA-MB-231-Luc cell line, as well as 
one overexpressing the ANK Bcl-3 mutant was also extracted. Bcl-3 and p50 protein complexes 
were then immunoprecipitated by centrifugation using antibodies bound to sepharose A beads. 
Representative western blots for Bcl-3 or p50 protein following coIP of a. Bcl-3 complexes or b. 
p50 complexes. Bar charts depicting the quantification and normalisation of protein band 
intensities using ImageJ following coIP of c. Bcl-3 complexes or d. p50 complexes. Error bars 
represent ±SEM of 3 independent experiments. (T-test, *=p<0.05, **=p<0.01, ***=p<0.001)
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FIG. 5.2 48H JS6 AND CB1 TREATMENT REDUCED CELL VIABILITY AT HIGHER DRUG 
CONCENTRATIONS 
The toxicity of both inhibitors were assessed using the CellTiter-Blue viability assay. Three TNBC 
cell lines and the non-tumourigenic MCF10a cell line were plated into assay plates and treated 
with three different concentrations of JS6, CB1 or DMSO control. Cells were incubated for 48h 
before CellTiter-Blue reagent was added and viability assessed. Percentage of viable cells for 
each treatment condition was normalised to the relevant controls for a. MDA-MB-436 b. MDA-
MB-231-Luc c. MDA-MB-231 d. MCF10a cell line. Error bars represent ±SEM of 3 independent 
experiments. (T-test, *=p<0.05, **=p<0.01, ***=p<0.001)
a
c
b
d
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5.4 48h CB1 treatment did not affect mammosphere numbers 
but significantly reduced mammosphere size 
	 The mammosphere assay was performed to assess the effect of the Bcl-3 
inhibitors on the stem-like anoikis resistant cell population. TNBC cell lines were treated 
with CB1 at concentrations of 1μM, 10μM,100μM or DMSO control for 48h before being 
disaggregated into single cells and plated into non-adherent mammosphere plates and 
cultured for 10 days. CB1 treatment did not affect the total number of mammospheres 
formed but at 10μM and 100μM concentrations, we saw a respective 30% and 60% 
significant reduction in average mammosphere sizes (Fig. 5.3).
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5.3 48h JS6 and CB1 impaired clonogenic survival at 100μM 
concentration 
	 Clonogenic potential was tested by treating MDA-MB-231-Luc cells with either 
JS6, CB1 or DMSO control at concentrations of 1μM, 10μM, or 100μM for 48 hours 
before plating the cells at low density in a colony formation assay and cultured for 10 
days before being fixed and stained with crystal violet. Treatment with JS6 and CB1 at 
100μM resulted in significantly reduced colony numbers as well as their average sizes 
(Fig. 5.4). The other drug concentrations did not significantly affect this cell line in this 
assay. 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FIG. 5.3 48H CB1 TREATMENT DID NOT AFFECT MAMMOSPHERE NUMBERS BUT SIGNIFICANTLY 
REDUCED MAMMOSPHERE SIZE 
TNBC cell lines were treated with CB1 at a range of concentrations for 48h before being 
disaggregated into single cells and plated into non-adherent mammosphere plates and cultured 
for 10 days. Representative bright-field microscopy images for a. MDA-MB-436, MDA-MB-231-
Luc, and MDA-MB-231 cell lines. b. Total mammosphere numbers and average mammosphere 
sizes for each cell line. Error bars represent ±SEM of 3 independent experiments. (T-test, 
*=p<0.05, **=p<0.01, ***=p<0.001)
b
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FIG. 5.4 48H JS6 AND CB1 TREATMENT IMPAIRED CLONOGENIC SURVIVAL AT 100ΜM 
CONCENTRATION 
Clonogenic potential was tested by treating MDA-MB-231-Luc cells with either JS6, CB1 or 
DMSO control at a range of concentrations for 48h before plating the cells at low density in a 
colony formation assay and cultured for 10 days before being fixed and stained with crystal 
violet. a. Representative bright-field images and b. total colony number and average colony 
coverage for MDA-MB-231-Luc cells. Error bars represent ±SEM of 3 independent experiments. 
(T-test, *=p<0.05, **=p<0.01, ***=p<0.001)
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5.4 48h JS6 and CB1 treatment did not affect NFkB activity 
	 Since previous Bcl-3 suppression experiments resulted in down regulation of NFkB 
activity, we wanted to test the effects of our Bcl-3 inhibitors to see if they acted in a 
similar manner. A luciferase NFkB reporter plasmid was used to quantify NFkB levels in 
MDA-MB-231-Luc cells following 48h treatment with either JS6, CB1 or DMSO control at 
10μM or 100μM concentrations. Cells were transfected with the luciferase NFkB reporter 
plasmid, LacZ control plasmid 24h after initial drug treatment and incubated for 24h. Cells 
were then lysed and NFkB activity measured as luminescence readout using a plate 
reader. NFkB activity was then normalised to LacZ luminescence to control for 
transfection efficiency. Surprising following 48 hours of JS6 or CB1 treatment at either 
10μM or 100μM concentrations, there were no significant changes to NFkB activity in the 
MDA-MB-231-Luc cell line (Fig. 5.5).
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FIG. 5.5 48H JS6 AND CB1 TREATMENT DID NOT AFFECT NFKB ACTIVITY  
A luciferase NFkB reporter plasmid was used to quantify NFkB levels in MDA-MB-231-Luc cells 
following 48h treatment with either JS6, CB1 or DMSO control at 10μM or 100μM 
concentrations. Cells were transfected with the luciferase NFkB reporter plasmid, LacZ control 
plasmid 24h after initial drug treatment and incubated for 24h. Cells were then lysed and NFkB 
activity measured as luminescence readout using a plate reader. NFkB activity was then 
normalised to LacZ luminescence to control for transfection efficiency. Error bars represent 
±SEM of 3 independent experiments.
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5.5 Affymetrix DNA microarray analysis following 48h CB1 
treatment 
	 To further investigate the transcriptional effects of Bcl-3 inhibition using our novel 
inhibitor, we carried out a global gene expression profiling experiment using the Affymetrix 
DNA GeneChip microarray platform. mRNA was extracted from MDA-MD-231-Luc cells 
treated for 48 hours with CB1 at 100μM concentration or DMSO control. Experimental 
data were normalised and analysed using GeneSpring GX Pathway Architect software. 
Genes were filtered based on their corrected p-values and a statistical cut off of 0.05 was 
chosen. In stark contrast to the changes seen following Bcl-3 siRNA knockdown, only 
110 out of 43590 genes satisfied this cut off following 48h CB1 treatment.

	 PANTHER functional classification, statistical overrepresentation and statistical 
enrichment analyses were carried out on the 110 significant gene hits and stratified by 
biological process, pathways, molecular function and cellular components.

5.5.1 PANTHER functional classification analysis 
For biological processes (Fig 5.6a) the genes changes primarily fell into: 

	 Cellular processes (28.6%), these are processes carried out at the cellular level 
such as cellular communication.

	 Metabolic processes (20.4%), these are chemical reactions including anabolism 
and catabolism by which living organisms transform chemical substances.

	 Biological regulation (9.2%), these are processes that modulate measurable 
attributes of any biological process, quality or function.

	 Cellular component organisation or biogenesis (8.7%), these are processes that 
biosynthesise constituent macromolecules, assembly, arrangement or disassembly of 
cellular components.

	 Developmental processes (7.7%), processes resulting in the progression from an 
initial condition to a later condition.

	 Response to stimuli (7.1%), processes that results in a change in state of a cell as 
a result of a stimulus.

	 Multicellular organismal process (7.1%), processes occurring at the level of a 
multicellular organism.
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	 Localisation (5.6%), these are processes in which a cell, substance or cellular 
entity is transported, tethered or otherwise maintained in a specific location.

For molecular functions (Fig 5.6b) the genes changes primarily fell into:

	 Catalytic activity (42.5%), catalysis of biochemical reactions at physiological 
temperatures.

	 Binding (39.7%), selective, non-covalent, interactions of a molecule with one or 
more specific sites on a another molecule.

	 Structural molecule activity (6.8%), contributing to the structural integrity of a 
complex or its assembly within or outside a cell.

	 Transporter activity (5.5%), the direct movement of substances into, out of, or 
between cells.

	 Signal transducer activity (4.1%), conveying a signal across a cell to trigger a 
change in cell function or state.

For cellular components (Fig 5.6c) the genes changes primarily fell into:

	 Cell part (38.3%), any constituent part of a cell.

	 Organelle (29.9%), organised structure of distinctive morphology and function.

	 Macromolecular complex (9.3%), stable assembly of two or more macromolecules 
functioning together.

	 Membrane (9.3%), lipid bilayer along with all proteins and complexes embedded in 
or attached to it.

	 Extracellular region (8.4%), space external to the outermost structure of a cell.

5.5.2 PANTHER statistical overrepresentation analysis 
	 Following PANTHER statistical overrepresentation analysis, only genes associated 
with nitrogen compound metabolism was found to be significantly overrepresented. No 
other specific PANTHER molecular functions or PANTHER signalling pathways were 
found to be significantly overrepresented through this analysis.

5.5.3 PANTHER statistical enrichment analysis 
	 Following PANTHER statistical enrichment analysis only genes associated with 
biological processes pertaining to cellular component organisation or biogenesis was 
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found to be down-regulated (p=0.003). Genes associated with molecular functions 
pertaining to DNA binding transcription factor activity was also found to be up-regulated 
(p=0.006). Finally genes associated with pathways linked to interleukin signalling (p=0.03) 
and gonadotropin-releasing hormone receptors (p=0.017) were found to be up-regulated.
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FIG. 5.6 PANTHER FUNCTIONAL CLASSIFICATION TOOL FOR 48H 100ΜM CB1 TREATMENT 
Genes found to be significantly up/down-regulated (p-value<0.05) in the MDA-MB-231-Luc 48h 
100μM CB1 treatment Affymetrix microarray experiment were used to perform PANTHER 
functional classification. Result of analyses are visualised as pie charts with information within 
each wedge detailing the number of genes and percent of genes against total hits for a. 
PANTHER biological processes b. PANTHER Molecular Function c. PANTHER Cellular 
Components.
Chapter 5: Results
5.5.4 Overlapping gene changes between CB1 treatment and 
Bcl-3 siRNA knockdown 
	 Within the 110 significant gene changes gene changes following CB1 treatment, 
there were 63 overlaps with significant changes also seen following Bcl-3 siRNA 
knockdown. These overlapping genes along with the corresponding Log Fold Change 
value associated with each condition are listed in the table below.

Gene Symbol CB1 Treatment (FC) Bcl-3 siRNA (FC)
FOS 1.669 1.364
HES1 1.582 1.216
CSF2 1.553 -1.179
CSF3 1.453 1.825
IL1B 1.451 1.843
ST6GALNAC2 1.388 -1.133
FHDC1 1.384 -1.861
RNASE1 1.377 -1.429
CYP1B1 1.354 1.083
KLF2 1.341 1.586
HTRA1 1.336 1.806
DUSP5 1.331 1.281
PTGES 1.320 1.466
GDF15 1.300 -1.671
IL24 1.289 1.376
COL6A3 1.266 1.416
PIM1 1.242 -1.486
EPAS1 1.238 -1.124
ITGA3 1.209 -1.077
SIK1 1.197 -1.515
TAGLN2 1.186 1.105
TNS4 1.184 -2.928
L1CAM 1.174 1.099
NTN4 1.164 1.170
TGFB1 1.149 1.136
PLAU 1.127 1.903
DHX32 1.112 1.138
GRN 1.102 1.257
 190
Chapter 5: Results
SLX1A 1.096 1.155
MARK4 1.086 1.144
EPN2 1.080 -1.144
CDCP1 1.077 -1.125
LOX 1.054 -1.283
DARS2 -1.098 1.097
POLR1A -1.104 -1.083
KIF18A -1.107 -1.344
GUF1 -1.119 -1.137
FERMT1 -1.121 -1.174
EOGT -1.127 1.192
INPP4B -1.129 -1.207
EPB41L2 1.133 1.118
BMP5 -1.134 2.189
POLR3B -1.144 1.229
RIF1 -1.147 -1.138
CHD1 -1.147 1.086
RIMS1 -1.149 -1.294
LINC01123 -1.164 -1.305
PARD6B -1.168 -1.162
LMNB1 -1.173 1.120
ANK3 -1.187 -1.127
SEMA3D -1.192 -1.316
TNFRSF10D -1.197 1.602
HAS2 -1.201 -1.947
ATP8B1 -1.224 -1.462
HHIP -1.228 -2.071
FRAS1 -1.236 -1.448
DCLK1 -1.240 -1.418
SDPR -1.255 -1.873
CNN1 -1.271 -1.414
RELN -1.297 1.176
CYP24A1 -1.303 -1.281
GRPR -1.364 -1.222
NRK -1.376 -1.617
CB1 Treatment (FC) Bcl-3 siRNA (FC)Gene Symbol
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5.6 Relative expression of a Bcl-3 responsive gene panel 
following siRNA knockdown, JS6 or CB1 treatment 
	 The surprisingly low number of significantly altered gene hits following 48 hours of 
CB1 treatment, especially when compared to the changes seen after Bcl-3 siRNA 
knockdown in the same cell line, prompted us to investigate and validate the effect of the 
Bcl-3 inhibitors in a time course experiment. We drafted a panel comprised of both 
significantly altered genes from the 48 hour CB1 Affymetric experiment (IL1B, ESM1, 
FOS, EGR1, IL6), as well as some genes that have been shown in the literature to be 
direct transcriptional targets of Bcl-3 complexes (TNFα, CDH2, MDM2, IL10).

	 Bcl-3 was shown to bind the TNFα promoter in RAW cells and inhibit its LPS-
induced activation (Kuwata et al., 2003). The N-cadherin (CDH2) promoter region has 
been shown to contain NFkB binding sites and DNA-bound Bcl-3 complexes were found 
within these regions in melanoma cells (Kuphal and Bosserhoff, 2005). Bcl-3 
overexpression in MCF-7 cells has been shown increase MDM2 expression. The 
activation of tumour suppressor p53 is controlled by modifications and interactions with 
its inhibitor MDM2 (Vousden and Prives 2005). ChIP analysis revealed that Bcl-3 
complexes bound the P2 promoter region of MDM2 leading to its stabilisation and 
resulting in lower levels of p53 (Kashatus et al., 2006). It has been shown that Bcl-3 is 
negatively implicated in the initiation of IL10 transcription in macrophages (Kuwata et al., 
2003).

	 The relative gene expression of the selected panel was quantified using TaqMan 
qRT-PCR probes in MDA-MB-231-Luc cells for the conditions of 48 hour knockdown with 
Bcl-3 siRNA, control siRNA or treatment with 100μM of JS6, CB1 or DMSO control for 
either 3 hours, 8 hours, 24 hours or 48 hours. We want to compare the transcriptional 
changes seen following Bcl-3 knockdown with siRNA versus treatment with our Bcl-3 
inhibitor compounds. The rationale is that if drug inhibition of Bcl-3 acted in a similar way 
as siRNA suppression, then we ought to observe a similar transcriptional signature.

	 Following 48 hour Bcl-3 siRNA knockdown, expression of TNFα (3.11-fold), IL1B 
(2.24-fold), FOS (1.84-fold) and EGR1 (1.79-fold) were all significantly up-regulated, ESM1 
and IL6 expression did not significantly change and expression of CDH2 (0.56-fold), 
MDM2 (0.51-fold) and IL10 (0.38-fold) were significantly down-regulated (Fig. 5.7a). 
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	 Following 3 hour JS6 treatment, IL1B (2.2-fold), FOS (2.2-fold) and IL6 (2.6-fold) 
were significantly up-regulated; CB1 treatment resulted in TNFα (2.4-fold), FOS (2.6-fold), 
EGR1 (2.1-fold) and IL6 (1.5-fold) to be significantly up-regulated (Fig. 5.7b).

	 Following 8 hour JS6 treatment, TNFα (3.3-fold), IL1B (2.9-fold), FOS (2.3-fold) and 
EGR1 (3.1-fold) were significantly up-regulated and ESM1 (0.52-fold) and MDM2 (0.64-
fold) was significantly down-regulated; CB1 treatment resulted in TNFα (2.5-fold), IL1B 
(2.5-fold), FOS (2.5-fold), EGR1 (1.8-fold) and IL6 (2.2-fold) to be significantly up-
regulated and ESM1 (0.45-fold), MDM2 (0.47-fold) and IL10 (0.46-fold) were significantly 
down-regulated (Fig. 5.7c).

	 Following 24 hour JS6 treatment, no significant changes were observed; CB1 
treatment resulted in TNFα (1.7-fold), IL1B (3.3-fold), FOS (2.5-fold), EGR1 (3.3-fold) and 
IL6 (2.5-fold) to be significantly up-regulated and ESM1 (0.53-fold), CDH2 (0.63-fold) and 
MDM2 (0.59-fold) were significantly down-regulated (Fig. 5.7d).

	 Following 48 hour JS6 treatment, no significant changes were observed; CB1 
treatment resulted in IL1B (1.5-fold), FOS (1.5-fold), EGR1 (1.7-fold) and IL6 (1.8-fold) to 
be significantly up-regulated and ESM1 (0.62-fold) to be down-regulated (Fig. 5.7e).
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FIG. 5.7 RELATIVE EXPRESSION A BCL-3 RESPONSIVE GENE PANEL FOLLOWING SIRNA 
KNOCKDOWN, JS6 OR CB1 TREATMENT. 
The relative gene expression of a selected panel was quantified using TaqMan qRT-PCR probes 
in MDA-MB-231-Luc cells with the conditions of 48 hour knockdown with a. Bcl-3 siRNA, 
control siRNA or treatment with 100μM of JS6, CB1 or DMSO control for either b. 3 hours, c. 8 
hours, d. 24 hours or e. 48 hours. Error bars represent ±SEM of 3 independent experiments. (T-
test, *=p<0.05, **=p<0.01, ***=p<0.001)
d
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5.7 Daily refresh of JS6 and CB1 more effectively impaired 
clonogenic survival 
	 It was evident from the qRT-PCR time course gene panel experiments that both 
Bcl-3 inhibitors most effectively imparted transcriptional signatures similar to that of 
siRNA knockdown within the 24 hour time point. By 48 hours many of the remaining 
significant gene changes had become much less pronounced and none of the changes to 
the genes that were direct transcriptional targets for Bcl-3 remained. This suggests that 
perhaps in order to maintain a comparable effect to siRNA knockdown, the drug 
treatment ought to be refreshed every 24 hours. The colony formation assay was used to 
test the effects of daily drug treatment.

	 MDA-MB-436 and MDA-MB-231-Luc cells were treated with either JS6, CB1 or 
DMSO control at a range of concentrations for 24 hours before plating the cells at low 
density in a colony formation assay. Medium containing either JS6, CB1 or DMSO control 
was replaced every 24 hours and cells were cultured for 10 days. Daily treatment with JS6 
or CB1 significantly reduced colony numbers as well as average sizes at all 
concentrations in the MDA-MB-436 cell line (Fig. 5.8). For the MDA-MB-231-Luc cell line, 
JS6 was able to significantly reduce colony numbers and average sizes at 10μM and 
100μM concentrations, while CB1 reduced colony numbers and sizes at all 
concentrations (Fig. 5.9).
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FIG. 5.8 DAILY REFRESH OF JS6 AND CB1 MORE EFFECTIVELY IMPAIRED CLONOGENIC 
SURVIVAL 
Clonogenic potential was tested by treating MDA-MB-436 cells with either JS6, CB1 or DMSO 
control at a range of concentrations for 24h before plating the cells at low density in a colony 
formation assay. Medium containing either JS6, CB1 or DMSO control was replaced every 24 
hours and cells cultured for 10 days before being fixed and stained with crystal violet. a. 
Representative bright-field images and b. total colony number and average colony coverage for 
MDA-MB-436 cells. Error bars represent ±SEM of 3 independent experiments. (T-test, *=p<0.05, 
**=p<0.01, ***=p<0.001)
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FIG. 5.9 DAILY REFRESH OF JS6 AND CB1 MORE EFFECTIVELY IMPAIRED CLONOGENIC 
SURVIVAL 
Clonogenic potential was tested by treating MDA-MB-231-Luc cells with either JS6, CB1 or 
DMSO control at a range of concentrations for 24h before plating the cells at low density in a 
colony formation assay. Medium containing either JS6, CB1 or DMSO control was replaced 
every 24 hours and cells cultured for 10 days before being fixed and stained with crystal violet.. 
a. Representative bright-field images and b. total colony number and average colony coverage 
for MDA-MB-231-Luc cells. Error bars represent ±SEM of 3 independent experiments. (T-test, 
*=p<0.05, **=p<0.01, ***=p<0.001)
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5.8 In vivo xenograft modelling 
	 Xenograft models have been extensively used as predictive models for cancer 
therapeutic efficacy. Before we can consider moving into human clinical trials, it is 
essential to evaluate drug efficacy and any potential toxicities in vivo. Though it is worth 
noting that although in vivo studies are valuable, the results has not consistently 
translated to the clinic and the significance of these studies can be hotly debated 
(Sausville and Burger, 2006). Nonetheless if we are to push forward with the ultimate goal 
of small molecule inhibition of Bcl-3 in human TNBC patients, it would be extremely 
beneficial to first demonstrate in vivo efficacy. Based on the results from in vitro assays, 
we decided a daily drug treatment regime was optimal provided it was well tolerated by 
the animals.

5.8.1 Xenograft model one: The effects of Bcl-3 inhibitors on 
metastatic seeding capabilities of MDA-MB-231-Luc cells 
We wanted to model the later stages of the metastatic seeding process using the 
luciferase expressing MDA-MB-231-Luc cell line we thoroughly characterised in previous 
chapters. This is an aggressive line that proliferated rapidly, meaning it would not have 
allowed for sufficient time for cells transplanted at the orthotopic site to metastasise before 
reaching a size impeding normal animal function. Therefore experimental metastases were 
established by intravenous injection of 2×105 MDA-MD-231-Luc cells. Cells were 
suspended in 100 μL of RPMI media and injected via the tail vein of 8-week old female 
Hsd: Athymic Nude-Foxn 1nu mice (Harlan Laboratories). It had been shown that tail vein 
tumours exhibited no gene profile differences when compared to metastases generated by 
orthotopic tumours (Rashid et al., 2013).
Metastatic progression to distal organs was assessed through bioluminescence 
imaging with the IVIS Spectrum In Vivo Imaging System (Perkin Elmer). Prior to imaging, 
an intraperitoneal injection of 100μL D-luciferin was administered to each animal. The mice 
were then anaesthetised with 2.5% isoflurane, oxygen mix and imaged with the charge-
coupled IVIS camera device selecting an exposure time of 2 minutes. Luminescence 
signal was measured through region of interest selection and quantified as total flux 
(photon count) overlaying corresponding grayscale photographs (Fig. 5.10) and composite 
images were analysed using the Living Image software (Xenogen Bioscience Corp).
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FIG. 5.10 QUANTIFICATION OF METASTATIC PROGRESSION THROUGH IN VIVO LUMINESCENCE 
IMAGING 
Experimental metastases were established by intravenous injection of 2×105 MDA-MD-231-Luc 
cells. Cells were suspended in 100 μL of RPMI media and injected via the tail vein of 8-week old 
female Hsd: Athymic Nude-Foxn 1nu mice (Harlan Laboratories). Metastatic progression to distal 
organs was assessed through bioluminescence imaging with the IVIS Spectrum In Vivo Imaging 
System. Prior to imaging, an intraperitoneal injection of 100μL D-luciferin was administered to 
each animal. The mice were then anaesthetised with 2.5% isoflurane, oxygen mix and imaged 
with an exposure time of 2 minutes. Luminescence signal was measured through region of 
interest selection and quantified as total flux (photon count) overlaying corresponding grayscale 
photographs and composite images were analysed using the Living Image software.
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5.8.1.1 Anti-metastatic efficacy of JS6 and 15F in xenograft 
model one 
The first experiment using xenograft model one tested the anti-metastatic efficacies 
of JS6 and another Bcl-3 inhibitor analogue, 15F. The mice were pretreated 24 hours and 
10 minutes prior to injection of cells with either 1% DMSO vehicle control (n=5), 3.5mg/kg 
of 15F (n=4) or 3.5mg/kg of JS6 (n=5); subsequent daily intraperitoneal injections were 
carried out for 9 days following first injection of cells. Imaging of animals was carried out 
on day 11, day 24, day 28, day 41 and day 47. Animals were sacrificed on day 47 and at 
this experimental endpoint, 5/5 mice in the DMSO control cohort, 2/4 mice in the 15F 
cohort and 0/5 mice in the JS6 cohort developed detectable tumours (Fig. 5.11a). When 
compared to DMSO controls, the mean metastatic burden was significantly reduced in the 
JS6 cohort (p<0.0001).
Two additional model one xenograft experiments both focusing on the efficacy of 
JS6 were carried out. In the second experiment, 3/5 mice in the DMSO control cohort and 
1/3 mice in the JS6 treated cohort developed detectable tumours (Fig. 5.11b). Animals 
were last imaged at day 30. In the third experiment, 2/3 mice in the DMSO control cohort 
and 3/4 animals in the JS6 cohort developed detectable tumours (Fig. 5.11c). Animals 
were last imaged at day 56. Although were no statistically significant differences between 
JS6 and DMSO control cohorts in these experiments, there was a noticeable trend of 
increased individual tumour burden within the control cohorts. When we consider results 
from all experiments, we can observe 3/13 (23%) of DMSO control mice were tumour free, 
contrasted to the much higher tumour free proportion of 2/4 (50%) for 15F treated mice 
and 8/12 (67%) of JS6 treated mice. 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FIG. 5.11 ANTI-METASTATIC EFFICACY OF JS6 AND 15F IN XENOGRAFT MODEL ONE 
The anti-metastatic efficacies of JS6 and 15F were investigated in MDA-MB-231-Luc cells using 
xenograft model one. Mice were pretreated 24 hours and 10 minutes prior to injection of cells 
with either 1% DMSO vehicle control, 3.5mg/kg of 15F or 3.5mg/kg of JS6; subsequent daily 
intraperitoneal injections were carried out for 9 days following first injection of cells. Imaging of 
animals was carried out periodically until experimental endpoint. a. b. c. Scatter plots with bars 
detailing average metastatic burden for each cohort and waterfall plots detailing the individual 
metastatic burden of each mouse in three independent model one xenograft experiments. Error 
bars represent ±SEM. (T-test, ***=p<0.001)
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5.8.1.2 Anti-metastatic efficacy of CB1 in xenograft model one 
The anti-metastatic efficacy of CB1 was tested in four independent model one 
xenograft experiments. Once again, mice were pretreated 24 hours and 10 minutes prior 
to injection of cells with either 1% DMSO vehicle control or 3.5mg/kg of CB1; subsequent 
daily intraperitoneal injections were carried out for 9 days. Imaging of animals was carried 
periodically until experimental endpoint.
In the first experiment, 2/5 mice in the DMSO control cohort and 0/4 mice in the 
CB1 cohort developed detectable tumours by experimental endpoint of day 63 (Fig. 
5.12a). In the second experiment, 3/4 mice in the DMSO control cohort and 3/10 mice in 
the CB1 cohort developed detectable tumours by experimental endpoint of day 35 (Fig. 
5.12b). In the third experiment, 3/4 mice in the DMSO control cohort and 0/3 mice in the 
CB1 cohort developed detectable tumours by experimental endpoint of day 41 (Fig. 
5.12c). In the fourth experiment, 3/6 mice in the DMSO control cohort and 6/10 mice in the 
CB1 cohort developed detectable tumours by experimental endpoint of day 41 (Fig. 
5.12d). For this experiment we closely monitored the health status of the mice past the 
final imaging date and did not cull them until signs of morbidity from tumour burden was 
observed. The CB1 treated cohort exhibited delayed time until morbidity when compared 
with DMSO controls as illustrated by the Kaplan-Meier curve detailing disease free survival 
(Fig. 5.12e).
Although there were no statistically significant differences between the average 
metastatic burden following CB1 treatment within each individual experiment, from the 
waterfall plots, we can observe a trend of DMSO control mice developing greater individual 
metastatic burdens. When we aggregate the results from all experiments, 8/19 (42%) of 
DMSO control mice were tumour free, contrasted to the much high proportion of 18/27 
(67%) of tumour free CB1 treated mice. 
 203
Chapter 5: Results
 
 204
c
b
a
Chapter 5: Results
 
 205
d
e
FIG. 5.12 ANTI-METASTATIC EFFICACY OF CB1 IN XENOGRAFT MODEL ONE 
The anti-metastatic efficacy of CB1 was investigated in MDA-MB-231-Luc cells using xenograft 
model one. Mice were pretreated 24 hours and 10 minutes prior to injection of cells with either 
1% DMSO vehicle control or 3.5mg/kg of CB1; subsequent daily intraperitoneal injections were 
carried out for 9 days following first injection of cells. Imaging of animals was carried out 
periodically until experimental endpoint. a. b. c. d. Scatter plots with bars detailing average 
metastatic burden for each cohort and waterfall plots detailing the individual metastatic burden of 
each mouse in four independent model one xenograft experiments. e. Kaplan-Meier curve 
detailing disease free survival for DMSO control and CB1 cohorts from experiment four. Error 
bars represent ±SEM 
* p=0.036
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5.8.1.3 JS6 and CB1 significantly reduced metastatic burden in 
xenograft model one 
Individual metastatic burden data from all xenograft model one experiments were 
aggregated and nonlinear regression analysis carried out in GraphPad Prism. Exponential 
growth curves were fitted to each experimental cohort (R-squared for DMSO=0.29, 
CB1=0.014, JS6=0.23, 15F=0.19) and paired t-tests were performed between DMSO and 
each drug treated cohort (Fig. 5.13). CB1 (p=0.035) and JS6 (p=0.024) treated cohorts 
were found to significantly reduce metastatic burden when compared to DMSO control 
animals.
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FIG. 5.13 CB1 AND JS6 SIGNIFICANTLY REDUCED METASTATIC BURDEN IN XENOGRAFT MODEL 
ONE 
Individual metastatic burden results from all xenograft model one experiments were aggregated 
and plotted as a scatter chart. Nonlinear regression analysis was carried out in GraphPad Prism 
and exponential growth curves were fitted to each experimental cohort (R-squared for 
DMSO=0.29, CB1=0.014, JS6=0.23, 15F=0.19). Paired t-tests were performed between DMSO 
and each drug treated cohort; CB1 (p=0.035) and JS6 (p=0.024) treatments were found to 
significantly reduce metastatic burden.
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5.8.2 Anti-metastatic efficacy of CB1 was maintained in 
xenograft model one when administered via oral gavage 
An important factor to consider when developing a drug is the different ways it can 
be administered. We wanted to test the oral availability and efficacy of CB1 when it is 
administered via oral gavage in an xenograft model one experiment. Mice were treated 
with either 3.5mg/kg (n=5), 20mg/kg (n=5) of CB1 or DMSO vehicle control (n=5) and 
tumour burden quantified periodically until the experimental endpoint at day 28. The lower 
CB1 concentration of 3.5mg/kg, did not significantly reduce tumour burden (p=0.173) with 
a small cohort size of 5 animals, but the higher concentration of 20mg/kg did profoundly 
reduce tumour burden (p=0.038) (Fig. 5.14). 1/5 (20%) of DMSO control mice, 2/5 (40%) 
3.5mg/kg CB1 treated mice and 3/5 (60%) of 20mg/kg CB1 treated mice were tumour free 
at the experimental endpoint. 
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FIG. 5.14 ANTI-METASTATIC EFFICACY OF CB1 WAS MAINTAINED IN XENOGRAFT MODEL ONE 
WHEN ADMINISTERED VIA ORAL GAVAGE 
The anti-metastatic efficacy CB1 was investigated in MDA-MB-231-Luc cells using xenograft 
model one. Mice were pretreated 24 hours and 10 minutes prior to injection of cells with either 
5% DMSO vehicle control, 3.5mg/kg or 20mg/kg of CB1; subsequent daily oral gavages were 
carried out for 9 days following first injection of cells. Imaging of animals was carried out 
periodically until experimental endpoint at day 28. a. Scatter plot with bars detailing average 
metastatic burden for each cohort and waterfall plot detailing the individual metastatic burden of 
each mouse. b. Exponential growth regression for each cohort. Error bars represent ±SEM. (T-
test, *=p<0.05, **=p<0.01, ***=p<0.001)
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5.8.3 Xenograft model two: The effects of Bcl-3 inhibitors on 
metastatic colonisation and expansion capabilities of MDA-
MB-231-Luc cells 
	 We were able to demonstrate with our first xenograft model that the Bcl-3 
inhibitors significantly reduced metastatic burden. This was especially evident in the 
context of reducing initial tumour seeding as a smaller proportion of animals in the drug 
treated cohorts developed detectable tumours compared to the controls. In the second 
xenograft model, we wanted to assess the efficacy of the inhibitors on subsequent 
colonisation and expansion of cells that have successfully seeded in their preferred distal 
sites.

5.8.3.1 JS6 and CB1 did not significantly inhibit metastatic 
colonisation and expansion 
Experimental metastases were once again established by intravenous injection of 
2×105 MDA-MD-231-Luc cells. Cells were suspended in 100 μL of RPMI media and 
injected via the tail vein of 8-week old female Hsd: Athymic Nude-Foxn 1nu mice (Harlan 
Laboratories). Cells were allowed to seed for 3 days and animals were treated from day 4 
with daily intraperitoneal injections of either 1% DMSO vehicle control, 3.5mg/kg of JS6 or 
CB1 until experimental endpoint. In vivo bioluminescence imaging was carried out 
periodically and metastatic burden quantified.
When we aggregate the metastatic burden data from all experiments, neither JS6 
(Fig. 5.15a) nor CB1 (Fig. 5.15b&c) was found to significantly inhibit metastatic 
colonisation and expansion in this experimental model. However 8/19 (42.1%) animals in 
the DMSO control cohorts developed no detectable tumours by the end of the 
experiments, while 5/9 (55.6%) animals in the JS6 cohort and 7/12 (58.3%) animals in the 
CB1 cohorts remained tumour free. 
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FIG. 5.15 JS6 AND CB1 DID NOT SIGNIFICANTLY INHIBIT METASTATIC COLONISATION AND 
EXPANSION 
The anti-metastatic efficacy of JS6 and CB1 was tested in MDA-MB-231-Luc cells using 
xenograft model two. Cells were allowed to seed for 3 days and animals were treated from day 4 
with daily intraperitoneal injections of either 1% DMSO vehicle control, 3.5mg/kg of JS6 or CB1 
until experimental endpoint. In vivo bioluminescence imaging was carried out periodically and 
metastatic burden quantified. Scatter plots with bars detailing average metastatic burden for each 
cohort and waterfall plots detailing the individual metastatic burden of each mouse for a. JS6 
treated cohort and b&c. CB1 treated cohorts. Error bars represent ±SEM. d. Exponential growth 
regression for each cohort.
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5.8.3.2 Daily JS6 and CB1 treatment did not significantly cause 
adverse toxicity 
	 An important factor to consider when administering daily drug treatments was 
whether the regime caused adverse side effects. We closely monitored the health status 
of each animal on a daily basis and recorded their weights as this is often a good indictor 
of toxicity even if the animals did not show signs of morbidity. We found no significant 
differences between the growth rates of animals treated with daily 1% DMSO vehicle 
control, or 3.5mg/kg of JS6 or CB1 (Fig. 5.16).
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FIG. 5.16 DAILY JS6 AND CB1 TREATMENT DID NOT SIGNIFICANTLY CAUSE ADVERSE TOXICITY 
Any possible toxicities associated with daily JS6 or CB1 i.p. injections was investigated using 
MDA-MB-231-Luc cells in xenograft model two. The health status of each animal was closely 
monitored on a daily basis and weights for animals treated with a. 1% DMSO vehicle control, b. 
3.5mg/kg JS6 or c. 3.5mg/kg CB1 was recorded over a period of 30 days.
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5.8.4 Xenograft model three: The effects of CB1 on TNBC 
orthotopic tumour growth 
	 Although the Bcl-3 inhibitors did not significantly inhibit tumour expansion once 
seeding had taken place in xenograft model two, there was a trend of decreased tumour 
sizes in the drug treated cohorts. In xenograft model three we wanted to investigate the 
effects of CB1 on TNBC tumour growth at the orthotopic site and see if we could 
recapitulate the reduced cell turnover seen with Bcl-3 suppression in the previous 
chapters.

5.8.4.1 CB1 significantly reduced orthotopic tumour growth 
	 Primary orthotopic metastases were established by subcutaneous injection of 
1×106 MDA-MD-231-Luc or MDA-MB-436 cells. Cells were suspended in 100 μL of RPMI/
Matrigel solution and injected into bilateral mammary fat pads of 8-week old female Hsd: 
Athymic Nude-Foxn 1nu mice (Harlan Laboratories). Cells were allowed to seed for 4 days 
and animals were treated from day 5 with daily intraperitoneal injections of either 1% 
DMSO vehicle control or 3.5mg/kg CB1 until experimental endpoint. Tumour sizes were 
measured and recorded periodically and animals were sacrificed when tumour diameter 
exceeded 20mm in any one dimension. Daily treatment of CB1 at a dosage of 3.5mg/kg 
was found to significantly reduce average orthotopic tumour sizes of both MDA-MB-231-
Luc and MDA-MB-436 cell lines from day 38 onwards (Fig. 5.17).

 213
Chapter 5: Results
 
 214
a
b
FIG. 5.17 CB1 SIGNIFICANTLY REDUCED ORTHOTOPIC TUMOUR GROWTH IN XENOGRAFT 
MODEL THREE 
Primary orthotopic metastases were established by subcutaneous injection of 1×106 MDA-
MD-231-Luc or MDA-MB-436 cells. Cells were suspended in 100 μL of RPMI/Matrigel solution 
and injected into bilateral mammary fat pads of 8-week old female Hsd: Athymic Nude-Foxn 1nu 
mice. Cells were allowed to seed for 4 days and animals were treated from day 5 with daily 
intraperitoneal injections of either 1% DMSO vehicle control or 3.5mg/kg CB1 until experimental 
endpoint. Tumour sizes were measured and recorded periodically and animals were sacrificed 
when tumour diameter exceeded 20mm in any one dimension. Average tumour volume and 
waterfall plot detailing individual tumour volume of each mouse on the final day for a. MDA-
MB-231-Luc and b. MDA-MB-436. Error bars represent ±SEM. (T-test, *=p<0.05, **=p<0.01, 
***=p<0.001)
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5.9 Discussion 
	 In the previous chapters we highlighted proto-oncogenic properties of Bcl-3 within 
TNBC cell lines and especially its associations with promoting an increased metastatic 
phenotype. Bcl-3 suppression was found to reduce overall cell turnover, decrease 
migration and generally promoted tumour suppressive phenotypes. Using structure based 
computational modelling, small molecule inhibitor compounds targeting the Bcl-3-p50/
Bcl-3-p52 protein interactions were designed and synthesised. In this final chapter, we 
focused on evaluating the efficacy of two lead compounds in TNBC cell lines, JS6 and a 
structurally novel analogue, CB1.

5.9.1 JS6 and CB1 disrupted Bcl-3-p50 protein-protein binding 
	 In order to confirm mechanism of action, we tested the capabilities of the inhibitor 
compounds to disrupt protein-protein binding of Bcl-3 and p50 using a 
coimmunoprecipitation setup. We chose the MDA-MB-231-Luc cell line stably 
overexpressing WT Bcl-3 for this experiment as it ensured a high concentration of Bcl-3 in 
the lysate used for protein pulldown. In line with expectations, both JS6 and CB1 
treatments at 50μM concentrations resulted in significant reductions of secondary p50 or 
Bcl-3 complexes depending on the primary protein pulldown when compared to DMSO 
controls. Two hour drug treatment duration proved to be more efficacious than thirty 
minutes and CB1 was found to be more effective than JS6 in both durations (Fig.5.1c&d). 
Despite there being similar quantities of p50 and p52 proteins in MDA-MD-231 cell lines 
(Eckhardt et al., 2013), we failed to find a suitably robust p52 antibody to carry out coIP 
pulldown and western blotting.

	 It was evident from the western blots that we were able to consistently pulldown 
similar amounts of Bcl-3 protein (Fig. 5.1a) despite the pcDNA control cell line having 
significantly less Bcl-3 than the overexpression mutant line. This suggested that we were 
able to saturate the sepharose protein beads with either Bcl-3 or p50 protein to achieve a 
consistent pulldown quantity each time. Interestingly, despite this constant Bcl-3 protein 
pulldown quantity, we found significantly less complexed p50 in the pcDNA control cell 
lysates, implying Bcl-3 in these cells bound less p50 compared to the WT Bcl-3 
overexpression line. When we pulled-down p50 (Fig. 5.1b), there were also significantly 
less complexed Bcl-3 in the pcDNA control cells. These results indirectly suggested that 
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overexpression of Bcl-3 led to increased p50 complexing dynamics. Lysates from cells 
overexpressing the Bcl-3 ANK mutant also resulted in significantly reduced quantities of 
bound p50 and Bcl-3 secondary complexes. This is due to the Bcl-3 ANK mutant being 
unable to bind p50.

5.9.2 JS6 and CB1 demonstrated in vitro efficacy 
	 We treated three TNBC cell lines with either JS6 or CB1 at a range of drug 
concentrations for 48 hours and observed their effects on cell viability (Fig. 5.2). JS6 
significantly reduced viability of two of the cell lines at the highest 100μM concentration, 
while CB1 had slightly better potency at the same concentration and was also 
significantly efficacious at 10μM. Neither inhibitors reduced cell viability in the non-
tumourigenic MCF10a cell line, similar to the effects seen following Bcl-3 siRNA 
knockdown in chapter 3, supporting the idea that the drug effect was Bcl-3 specific.

	 In line with our previous Bcl-3 suppression findings, 48 hour CB1 treatment did not 
affect the number of mammospheres formed but instead reduced their average sizes (Fig. 
5.3). This meant CB1 did not preferentially target the anoikis resistant cell populations in 
this assay. Subsequently resulting mammospheres were not serially passaged, so we 
cannot conclude on the effects of CB1 on self-renewal and the stem-like cell population 
in TNBC cells. 48 hour JS6 and CB1 treatment at 100μM was also able to significantly 
impair clonogenic survival of MDA-MB-231-Luc cells (Fig. 5.4). Interestingly, unlike the 
previous Bcl-3 suppression experiments, 48 hour period of CB1 treatment did not have 
any effects on NFkB activity when assayed with a reporter construct (Fig. 5.5).

5.9.3 Global gene expression profiling following 48 hour CB1 
treatment 
	 In order to investigate the transcriptional effects of CB1, we carried out an 
Affymetrix DNA GeneChip microarray experiment on RNA harvested from MDA-MB-231-
Luc cells treated with 100μM CB1 for 48 hours. We chose these treatment conditions as 
at this concentration we saw comparable effects to those seen in previous in vitro Bcl-3 
suppression assays. We hypothesised that if small molecule inhibition of Bcl-3 acted 
upon similar transcriptional pathways as Bcl-3 siRNA knockdown, then we should see a 
degree of overlap between the subsequent gene changes. Surprisingly, we only saw 110 
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significantly altered genes out of a possible 43590 following CB1 treatment. This is in 
stark contrast to the >4000 significant changes following Bcl-3 siRNA knockdown, 
however there were many interesting biologically significant overlaps.

5.9.3.1 Overlapping genes in similar directions following CB1 
and siRNA 
	 A large number of the significantly overlapping gene changes following both CB1 
treatment and Bcl-3 siRNA knockdown supported biological relevant rationales for the 
tumour suppressive functional outcomes we observed. In the next section we will list and 
explore some of the most relevant overlaps and their transcriptional roles.

	 HtrA Serine Peptidase 1 (HTRA1) was up 1.34-fold (1.81-fold with siRNA) and 
encodes a highly conserved member of the trypsin family of serine proteases. It has been 
recently implicated in suppression of EMT and cell motility in breast cancer by inhibiting 
TGF-beta signalling and its down-regulation is also associated with shorter patient 
survival (Lehner et al., 2013). Kindlin-1 (FERMT1) was down 0.83-fold (0.85-fold with 
siRNA) and encodes an integrin-interacting protein implicated in the activation of TGF-
beta/Smad3 signalling. Functionally, Kindlin-1 promoted proliferation and was required for 
EMT in colorectal cancer (Kong et al., 2016). Transforming growth factor beta 1 (TGFB1) 
was up 1.15-fold (1.14-fold with siRNA) and encodes a secreted ligand of TGF-beta 
superfamily of proteins. It is a multifunctional regulatory cytokine that controls 
proliferation, differentiation and many other cellular functions, with both tumour 
suppressor and promoting effects in breast cancer depending on cancer stage 
(Zarzynska, 2014). These findings support a recent publication detailing the involvements 
of Bcl-3 with the stabilisation of Smad3 within TGF-beta signalling (Chen et al., 2016).

	 Kinesin family member 18A (KIF18A) was down 0.91-fold (0.74-fold with siRNA) 
and encodes a plus-end directed microtubule depolymerase kinesin. It has been found to 
be overexpressed in human breast cancer and is associated with higher grade, 
metastasis and poor survival. Its inhibition was shown to critically affect mitotic function 
as well as reducing migration by stabilising microtubules at the leading edges and 
induction of anoikis following inactivation of PI3K-Akt signalling (Zhang et al., 2010). 
Inositol polyphosphate-4-phosphatease type II B (INPP4B) was down 0.88-fold (0.83-fold 
with siRNA) and encodes one of the enzymes involved in phosphatidylinositol signalling 
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pathways. INPP4B has been shown to mediate PI3K signalling in breast cancer, 
enhancing SGK3 activation and suppressing Akt phosphorylation, all processes required 
for 3D proliferation, invasive migration and tumourigenesis in vivo (Gasser et al., 2014).

	 Hyaluronan Acid Synthase 2 (HAS2) was down 0.83-fold (0.51-fold with siRNA) and 
it encodes a protein that catalyses the synthesis of hyaluronan acid (HA), a high molecular 
weight unbranched polysaccharide that is one of the main components of the 
extracellular matrix. HA been shown to actively regulate cell adhesion, migration and 
proliferation by interacting with surface receptors such as CD44. HAS2 has been 
observed to be overexpressed in breast cancer cell lines and its high expression has been 
correlated with lymph node metastasis. Functional assays showed that knockdown 
of HAS2 inhibited proliferation both in vivo and in vitro, through the induction of apoptosis 
or cell cycle arrest (Li et al., 2015). Dual specificity phosphatase 5 (DUSP5) was up 1.33-
fold (1.28-fold with siRNA) and it encodes a negative regulator of mitogen-activated 
protein kinase pathways. In basal-like breast cancers low DUSP5 expression was 
significantly correlated with poor survival, paclitaxel resistance and tumour progression (T. 
Liu et al., 2018).

	 Par-6 family cell polarity regulator beta (PARD6B) was down 0.85-fold (0.86-fold 
with siRNA), it encodes a PAR6 family member, an essential component in epithelial cell 
tight junction formation and maintenance of polarity in breast cancer cell lines. Its 
imbalance radically alters epithelial cell architecture and was found to contribute to 
tumour progression (Cunliffe et al., 2012). Netrin 4 (NTN4) was up 1.16-fold (1.17-fold with 
siRNA), it encodes a laminin-related protein and its decreased expression in TNBC has 
recently been associated with EMT-related biomarkers. NTN4 overexpression attenuated 
cell migration and invasion, and induced N-cadherin and vimentin downregulation, 
while NTN4 siRNA knockdown significantly increased migration and invasion (Xu et al., 
2017). Semaphorin 3D (SEMA3D) was down 0.84-fold (0.76-fold with siRNA), it encodes a 
protein typically associated with migration of blood vessels during angiogenesis and 
neuronal axons during development. SEMA3D up-regulation has been implicated in the 
promoting metastasis in pancreatic ductal adenocarcinomas (Foley et al., 2015).Together 
these gene changes further highlight the links between Bcl-3 and transcriptional changes 
affecting the EMT process and tumour interactions with the microenvironment.
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	 Interleukin 1 beta (IL1B) was up 1.45-fold (1.84-fold with siRNA) and encodes a 
member of the IL1 cytokine family. A recent study showed that up-regulation and 
secretion of IL1B production by TNBC cells induced a significant infiltration of anti-tumour 
neutrophils into the metastatic niche by chemotaxis (Zhao et al., 2018). Prostaglandin E 
synthase (PTGES) was up 1.32-fold (1.47-fold with siRNA) and encodes a glutathione-
dependent prostaglandin E synthase. Its expression has been shown to be to be induced 
by IL1B, as well as TP53, and may be implicated in p53-mediated apoptosis (Lee et al., 
2010). Colony stimulating factor 3 (CSF3) was up 1.45-fold (1.83-fold with siRNA) and 
encodes another cytokine associated with the recruitment of tumour associated 
macrophages (Hollmén et al., 2016). Interleukin 24 (IL24) was up 1.29-fold (1.37-fold with 
siRNA) and has been shown to be a tumour suppressor cytokine capable of reducing in 
vivo breast cancer growth by promoting the up-regulation of pro-apoptotic BAX as well as 
notable inhibition of tumour angiogenesis (Wei et al., 2015). A different animal study 
showed that IL-24 transformed the tumour microenvironment in colorectal cancer and 
promoted local CD4(+) and CD8(+) T cells to secrete interferon gamma, which enhanced 
the cytotoxicity of CD8(+) T cells (Ma et al., 2016). These overlapping gene changes 
proposed a very interesting alternative mechanism of drug action centred around immune 
signalling, as pharmacological activation of inflammatory cytokines could potentially 
augment the host innate immunity and promote suppression of metastatic colonisation.

	 Kruppel-like factor 2 (KLF2) was up 1.34-fold (1.59-fold with siRNA) and encodes a 
transcription factor that displays anti-carcinogenic properties. It is often found to be 
down-regulated in breast cancers and its expression positively correlates with patient 
survival. A recent study showed that KLF2 acted upon the retinoic acid pathway and 
induced the expression of tumour suppressive cellular retinoic acid-binding protein 
2 (CRABP2) and inhibited the expression pro-tumourigenic fatty acid-binding protein 
5 (FABP5) (Zhang et al., 2015). Vitamin D 24-hydroxylase (CYP24A1) was down 0.77-fold 
(0.78-fold with siRNA) and encodes a member of the cytochrome P450 superfamily of 
enzymes. Dysregulated CYP24A1 acts likes a putative oncogene and its 
suppression conferred breast cancer cells with increased susceptibility to apoptosis and 
inhibited anchorage-independent growth (Osanai and Lee, 2016). Rap1-interacting 
protein 1 (RIF1) was down 0.87-fold (0.88-fold with siRNA) and encodes a protein 
involved in homologous recombination-mediated DNA double-strand break repair. It was 
found to be highly expressed in breast cancers and correlated positively with invasion 
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(Wang et al., 2009). These gene changes suggest that Bcl-3 signalling could be further 
implicated in cellular metabolism as well as DNA repair pathways.

	 Although most of the overlapping changes supported a tumour suppressive 
function for Bcl-3 inhibition, there were a few gene changes that argued against this 
notion. Proto-oncogene c-fos (FOS) was up 1.67-fold (1.36-fold with siRNA), this encodes 
the early gene product part of the activator protein-1 (AP-1) transcription factor and has 
been associated with mechanisms of cell proliferations, differentiation, apoptosis and 
transformation. Although the mainstream opinion on FOS considers it an oncogene some 
reports describe a tumour suppressive function(Durchdewald et al., 2009). Hairy and 
enhance of split homolog-1 (HES1) was up 1.58-fold (1.21-fold with siRNA) and encodes 
a transcription factor regulated by NOTCH, Hedgehog and Wnt signalling pathways. It 
has been associated with invasiveness, induction of EMT and tumour survival (Rani et al., 
2016). Serum deprivation response (SDPR) was down 0.8-fold (0.53-fold with siRNA) and 
encodes a calcium-independent phospholipid-binding protein whose overexpression in 
metastatic breast cancer models promoted apoptosis and suppressed the formation of 
metastatic lesions in mice (Ozturk et al., 2016). Ultimately any given cellular phenotype 
will be the result and summation of a myriad of different signalling pathways, nonetheless 
it is important to pay attention to this balance.

5.9.3.2 Overlapping genes in opposing directions following CB1 
and siRNA 
	 There were a number of biologically interesting gene changes that overlapped 
between the two conditions but in opposing manners. It would be interesting to further 
investigate these targets to try and better understand the differences between small 
molecule Bcl-3 inhibition and siRNA knockdown.

	 Growth differentiation factor 15 (GDF15) was up 1.3-fold (down 0.60-fold with 
siRNA). It encodes a secreted ligand of the TGF-beta superfamily and expression of this 
inflammatory cytokine is associated with EMT, drug resistance and disease progression.A 
recent study demonstrated the association of GDF15 with high tumour grade, ER-
negativity, and HER2 overexpression in breast cancer patients. Stable overexpression 
of GDF15 up-regulated expression of mesenchymal markers, and increases cellular 
invasion (Peake et al., 2017). PIM1 was up 1.24-fold following CB1 treatment, (down 0.67-
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fold with siRNA). PIM has recently been associated with MYC and its inhibition in TNBCs 
has been shown to promote apoptosis and enhance sensitivity to chemotherapy (Zhao et 
al., 2017). Tensin 4 (TNS4) was up 1.18-fold (down 0.34-fold with siRNA) and it is involved 
in MET tyrosine kinase receptor signalling. TNS4 has been shown to directly interact with 
phosphorylated MET to positively regulate cell survival, proliferation, and migration, 
through increased MET protein stability (Muharram et al., 2014). Bcl-3 suppression with 
siRNA in these cases appeared to have been associated with beneficial therapeutic 
outcomes, while CB1 treatment signalled in the opposite direction.

	 There were also a number of gene changes where CB1 treatment correlated with 
beneficial outputs, while siRNA had the opposite effect. ST6GalNAc2 was up 1.39-fold 
(down 0.88-fold with siRNA) and this sialyltransferase has been identified as a novel in 
vivo breast cancer metastasis suppressor by altering the profile of O-glycans on the 
tumour cell surface, preventing the binding of soluble lectin galectin-3 (Murugaesu et al., 
2014). TRAIL receptor 4 (TNFRSF10D) was down 0.83-fold (up 1.60 fold with siRNA) and 
encodes a member of the TNF-receptor superfamily. Tumour necrosis factor (TNF)-related 
apoptosis inducing ligand (TRAIL) selectively induced apoptosis in cancer cell and not 
normal cell, but expression of TRAIL-R4 in breast cancer cells is well correlated with 
TRAIL resistance (Sanlioglu et al., 2005). RNA Polymerase III subunit B (POLR3B) was 
down 0.88-fold (up 1.22-fold with siRNA) and it encodes the second largest subunit of 
RNA polymerase III. It has been shown to be down-regulated following chemotherapy in 
ER negative breast cancer (Einbond et al., 2010).

5.9.3.3 Gene changes seen only following CB1 treatment 
	 There were a number of gene changes that did not overlap with Bcl-3 siRNA 
knockdown, but may still reflect biologically important drug responses. Pharmacological 
inhibition of Bcl-3 targeting its protein-protein interactions will fundamentally operate 
differently on a mechanistic level from knockdown of a particular gene. It is possible for 
the Bcl-3 protein to have novel involvements within cellular signalling pathways beyond 
simply their interactions with p50 and p52.

	 Early growth response 1 (EGR1) was up 1.74-fold and it encodes a stress response 
Cys2-His2-type zinc-finger transcription factor. It plays an important role in the regulation 
of cell survival, proliferation and cell death. It has been shown to regulate and activate the 
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expression of multiple tumour suppressors such as TP53 and TGFB1, thereby helping in 
the prevention of tumour formation (Baron et al., 2006). Interleukin 6 (IL6) was up 1.44-
fold, this pleiotropic cytokine plays an important role in regulating systemic inflammation 
and studies have linked intra-tumour IL6 signalling with inhibited proliferation in breast 
cancer (Dethlefsen et al., 2013). Endocan (ESM1) was down-regulated 0.63-fold, it 
encodes a secreted protein and its high expression in MDA-MB-231 cells is associated 
with aggressive disease and worse in vivo relapse-free survival (Sagara et al., 2017). 

	 There were a few changes that did not seem to align with our therapeutic goals 
and it may be important to monitor them in future studies. Inhibitor of DNA binding 1 (ID1) 
and inhibitor of DNA binding 3 (ID3) were both up 1.24-fold, these encode TGF-beta 
target genes shown to be stabilised by Bcl-3 and their expression was associated with 
breast cancer metastatic progression (Chen et al., 2016). miR-222, a microRNA 
implicated in the development of many cancers, including breast was up 2.1-fold, though 
high miR-222 expression is typically associated with poor overall survival (Wei et al., 
2016). ATP binding cassette subfamily C member 3 (ABCC3) was up 1.59-fold and 
encodes a transporter protein majorly implicated with multi-drug resistance in breast 
cancer (Balaji et al., 2016).

5.9.4 CB1 found to most effectively confer transcriptional 
changes between the 8 and 24 hour time points 
	 Leading on from the CB1 microarray experiment, we were curious to further 
explore why following 48h drug treatment we saw only a fraction of the transcriptional 
changes seen after 48h Bcl-3 siRNA knockdown. A gene panel consisting of five 
significantly altered genes following CB1 treatment (IL1B, ESM1, FOS, EGR1, IL6), and 
four known transcriptional targets of Bcl-3 (TNFα, CDH2, MDM2, IL10) were chosen.

	 First, Bcl-3 siRNA was used to characterise and valid the targets in the panel. All 
genes other than ESM1 and IL6 were found to significantly change in the correct, 
biologically accurate direction following 48h Bcl-3 knockdown (Fig. 5.7a). Next, we 
treated MDA-MB-231-Luc cells with either 100μM of JS6, CB1 or DMSO control for 3h, 
8h, 24h or 48h and compared the gene expression profiles with that of siRNA. At 3h, we 
saw modest increases in TNFα, IL1B, FOS, EGR1 and IL6 expression, mostly with CB1 
treatment (Fig. 5.7b). At 8h, the expression profiles began to more closely match that of 
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siRNA for both JS6 and CB1 treated cells (Fig. 5.7c). By 24h, all significant changes 
associated with JS6 treatment was lost, but CB1 treated cells retained most of the 
transcriptional responses previously seen (Fig. 5.7d). By 48h, no significant changes were 
seen with JS6 treatment and only dampened responses for IL1B, FOS, EGR1, ESM1 and 
IL6 remained following CB1 treatment (Fig. 5.7e). The results from these qRT-PCR 
experiments suggested that CB1 was able to accurately replicate transcriptional changes 
seen with siRNA knockdown, but only within a 8 to 24 hour timeframe. JS6 was also able 
to impart similar effects, but its efficacy was entirely lost by 24 hours. These findings also 
implied, there may have been substantially more gene changes if we carried out a 
microarray experiment using samples from cells treated with a shorter timeframe as by 
48h, all expression of Bcl-3 specific targets within our panel had returned back to basal 
levels.

5.9.5 Daily JS6 and CB1 treatment improved drug efficacy 
	 Based on the observation that transcriptional changes following drug treatment 
faded beyond 24 hours, it was possible our small molecule inhibitors were unstable within 
standard cell culture conditions, or perhaps the cells metabolised the compounds within 
this timeframe. Therefore we wanted to investigate the effects of refreshing inhibitor 
treatments in one of the longer functional assays. We chose the colony forming assay as 
this assessed clonogenic survival over the course of 10 days. In both MDA-MB-231-Luc 
(Fig. 5.9) and MDA-MB-436 cells (Fig. 5.8), daily treatment with JS6 or CB1, by replacing 
culture media preventing drug accumulation, drastically improved the efficacy and 
lowered the concentration required to achieve significant growth inhibition when 
compared with previous single 48h treatment.

5.9.6 Bcl-3 inhibitors demonstrated in vivo efficacy 
	 We designed a number of xenograft models to assess the in vivo efficacy of Bcl-3 
inhibitors in several different aspects of metastatic disease. We generated experimental 
TNBC metastases in athymic nude mice through tail vein injections of MDA-MB-231-Luc 
cells and used this model to test the anti-metastatic capabilities of our inhibitor 
compounds. The first model pre-treated animals with inhibitors before injection of cancer 
cells and daily intraperitoneal drug treatments were subsequently carried out for 9 
consecutive days. Both JS6 and CB1 were found to inhibit the initial metastatic seeding 
 223
Chapter 5: Results
process and significantly reduced average tumour burden, as well increasing the 
proportion of disease free animals by experimental endpoints (Fig. 5.13). When we 
tracked the health status of one experiment past the final imaging date, it was found that 
CB1 treatment also significantly delayed time until morbidity and extended the survival 
time of treated cohort (Fig. 5.12e).

Due to the high variance nature of biological systems and in vivo experimentation, 
not all animals in the DMSO control cohorts developed detectable tumour burdens within 
the designated experimental timeframe. This was problematic as it made it difficult to 
derive statistical significance between cohorts within individual experiments. It was hard to 
explain whether the lack of detectable tumour load was due to natural variance or drug 
efficacy. Therefore it was especially important to increase overall sample sizes by carrying 
out biological repeats for each experimental cohort in order to obtain biologically 
representative results. When we integrated the results from all individual model one 
experiments, it allowed us to derive statistical significance for drug treated cohorts 
compared to DMSO controls.
	 The oral efficacy of CB1 was also tested using this first metastasis model and mice 
were treated with the intraperitoneal dose (3.5mg/kg) as well as a higher dose (20mg/kg) 
via oral gavage. In this experiment the higher oral dose was found to significantly reduce 
metastatic burden (p=0.038) when compared to the DMSO vehicle controls. Although the 
lower CB1 dose only exhibited a trend of reduced metastatic burden (p=0.173), this was 
most likely due to the low experimental animal numbers per cohort (n=5) and biological 
repeats should be carried out (Fig. 5.14). But based on the results from this experiment 
alone, we cannot rule out the possibility that treatment via oral gavage is less effective 
than intraperitoneal injections at the same concentrations.

Our first xenograft model was able to significantly demonstrate the efficacy of both 
JS6 and CB1, especially in the context of disrupting the earliest seeding processes of 
metastatic disease. In our second xenograft model we tweaked the drug treatment timings 
to determine whether the Bcl-3 inhibitors also disrupted the subsequent colonisation and 
expansion of established tumour cells. Experimental metastases were established using 
the same intravenous injection of MDA-MD-231-Luc cells, but this time the cells were 
allowed to seed for 3 days before animals were treated with either JS6, CB1 or DMSO 
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control. Drug treatments were continuously administered daily and animals imaged 
periodically until experimental endpoint. We closely monitored the weights and health 
status the animals following daily drug treatment in case there were accumulated toxicities 
associated with long term drug treatments. We observed no significant differences 
between JS6, CB1 and DMSO control animal cohorts over the course of 30 days (Fig. 
5.16).
When the results from all individual experiments were aggregated, we saw no 
significant reductions in average metastatic burden between JS6, CB1 or DMSO control 
treated cohorts (Fig. 5.15). Although similar to model one, there was an increased 
proportion of animals within the drug treated cohorts that remained completely tumour free 
by the experimental endpoint compared to the controls. This suggested that the Bcl-3 
inhibitors most likely acted by completely disrupting the ability of a subset of circulating 
tumour to seed and establish during the earliest stages of metastasis. Once tumour cells 
have successfully colonised, the inhibitors cannot effectively suppress their expansion, as 
we have only been able to observe modest effects upon proliferation in vitro. Therefore it is 
likely neither JS6 nor CB1 can be considered as effective mono-therapies in the clinical 
setting and their primary effects in vivo appeared to be suppression of metastatic seeding.
Although in model two there were no significant effects on tumour expansion once 
seeding had taken place, there was a trend of reduced tumour size in the drug treated 
cohorts. In our final xenograft model we wanted to test the effects of CB1 on primary 
orthotopic tumour growth. We established primary orthotopic tumours via subcutaneous 
injection of either MDA-MD-231-Luc or MDA-MB-436 cells into the bilateral mammary fat 
pads of mice. Cells were allowed to seed for 4 days before animals were treated with daily 
intraperitoneal injections of CB1 (3.5mg/kg) until experimental endpoint. Tumour volumes 
were recorded and CB1 was found to significantly reduce average tumour sizes of both 
cell lines from the 38th day onwards (Fig. 5.17). This finding supported our in vitro 
observations of growth suppression and although CB1 was not able to cause tumour 
regression, it was nonetheless able to impart a modest growth suppression within TNBC 
cells.
	 In recently years there has been significant advances in the development of 
patient-derived tumour xenografts (PDX). PDX models have the advantage of maintaining 
the molecular and histological heterogeneity of the original tumour. Breast cancer PDX 
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models have been shown to effectively recapitulate the molecular, stromal, and 
phenotypic heterogeneities seen within breast cancer (DeRose et al., 2013). Additionally 
they have been shown to be superior at predicting drug responses compared to standard 
cell cultured xenograft models (Hait, 2010). It would be interesting to investigate the 
efficacy of CB1 within these tumour models for future studies.

5.9.7 Concluding remarks 
In this chapter we demonstrated that our two lead Bcl-3 inhibitor compounds were 
able to recapitulate in vitro biological phenotypes seen previously with Bcl-3 suppression in 
TNBC cell lines. CB1 was consistently found to have a greater efficacy than JS6. We also 
found a large number of biologically relevant overlapping transcriptional signalling changes 
following Bcl-3 inhibition with CB1 and siRNA. There were also a number of interesting 
non-overlapping changes, as well as opposing overlapping changes, highlighting the 
mechanistic differences between pharmacological disruption of Bcl-3 protein-protein 
interactions and siRNA gene expression knockdown. It would be very interesting to further 
investigate and validate the overlapping downstream signalling pathways following drug 
treatment and siRNA in regards to the tumour suppressive phenotypes observed to 
elucidate a more exact mechanism of action for Bcl-3. CB1 was also demonstrated have 
potent in vivo anti-metastatic efficacies, as well as a lack of non-specific toxicities, it could 
present as an effective combination treatment option in TNBCs. When paired with a more 
traditional chemotherapeutic designed to regress the tumour bulk, Bcl-3 inhibition could 
more effectively contain the disease and impair the ability of any subsequently circulating 
metastatic cells from seeding in distal organs.
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6.1 General Discussion 
	 We began this project by carrying out ectopic Bcl-3 suppression in four different 
TNBC cell lines using siRNA. We wanted to characterise the effects of knocking down this 
widely accepted proto-oncogene in a range of functional assays. Following Bcl-3 
knockdown, we saw significant reductions in overall cell turnover in all TNBC lines. This 
phenotype was comprised of a reduction in proliferation, seen by decreased Ki67 and 
phospho-histone H3 expression, a shift away from the S and G2/M cell cycle phases 
towards the G0/G1 resting phase, as well as increased apoptosis, seen by increased 
caspase-3/-7 activities, along with the identification of an atypical subG1 cell cycle phase 
indicative of apoptotic bodies. By transfecting the cell lines with a NFkB reporter plasmid, 
we were able to show that Bcl-3 knockdown resulted in an overall reduction in 
transcriptional activity specifically targeting NFkB DNA binding elements. Since NFkB 
signalling is generally associated with promoting cancer cell proliferation, this could be an 
explanation for the observed reduction in cell growth. Following Bcl-3 knockdown in the 
non-tumourigenic MCF10a cell line, we didn’t observe any of similar changes, which 
helps support the idea that the oncogenic roles of Bcl-3 were specific to our TNBC cell 
lines. However we could further test this specificity by knocking down Bcl-3 in a range of 
different non-tumourigenic tissue types, such as HMECs, a human dermal microvascular 
endothelium cell line.

	 Leading on from siRNA suppression of Bcl-3 we wanted to investigate the effects 
of ectopic overexpression. Two TNBC cell lines stably overexpressing wild type Bcl-3 
protein were generated. Surprisingly, not only did we not see oncogene-driven increased 
cell growth, both overexpression cell lines exhibited reductions in overall cell turnovers. 
When we stained for proliferative markers, Bcl-3 overexpression indeed resulted in 
increased Ki67, pHH3, as well as larger G2/M dividing cell cycle phases. However both 
cell lines also featured increased subG1 cell cycle populations, along with increased 
caspase-3/-7 activities. The resulting cell turnover indexes demonstrated a greater ratio of 
cell undergoing apoptosis than those proliferating, explaining the overall reductions in cell 
growth. The NFkB reporter assay demonstrated overall increases in NFkB activity 
following ectopic overexpression, correlating with the increased proliferative phenotype. 
While most reports in the literature demonstrated pro-proliferative outcomes following 
Bcl-3 up-regulation, there were a few cases of Bcl-3 overexpression resulting in higher 
rates of apoptosis (Gehrke et al., 2017) and reduced tumourigenesis (Tang et al., 2016).
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	 Gene expression profiling was carried out for MDA-MB-231-Luc cells comparing 
Bcl-3 siRNA knockdown with control. Bcl-3 suppression resulted in a significant up-
regulation of genes positively associated with apoptosis signalling. Within this group, we 
saw many gene changes associated with promotion of the intrinsic mitochondria-
mediated apoptosis pathway, such as down-regulated BCL2, up-regulated BAK1, BAX, 
MCL1 and TP53 expressions. These findings suggesting that Bcl-3 potentially plays an 
important role in protecting TNBCs against the activation of the intrinsic apoptosis 
pathway. There were also significant changes to a number of genes associated with the 
extrinsic receptor-mediated apoptosis pathways, as well as pathways linked to stress 
induced apoptosis. However the mixed expression change for these genes indicate a 
more complex regulatory involvement requiring further investigation.

	 Bcl-3 siRNA knock was also found to significantly impair three different modes of 
cellular migration in TNBC cell lines. We saw reduced collective migration, in the wound 
healing assay, reduced amoeboid-like single cell migration when cells were tasked to 
move across narrow pores, and also reduced mesenchymal-like single cell migration, 
when single cell motility was tracked with time-lapse microscopy. Gene expression 
profiling highlighted significantly down-regulated cytoskeletal regulation by Rho GTPase 
signalling pathways following Bcl-3 suppression. We saw changes in many important 
motility associated genes such as up-regulated RHOB, CFL2 and down-regulated 
ROCK1, CDC42, PAK1and PFN2 expressions, encompassing diverse downstream 
metastasis related pathways such as Ras, RAF, MEK, ERK, PI3K, Akt, mTOR, MAPK, 
TGFB, VEGF and Wnt signalling. These findings fit our existing understanding of Bcl-3 
and suggest that in TNBCs, its expression could potentially be extensively correlated with 
metastatic progression.

	 When WT Bcl-3 was ectopically overexpressed, we saw reductions in collective 
migration, conversely both amoeboid-like and mesenchymal-like single cell migratory 
outputs were increased. It is important to consider the natures of the assays, the wound 
healing assay featured collective cell monolayers and was sensitive the effects of cell 
turnover and apoptosis, the single cell assays only assessed viable cells and were 
therefore independent of cell growth and death. These results supported the role of Bcl-3 
in contributing towards an increased single cell associated motility phenotype.
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	 Tail vein injection of MDA-MB-231 cells treated with Bcl-3 siRNA resulted in a 
significantly lower total number of individual metastatic lesions in an in vivo murine tail 
vein xenograft model of metastasis. However there were no significant differences 
between average size most likely due to the transient nature of siRNA suppression. Tail 
vein injection of cells ectopically overexpressing WT Bcl-3 resulted in greatly increased 
numbers of metastatic lesions in the lungs, although each individual tumour was much 
smaller in size compared to the controls. Overexpressing Bcl-3 also drove cells to seed 
and colonise at novel distal organs such as the heart, mammary gland and bone marrow, 
sites previously unseen with control cells. Orthotopic tumours generated with Bcl-3 
overexpression cells results in tumours significantly smaller than controls at the 
experimental endpoint. These in vivo findings are in line with the phenotypes observed in 
our in vitro functional assays.

	 A recent study in mouse embryonic stem cells reported that Bcl-3 overexpression 
resulted in significantly reduced proliferation, as well as self-renewal; interestingly, siRNA 
knockdown also produced comparable results. Bcl-3 was found to be a transcriptional 
repressor of Nanog gene expression and a cell-type specific optimal concentration of 
Bcl-3 was critical for the maintenance of normal functions (Kang et al., 2018). In light of 
similar observations in our TNBC cell lines, it is perhaps feasible for different cancers to 
have different optimal Bcl-3 concentrations where its oncogenic properties are best 
balanced to promote tumourigenicity without triggering transcriptional imbalances that 
might promote apoptosis. In order to take further investigate these hypotheses, it would 
be imperative to investigate ectopic Bcl-3 overexpression in other cancer cell line models 
and determine cell line specific effects.

	 Up to this point in the project we were able to successfully demonstrate Bcl-3 as a 
potential therapeutic target following tumour suppressive phenotypes seen after 
knockdown of the Bcl-3 gene with either siRNA knockdown, or disruption of the Bcl-3 
protein-protein interactions through overexpression of a dominantly negative, non-binding 
Bcl-3 ANK mutant protein in TNBC cell lines. The effects were also likely to be TNBC 
specific as the anti-tumour phenotypes were not replicated in the non-tumourigenic 
MFC10a breast cancer cell line. This allowed us to use computational modelling to design 
and synthesise small molecule inhibitors that targeted Bcl-3 protein interactions. We 
screened two lead compounds (termed JS6 and CB1) in a number of in vitro functional 
assays and showed that they were both able to recapitulate previously reported 
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phenotypes associated with Bcl-3 inhibition. CB1 was found to be consistently more 
efficacious and was ultimately selected as the primary drug lead. The Bcl-3 small 
molecule inhibitors were tested in a number of in vivo xenograft TNBC models and was 
found to significantly inhibit the initial tumour seeding process in a tail vein metastasis 
model, as well as displaying modest growth suppression capabilities in an orthotopic 
mouse model. Together with no observable long term non-specific toxicities and 
significant oral uptake availability, our Bcl-3 inhibitor appears to be a promising anti-
metastatic agent. Also due to its non-cytotoxic nature, we propose it could be an 
excellent candidate for both combination therapy with existing standard of care 
chemotherapy, as well as perhaps an effective long term prophylactic for metastasis 
suppression following early cancer identification.

	 We performed gene expression profiling comparing CB1 treatment with siRNA 
knockdown and found a large number of biologically relevant overlapping gene changes. 
This supports the target specificity of our inhibitor and provides some interesting 
mechanistic explanations for the therapeutic outcomes we observed. The results showed 
both CB1 and Bcl-3 siRNA significantly imparted gene changes associated with TGF-beta 
signalling, PI3K-Akt signalling, extracellular matrix remodelling, EMT, DNA damage repair, 
and immune-surveillance related cytokines. The later is of particular interest as the field of 
immunotherapy has become very prominent in recent years. It is possible for Bcl-3 in 
TNBC to have roles in regulating the secretion of cytokines responsible for transforming 
the tumour microenvironment. This will potently affect the recruitment and functions of 
the host immunity and can provide interested alternative mechanisms of drug action for 
our small molecule inhibitor in regards to the suppression of metastatic progression.

	 It might also be interesting to query Bcl-3 expression in different TNBC cell lines 
and patient tissues already published in publicly available databases to try and compare 
whether changes seen in our microarray experiment could be correlated. This meta-
analysis approach allows us to either bolster or disprove the findings in this study as it 
bypasses the need for repeated experimentation within additional TNBC cell lines, 
provided different groups has previously published on the relevant data. These findings 
provided a general overview into the complex signalling pathways associated with the 
Bcl-3 protein in TNBCs and perhaps offers insight into new therapeutic targets. It is also 
possible to further investigate some of the significantly altered targets and ask the 
question of whether one of them could serve as a biomarker for clinical response. 
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Ascertaining a robost biomarker will also be especially important in order to push our 
small molecule inhibitor into clinical trials. Also it is important to remember Bcl-3 has been 
shown to be dysregulated and oncogenic in a wide range of different cancers and 
diseases. Our novel small molecule inhibitor paves the ways for an easy method to further 
study the effects of Bcl-3 suppression in a range of different biological models. 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